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Abstract 
 
The survival of many patients with advanced solid tumours has remained poor over the 
past 40 years, despite improvements in existing therapies. Progress in the field of 
molecular biology has made gene therapy a feasible treatment modality. Viruses are the 
most promising vectors, with an adenovirus the first to receive a government licence in 
2003. However, the efficacy of adenoviral monotherapy has been disappointing in 
clinical trials. Vaccinia virus is an attractive alternative, with many superior 
characteristics. There are several strains of vaccinia virus, some of which have 
established safety profiles following their use as smallpox vaccines in millions of 
humans. The dominant strain in cancer research, Western Reserve, has been reported as 
the most potent oncolytic virus for cancer treatment, but is a non-vaccine strain. Other 
strains, such as the European vaccine Lister strain, are largely untested. 
 
This study evaluated the anti-tumour potency and biodistribution of different vaccinia 
virus strains using in vitro and in vivo models of cancer. 
 
Lister strain vaccinia virus demonstrated superior anti-tumour potency and cancer-
selective replication in vitro and in vivo, compared to Western Reserve; especially in 
human cancer cell lines. Studies examining the safety of the virus following local and 
systemic delivery to immunocompetent mice bearing tumours confirmed favourable 
viral biodistribution of the Lister strain; with higher viral titres in the tumours. 
Examination of the serum from a mouse cancer model found lower levels of pro-
inflammatory cytokines following Lister strain treatment. 
 
Strategies to further improve the Lister strain virus were considered, and a Lister strain 
virus expressing the anti-inflammatory cytokine IL10 was shown to increase anti-
tumour potency and viral titres within treated tumours. 
 
This study suggests that the Lister strain is a more promising vaccinia virus strain than 
the Western Reserve strain for oncolytic viral gene therapy.  IL10 expressed as a 
transgene enhances intratumoural viral persistence and anti-tumour potency. 
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1. Introduction 
 
1.1. Cancer 
 
Cancer was responsible for 7.6 million human deaths in 2007 globally; and is the 
second highest cause of death in the developed world, behind cardiovascular disease. 
1
  
This figure is expected to increase to 17.5 million by 2050 due to population growth and 
aging. From a UK perspective, the most recent figures document 293,000 new cancer 
diagnoses and 155,000 cancer deaths in 2007. In the UK, breast, lung, colorectal and 
prostate are the most common forms of cancer; accounting for 54% of all new cancer 
diagnoses. From 1977 to 2006 cancer incidence rates have increased by 25%; however, 
more recently this rate has stabilised. In terms of survival, there is evidence of 
improvements in some cancer types (Figure 1.) due to advances in disease detection and 
treatment. However for many cancers (such as head and neck, pancreatic and lung) the 
prognosis for patients is largely unchanged. To address this impasse, cancer has become 
the main focus of medical research globally. 
2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of relative survival rates for major cancers over 30 years. 
3
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Advances in the field of molecular biology have allowed a greater understanding of the 
process of carcinogenesis; enabling progress in cancer prevention and treatment. 
Genetic changes, either inherited or acquired later in life, are the basis for uncontrolled 
cell proliferation that causes cancer. Gene therapy aims to treat cancer by delivering 
genetic sequences to patient’s cells. The mechanism for this gene delivery relies on 
vectors, of which viruses are the most promising type; with the world’s first gene 
therapy product (an engineered adenovirus) licensed for clinical application in 2003. 
4
  
 
Currently the greatest challenge for gene therapy is developing efficacious vectors that 
selectively replicate in cancer cells and are safe for human application. As a result many 
different species of virus are being evaluated, with adenovirus being the most 
extensively investigated. However the potency of adenovirus is limited by its 
dependence on a specific receptor for entry into the host cell, which can be altered 
during malignant transformation. 
5
 Consequently alternative vectors are being 
examined. One such alternative is vaccinia virus, of which there are many strains. A 
number of strains of vaccinia virus were used around the world as part of the smallpox 
eradication programme in the 1950s. The uses of vaccine-derived strains in cancer 
therapy have the major benefit in that they have been used extensively in human 
populations, and hence are relatively safe. Comparison of the in vitro and in vivo 
efficacy and safety between the dominant laboratory strain (Western Reserve), which 
has undergone minimal human testing, and the European smallpox vaccine strain 
(Lister) shall be made. Efficacy of viral gene therapy depends on the interaction 
between the host immune system and the virus. A new Lister strain vaccinia virus 
mutant (VVIL10) encoding an immune-modulating gene (IL10) will also be evaluated 
for efficacy and safety in vitro and in vivo. 
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1.2. Cancer cell biology 
 
 
 
Figure 2. The Hallmarks of Cancer.
6
 
 
Carcinogenesis is an onco-evolutionary process by which normal cells acquire, through 
a multi-step process, a succession of biological capabilities to become malignant. These 
six capabilities have been defined as the “Hallmarks of Cancer” and provide a robust 
framework to our understanding of neoplastic disease. 
7
 Acquisition of these hallmarks 
is made possible due to two enabling characteristics: genomic instability, caused by 
disruption of genome-maintenance and surveillance systems, and tumour 
immunoevasion. Additionally, recruited normal tumour surrounding cells (tumour-
associated stroma) play a vital role in the development of cancer. 
 
1. Sustaining Proliferative Signalling 
 
Malignant tissues develop the ability to deregulate growth signals, leading to 
uncontrolled cell proliferation and growth compared to normal tissues; thus disrupting 
tissue architecture and function. Cancer cells can acquire this capability through 
production of growth factor ligands (autocrine proliferation); signalling to tumour-
associated stroma, which in turn produce tumour proliferating signals; 
overexpression/structural alteration of receptor proteins leading to hyper-
responsiveness; constitutive activation of the downstream signalling pathways; and 
disruption of negative feed-back signalling mechanisms. For example, RAS oncogene 
mutations abrogate Ras GTPase activity, which physiologically results in negative 
feedback on proliferation signalling. 
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2. Evading Growth Suppressors 
 
Tumour suppressor genes, such as Retinoblastoma (Rb) and p53, encode proteins that 
acts as cellular gatekeepers; controlling proliferation through activation of senescence or 
apoptosis in response to extracellular signals, intracellular stresses or genomic damage. 
Additionally, abrogations of the mechanisms of cellular growth contact inhibition are 
seen in many cancers, with involvement of Merlin (NF2 gene product) and LKB1 
proteins recently elucidated. These proteins in normal cells maintain tissue integrity and 
suppress mitogenic signals. 
8,9
  
 
3. Resisting Cell Death 
  
Subversion of apoptosis by cancer cells despite cellular stresses is an important hurdle 
in tumourigenesis. 
10
 The apoptotic machinery is divided into upstream regulators and 
downstream effectors; with the regulators are further divided into an extrinsic death 
receptor pathway (responding to extracellular signals, such as Fas ligand and TNFα) and 
an intrinsic stress pathway (responding to intracellular signals, primarily regulated by 
the Bcl-2 family). A final common pathway involves activation of either caspase 8 and 
9, activation of effector caspases (3, 6, 7), and subsequent cellular destruction. 
10
 
Apoptosis initiation is triggered by the balance of pro- (Bax and Bak) and anti- (Bcl-2, 
Bcl-XL, Bcl-w, Mcl-1 and A1) apoptotic members of the Bcl-2 protein family. Bax and 
Bak activation results in cytochrome c release, and downstream caspase-mediated 
proteolysis. Stimulation of the intrinsic stress pathway is thought to be most important 
in cancer development, 
6
 and several stress sensors, including the TP53 DNA-damage 
sensor, have been implicated in tumourigenesis. Additionally under-expression of cell 
survival factors, such as insulin-like growth factor 1/2 in epithelial cells, or hyperactive 
oncoprotein signalling, such as Myc, can induce apoptosis. 
11
 Cancer cells avoid 
induction of apoptosis by reducing expression of these stress sensors and pro-apoptotic 
regulators or, conversely, increasing expression of cell survival and anti-apoptotic 
proteins. 
 
More recently further mechanisms of cell death, other than apoptosis, have unfolded. 
Autophagy is a process of lysosome-mediated cellular organelle breakdown in response 
to nutrient restricted environments, such as those found within cancers. The resultant 
catabolites are then available for more essential processes ensuring cell survival.
12
 
Beclin-1 protein has been demonstrated to be a key autophagy regulatory protein; with 
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mice bearing inactivated Beclin-1 genes more susceptible to cancer. 
12
 However the role 
of autophagy in cancer is conflicting with evidence of autophagy resulting in a pro-
cancer survival state, allowing tumour re-growth in the presence of more favourable 
conditions.
13
 Necrosis cell death differs from apoptosis and autophagy in that the dead 
cells contents are released into the tissue microenvironment. This induces recruitment of 
immune cells to clear up the necrotic debris. However there is evidence of a tumour 
promoting role of these recruited immune cells, releasing pro-proliferative factors, such 
as IL-1α, to act on neighbouring cells and induce neoplasia. 14  
 
4. Enabling Replicative Immortality 
 
Non-malignant cells have a limited number of cell-cycles, in contrast to cancer cells 
which possess the ability to propagate almost indefinitely – immortalisation. Tandem 
TTAGGG repeats at the end of chromosomes, called telomeres, shorten progressively 
with each cell cycle in normal cells until the ends of the chromosomes can no longer be 
protected from fatal DNA fusions; resulting in senescence or cell death. 
15
 Specialised 
DNA polymerases, called telomerases, are over-expressed in the majority of cancers, 
but absent in normal cells, are able to add telomeres to DNA; thereby allowing almost 
limitless replication.  
 
In contrast to the dogma that all malignancies over-express telomerase, recent evidence 
has shown that some early stage malignancies are unable to express significant levels of 
telomerase and undergo cell death. 
16
 As such these cells are unable to progress to later 
stage malignancies. Transient telomere deficiency may even facilitate malignant 
progression, by increasing genomic instability, and therefore mutations of oncogenes 
and tumour suppressor genes. This has been demonstrated to occur in mice lacking 
TP53-mediated genomic surveillance and telomerase.
17
 Therefore it has been proposed 
that in the early stages of carcinogenesis telomere deficiency allow tumour promoting 
mutations to occur, whereas at later points in the development of cancer telomerase 
function stabilises the malignant genome allowing limitless replication. 
6
 Furthermore 
telomerase may have tumour-promoting roles by enhancing cell proliferation and 
apoptosis resistance. 
18
 
 
5. Inducing Angiogenesis 
 
Tumours are able to switch on physiologically quiescent angiogenesis to provide 
vasculature for their ever increasing metabolic requirements early on in their 
22 
 
development. This “angiogenic switch” is governed by the balance of stimulatory and 
inhibitory factors on vascular endothelial cells,
19
 as well as peri-tumoural inflammatory 
cells.
20
 The prototypal stimulator of angiogenesis is vascular endothelial growth factor-
A (VEGF-A), via tyrosine kinase receptors (VEGFR- 1-3). VEGF expression can be 
upregulated by hypoxia and oncogene signalling. Conversely thrombospondin-1 (TSP-
1) can bind to transmembrane receptors on endothelial cells and inhibit angiogenesis. 
21
 
Other endogenous inhibitors of angiogenesis include angiostatin (plasmin fragment) and 
endostatin (type 18 collagen fragment) have a role in wound healing and act to prevent 
angiogenesis in neoplasia.
21
 
 
6. Activating invasion and metastasis 
 
The “invasion and metastasis cascade” encompasses a multistep process of cancer cells, 
22
 and is associated with changes in shape, attachment to other cancer cells and the 
extracellular matrix (ECM) of cancer cells. E-cadherin is a key cell to cell adhesion 
molecule and is frequently downregulated in human carcinomas. 
23
 Conversely adhesion 
molecules normally associated with cell migration are upregulated in invasive cancers; 
such as N-cadherin. 
6
 
 
The “epithelial-mesenchymal transition” (EMT) is a developmental regulatory program 
that is crucial for embryogenesis and wound healing. 
24
 This program can be activated 
by cancer cells allowing invasion and metastasis. EMT-inducing transcription factors 
identified as controlling the program include Snail, Slug, Twist and Zeb1/2; with 
overexpression of some eliciting metastasis experimentally.
25
 
 
Yet again the importance of tumour stromal cells in carcinogenesis is apparent, with 
evidence that these cells, in addition to stimulating angiogenesis, have a role in cancer 
cell invasion and metastasis. 
26
 For example, tumour associated macrophages (TAMs) 
produce matrix-degrading enzymes that facilitate local invasion. 
27
 
 
Dissemination of cancer cells from the primary tumour must be followed by survival 
and growth in the new tissue microenvironment for metastasis to be successful; this, 
however, does not always occur. 
22
 Some metastases remain dormant until treatment or 
after long periods of time following treatment. Causes for this include: failure to 
activate angiogenesis, 
28
 induction of autophagy due to starvation, 
29
 anti-growth signals 
of normal extracellular matrix, 
30
 and immune tumour-suppressive actions. 
31
 The 
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timing and location (primary or secondary site) of the acquisition of the capability of 
metastases to establish themselves in the new tissues is unclear.  
 
 
In addition to the six core hallmarks first described in 2000, 
7
 two emerging hallmarks 
have been described: reprogramming of energy metabolism and evasion of immune 
destruction. 
6
 The importance and mechanistic independence from those initially 
described has yet to be definitively established.  
 
Reprogramming of glucose-dependent ATP production from oxidative phosphorylation 
to the glycolysis, even in the presence of ample oxygen, – the so-called “Warburg 
effect”, 32 or “aerobic glycolysis” - has been observed in many cancers. This method of 
energy metabolism is 18 times less efficient, however it allows for the diversion of 
glycolytic intermediates into biosynthetic pathways that are of vital importance for 
rapidly proliferating cells. 
33
 
 
The role of the immune system, in particular the innate arm, has historically been 
thought to attempt to destroy cancer cells through immunosurveillance. Better 
prognoses have been demonstrated in patients with tumours showing heavy CTL and 
NK infiltration. 
34
 Cancer cells themselves have been shown to secrete TGF-β and other 
immunosuppressive cytokines to evade the host immune system. 
35
 
 
 
1.3. Gene Therapy 
 
Gene therapy has been defined in the 2003 United Kingdom Government white paper, 
“Our inheritance, our future – realising the potential of genetics in the NHS”, as “the 
deliberate introduction of genetic material into patient’s cells in order to treat or prevent 
a disease”. 36 This document suggested that gene therapy would have diverse 
applications from “cancer to coronary artery disease”; and gave hope for licensed 
treatments “within five to ten years”.   
 
Gene therapy was initially applied to inherited diseases with single gene mutations 
(monogenic); such as Severe Combined Immunodeficiency Disease (SCID), Cystic 
Fibrosis and Haemophilia. However permanent corrective gene expression in such 
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illnesses has been unsuccessful. This together with the development of leukaemia in 
children with SCID, and the death of a patient with ornithine transcarbamylase 
deficiency following viral gene therapy highlighted the potential risks of such 
treatments. 
37
 With this in mind new applications for gene therapy, such as cancer and 
cardiovascular disease, were considered; where transient gene delivery would be more 
likely to be achieved, and provide a safe and clinically significant effect. 
38
 
 
Cancer is a genetic disease, with normal cells undergoing multiple mutations, as part of 
an “onco-evolutionary process”, to transform into malignant cells. Mutations in the cell 
behaviour regulating genes (proto-oncogenes and tumour suppressor genes) lead to cell 
growth self-sufficiency, insensitivity to anti-growth signals, evasion of apoptosis, 
sustained angiogenesis, limitless replicative potential and tissue invasion and metastases 
– the hallmarks of cancer, as previously described. 7 All of these changes are potential 
targets for gene therapy and has resulted in cancer gene therapy dominating the gene 
therapy research field; with two-thirds of clinical trials for cancer applications. 
39
 
However success at clinical trial has been disappointing mainly due to poor efficiency 
of gene transfer rather than a paucity of potential therapeutic genes. 
40
 Strategies to 
overcome this have focused on modulating the host immune response to the virus, 
optimising existing viruses, discovering/creating new viruses and, finally, identifying 
tumour-associated genes that can improve viral potency.  
 
1.4. Choice of genes for cancer therapy 
 
Following the mapping of the human genome in 2008, there is an extensive array of 
genes available as potential therapeutic transgenes for cancer gene therapy. There are 
three main strategies that characterise the type of gene used: corrective, cytoreductive 
and immunomodulatory. 
 
1.4.1. Corrective 
 
Cancer is caused by mutations in oncogenes and tumour suppressor genes (TSG) 
resulting in uncontrolled cell growth. Corrective gene therapy attempts to block 
oncogene or replace TSG function, thereby returning cells to normal cell growth. p53 
TSG mutations are implicated in over 50% of all cancers, and is thus is considered to be 
a potential magic bullet for corrective cancer gene therapy. 
41
 In 2003 the world’s first 
government licensed gene therapy product featured a recombinant adenovirus 
25 
 
expressing p53 (Gendicine
TM
; SiBiono Schenzhen, China). 
4
  Oncogenes can be 
overexpressed or amplified in cancer; and their action can be blocked therapeutically at 
either the transcriptional or translational level. 
 
1.4.2. Cytoreductive 
 
Cytoreductive gene therapy aims to directly or indirectly kill cancer cells, rather than 
correct the underlying genetic defect. This can be achieved by augmenting the effects of 
chemotherapy, by introducing a transgene that can convert an inactive pro-drug to a 
potent anti-cancer agent, for example the nitroreductase gene and CB1954. 
7
 Other 
strategies include inhibiting angiogenesis, 
42
 or inducing apoptosis. 
4
 
 
1.4.3. Immunomodulatory 
 
The host immune response detects tumour associated antigens (TAA) which allows 
CD8+ cytotoxic T cells to induce tumour lysis. Cancer cells can subvert this immuno-
surveillance through three broad strategies of tumour escape; which have been 
suggested to represent a “seventh hallmark of cancer”. 43 One common strategy is to 
reduce the immunogenicity of the cancer cells by modulating the interaction of peptides, 
MHC molecules and T cell receptors – a process termed antigenic drift. 44 Also MHC 
class I down–regulation by tumour cells reduces the cancer cell sensitivity to CTL 
mediated lysis.
45
 A second strategy is to develop resistance to immune-mediated killing 
by impairing perforin binding, 
46
 down-regulation or mutation of Fas, 
47
 and mutations 
in TNF-related apoptosis-inducing ligand receptors in tumours.
48
 A final strategy is to 
subvert the immune response through failure to produce danger signals that activate 
DCs (which can lead to development of immunosuppressive Tregs),
49,50
 down-
regulation of endothelial adhesion molecules,
51
 induction of tryptophan deficiency 
(which inhibits T cell proliferation),
52
 secretion of immunosuppressive mediators (such 
as nitric oxide, TGFβ, IL10),53-55 tumour expression of Fas ligand (which can kill 
infiltrating immune cells),
56
 and induction of myeloid suppressor cells (which inhibit  
CD8+ T cell/ NK activity and DC maturation).
57
 
 
Gene therapy can reverse this tumour-induced immuno-tolerance by increasing TAA 
presentation or upregulating MHC I expression. 
40
 This has been achieved by using 
cytokines as transgenes, with resulting enhanced antitumour efficacy; for example IL2 
and IL12 delivery by vaccinia virus in a glioma mouse model. 
58
 Furthermore, clearance 
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of the viral vector or oncolytic virus by the host immune response can also be reduced 
by this approach. 
59
 
 
1.5. Vectors for Gene Therapy 
 
The greatest limitation to cancer gene therapy becoming an effective everyday clinical 
treatment modality is the accuracy and efficiency of gene transfer to the target cells. 
40
 
The ideal vector should be efficient, safe and tumour selective; preferentially affecting 
cancer cells and sparing normal cells. Tumour selectivity can be achieved by 
administering the vector directly into the tumour, or through engineering the vector 
physically or genetically. The latter strategy is more attractive as this would allow for 
systemic administration which would be able to treat inaccessible or multiple lesions. 
However to reach its target the vector would have to overcome clearance of circulating 
virus by complement and the reticulo-endothelial cell-based mechanisms, leading to 
phagocytosis of viral particles by macrophages or liver Kupffer cells. 
60
 
 
The two main groups of vectors used in cancer gene therapy research are viral and non-
viral. Approximately 70% of clinical trials and the majority of research to date have 
used viral vectors. 
38
 Non-viral vectors use either physical transfection or particle-
mediated systems to introduce foreign DNA into the target cells. They are generally less 
immunogenic than viral vectors which allows for repeated administration. 
61
 
Additionally they are cheaper to produce, and can carry more DNA; however their 
major disadvantage is low transfection rates. 
 
Viruses are obligate intracellular pathogens which require host cell machinery to 
complete their life cycles. They have evolved over millions of years to be highly 
effective at infecting, replicating within and generally lysing host cells. Viruses have 
also developed mechanisms that allow them to subvert the host immune system and 
thereby increase their infectivity, such as expressing interferon γ decoy receptors. Viral 
vectors commonly induce mild flu-like illnesses, but have the potential for causing 
acute life-threatening toxicity. Some “oncolytic” viruses can also exert an anti-cancer 
directly themselves. Apart from different viral species, a common classification of viral 
vectors is whether they have the ability to replicate. Non-replicating viruses were the 
first vector systems for the delivery of foreign genes and most research to date has 
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utilised such viruses. 
62
 However, the efficacy of gene transfer of these viruses is poor, 
and for successful cancer treatment every tumour cell would have to be infected.  
 
In contrast replicating viruses allow more cancer cells to be infected as their progeny 
can go on to infect more cells and destroy the host cell as a direct consequence of their 
replication. 
62
 Replication-selective viruses have the ability to replicate in tumour cells, 
but not normal cells. Some viruses exhibit inherent tumour selectivity, such as Reovirus 
and Newcastle virus; whereas other viruses can be genetically modified to improve 
tumour selectivity. This can be achieved by inserting tumour-specific promoters, such 
as prostate-specific antigen (PSA) or deleting genes that are needed for viral replication 
in normal cells but not tumour cells, such as thymidine kinase. 
 
The most commonly used virus for gene therapy is the adenovirus. It is non-integrative, 
has high transfection efficiency and can be produced in high titres to good 
manufacturing process (GMP) standards. However the anti-tumour efficacy in many 
clinical trials has been poor. 
4,63
 
 
1.6. Oncolytic viruses 
 
Oncolytic viruses are self-replicating, tumour-selective viruses that are able to lyse 
cancer cells. 
64
 In this way they differ from our original notion of viral gene therapy 
whereby a viral vector is used to deliver specific gene expression to a host tissue to 
correct an underlying genetic defect. However, oncolytic viruses can also be armed with 
therapeutic genes, such as anti-angiogenic or immunomodulatory genes, to enhance 
their anti-tumour potency. 
 
At the beginning of the last century the oncolytic effects of viral infections were first 
noted, whereby periods of clinical remission were observed in patients with leukaemia 
following influenza infection. 
65
 Oncolysis is achieved through multiple mechanisms, 
including direct lysis, apoptosis, expression of toxic proteins, autophagy, protein 
synthesis shut-down and induction of anti-tumoural immunity. 
66
 The 1950s and 1960s 
saw clinical trials of several wild-type oncolytic viruses (first generation) including 
reovirus, adenovirus, vaccinia virus and Newcastle disease virus. However it wasn’t 
until 1991 that advances in molecular biology allowed the development of the first 
genetically-engineered, replication-selective oncolytic virus (second generation), using 
a herpes simplex virus. 
67
  Subsequent research has continued investigation into genetic 
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modifications to the viral backbone to improve tumour selectivity and anti-tumour 
potency, including arming of viruses with transgenes (third generation). In 2005 China 
approved the world’s first oncolytic virus treatment, the genetically modified 
adenovirus Onyx015/dl1520, or H101, for late-stage refractory nasopharyngeal cancer 
in combination with chemotherapy. 
68
  
 
Adenovirus has been the most extensively researched of the oncolytic viruses. 
Adenoviruses are double stranded DNA viruses, whose natural pathogenicity is 
associated with only mild respiratory infections. The main strategy used to achieve 
adenoviral tumour selectivity has been through deletion of the E1B-55K region, which 
normally encodes a p53 binding protein that prevents virally induced apoptosis or cell 
cycle arrest in normal cells. 
62
 As approximately half of all malignancies are p53 
deficient, 
41
 E1B-55K deletion confers restricted adenoviral replication to tumour cells, 
sparing normal tissue. Onyx015 or dl1520 virus has shown to be well tolerated in phase 
I and II clinical trials alone or in combination with chemotherapy; however objective 
tumour responses have been disappointing. 
69,70
 It has been postulated that poor 
adenoviral anti-tumour potency could be due to downregulation of CAR receptors on 
the tumour cell surface, thus limiting adenoviral cellular infection. 
71
 Further limitations 
of adenovirus arise due to the fact that adenoviruses are common pathogens; with most 
adults exposed to the most widely used serotype 5 adenovirus (Ad5). 
72
 Neutralising 
antibodies to systemically administered adenovirus attenuate its efficacy as an oncolytic 
virus through rapid viral clearance. 
 
Systemic delivery is compromised not only by circulating neutralising antibodies, but 
also by due to Kupffer cell-mediated liver sequestration and complement; 
73
  limiting 
current adenovirus therapy to intratumoural injection and, therefore, making the 
treatment of disseminated disease difficult. 
 
Recent research has identified carcinoembryonic antigen-related cell adhesion molecule 
6 (CEACAM6) expressed by some cancer cells as having a role in limiting the ability of 
adenovirus to infect cancer cells. 
74
 CEACAM6 has been shown to block adenovirus 
trafficking via the Src pathway which interferes with the cytoskeleton of cancer cells.  
 
Finally, the lack of immunocompetent mouse models for investigating the in vivo 
efficacy of adenovirus is a major barrier to developing adenoviruses suitable for clinical 
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trial. These limitations of adenovirus have led researchers to consider other oncolytic 
viruses, such as vaccinia. 
 
1.7. Vaccinia Virus 
 
Vaccinia virus has a long history of medical use in humans. In 1796 Edward Jenner 
isolated cowpox from the hand of a milk-maid, and subsequent inoculation of a boy 
conferred protection to small pox. 
75
 Vaccination against smallpox continued and in 
1980 smallpox eradication was declared complete at the 33
rd
 World Health Assembly. 
The exact origin of the vaccinia virus strain has not been definitively established, but it 
is thought to be derived from the cowpox. 
76,77
 
 
Vaccinia has several characteristics that make it a more attractive vector compared to 
adenovirus. It has a much larger cloning capacity of 25kb, compared to 7kb for 
adenovirus, and has strong promoters to drive high levels of transgene expression. It has 
a wide host range and a natural tumour tropism; infecting cells through membrane 
fusion rather than a defined cell surface receptor. 
78
 Four to six hours following vaccinia 
infection host protein synthesis is shut down, facilitating rapid viral replication with ~10 
000 copies of the viral genomes produced within 12 hours. 
79
 Vaccinia does not 
integrate DNA into the host genome, which is a safety concern of other viral vectors; 
instead replicating in viral factories within the cytoplasm.  The short life cycle compares 
favourably with the 48-72 hours life cycle for adenovirus; resulting in rapid cell death. 
80
 During its life cycle, vaccinia virus exists in different forms; however the 
extracellular enveloped virion (EEV) form is derived from host cells membrane and 
therefore has limited antigenicity allowing unharmed passage through the host 
bloodstream to distant tumours following systemic delivery. Vaccinia virus has also 
been shown recently to replicate well in the hypoxic environments often present in solid 
tumours. 
81
 Further advantages include rapid cell to cell spread, strong lytic ability and 
reliance on its own encoded proteins for replication, rather than the host cell. This latter 
advantage is in contrast to adenovirus which depends on many host encoded proteins for 
its replication, which can be lost during tumourigenesis. Finally, its safety profile is well 
established following its use globally as a smallpox vaccine, with established antiviral 
agents available to treat adverse responses, such as vaccinia immunoglobulin and 
cidofovir.  
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1.7.1. Vaccinia virus biology 
 
Vaccinia virus is a member of the genus Orthopoxvirus from the Poxviridae family. 
There are many strains of vaccinia virus, some of which are smallpox vaccine strains 
developed in different countries during the global eradication programme and 
consequently have considerable data regarding their safety in humans. Other strains are 
considered of limited oncolytic potential in humans due to their inability to replicate in 
mammalian cells or toxicity. 
60
 Certain strains show higher levels of inherent tumour 
selectivity making these strains preferable for anti-cancer treatments. 
 
The New York City Board of Health (NYCBH) or Wyeth strain was obtained from 
England in 1856 and was used as the smallpox vaccine strain in North America. 
77
 The 
Western Reserve (WR) strain is derived from the NYCBH strain following serial 
passage in mice brains; and has demonstrated superior virulence and anti-tumour 
potency in vitro. 
82
 However WR is not a vaccine strain and therefore its safety in 
humans is largely unknown. Additionally WR has been show to exhibit significant off-
target replication in ovaries and bone marrow, 
83
 and may cause death by overwhelming 
pulmonary replication. 
84,85
 These safety concerns have led to research into identifying 
and modifying other vaccinia virus strains for cancer therapy. 
 
The Modified Vaccinia Ankara (MVA) and New York Vaccinia (NYVAC) are highly 
attenuated and consequently have a good safety profile; however they do not replicate in 
mammalian cells. 
60
 The Tian Tian strain is the Chinese vaccine strain and was used 
extensively during smallpox eradication. It has been used as a cancer vaccine, but has 
unknown potential as an oncolytic agent. 
60
 The Copenhagen strain was the Northern 
European vaccine strain, but was withdrawn due to toxicity. The other European 
vaccine strain is the Lister strain. The Lister strain was developed in the Elstree 
laboratories at the Lister Institute in London. Both Lister and WR can be cost-
effectively mass produced to high titres. Despite the Lister virus having been fully 
sequenced, 
86
 this strain has not been extensively researched in terms of its oncolytic 
potential and may represent a promising virus strain for such an application.  
 
This study will compare the perceived gold standard laboratory WR vaccinia strain, 
which has limited clinical testing as a non-vaccine strain, against the European smallpox 
vaccine strain, Lister; which has been used in millions of humans as part of the 
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smallpox vaccination program, but for which we have few data regarding its efficacy as 
an oncolytic virus. 
 
 
 1.7.2. Vaccinia virus structure 
 
Poxviruses, including vaccinia, are brick-shaped particles (350nm in diameter) 
consisting of outer lipoprotein membranes surrounding a complex core structure (Figure 
3.). 
75
 The genome contains double-stranded DNA with inverted terminal repeats and 
terminal hairpin loops; consisting of 191 636 bp encoding 2063 proteins. 
86
 
 
 
Figure 3. Vaccinia virus structure. 
 
Vaccinia virus spends its life cycle in the host cell cytoplasm and does not integrate into 
the host genome (Figure 4.). There are four forms of the virus (Figure 4.): the 
intracellular mature virion (IMV), intracellular enveloped virus (IEV), cell associated 
enveloped virus (CEV), and the extracellular enveloped virion (EEV); which differ in 
structure by the number and origin of their lipid membrane. The IMV form is the initial 
viral particle produced by the cytoplasmic viral factories. It is surrounded by a single 
lipoprotein layer and is released when infected cells are lysed. The IEV form is triple 
lipoprotein-enveloped and is produced after fusion with the trans-Golgi network or early 
endosomes. The CEV form is a result of the fusion of the IEV form with the cell surface 
membrane. The EEV form is a double lipoprotein-enveloped virus and is released from 
the cell by membrane fusion; it is this form that is responsible for cell to cell spread. It 
has host-derived complement control proteins in the outer envelope, making it more 
resistant to antibody neutralisation than the IMV form.
87
 However the EEV form is too 
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fragile to survive the purification process during its manufacture; 
88
 as a result the form 
of the virus made for experimental use is the more immunogenic IMV form.  
 
Figure 4. Vaccinia virus morphogenesis. 
87
 
 
 
Vaccinia virus has a wide tropism and can enter most mammalian cell lines. 
89
 Although 
no specific vaccinia virus receptor has been identified for cellular entry, several outer 
membrane proteins, including A27L, A28L and D8L, are thought to facilitate the 
process. 
78,90-94
 These proteins bind to heparan sulphate and chondroitin sulphate on the 
host cell surface. 
91,92
 The mechanism of vaccinia virus cell entry is dependent on the 
infectious form with IMV forms entering by plasma membrane fusion and EEV forms 
entering by endocytosis. 
78
 
 
 
 
Figure 5. Vaccinia virus life cycle. 
90
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Viral entry into the cell is rapidly followed by release of viral transcription enzymes that 
transcribe early viral mRNA, which encodes proteins involved in uncoating viral DNA 
and transcribing intermediate mRNA (Figure 5.). Intermediate mRNA encodes late 
transcription factors leading to late mRNA synthesis, with late proteins including viral 
structural proteins and early transcriptional factors to be incorporated into the mature 
virion. DNA replication produces concatemers which are cut into individual genomes 
and assembled into mature virions. The mature virion contains three membranes, the 
outer membrane fuses with the host cell membrane, releasing a double-membrane EEV. 
The A34L vaccinia gene product keeps the EEV attached to the cell membrane, 
allowing the virus to spread to another cell without being released into the blood-
stream. 
95
 This replication process is very efficient; within 4 – 6 hours host protein 
synthesis is shut down, within 8 hours the first viral particles are produced and the 
infected cell is destroyed after 12 hours. 
60
 
 
1.7.3. Tumour selectivity 
 
Vaccinia has a natural tropism for tumours. Following IV administration of wild-type 
WR strain the highest viral titres are found in the tumour followed by the ovary, with 
intermediate titres in brain and bone marrow, and minimal virus in other tissues. 
96
 It 
has been postulated that this may be due to tumour capillaries lacking an intact 
basement membrane and having large gaps between endothelial cells, allowing the 
350nm vaccinia virus to “leak” into the extravascular space. 97 This theory is supported 
by evidence of hypothermia improving vaccinia dissemination through induction of 
capillary dilatation. 
98
 Other factors that may explain VV cancer tropism include 
improved viral replication in cells with: activated epidermal growth factor receptor 
(EGFR) – Ras pathway (which is present in most human cancers), vascular endothelial 
growth factor (VEGF) expression (Hiley et al, unpublished work) and loss of host 
cancer cell immunological factors, including interferon gamma (IFNγ) anti-viral 
responses. 
99
 
 
However it has been possible to further improve tumour selectivity by deleting viral 
genes responsible for transforming a normal cell into an optimal state for viral 
replication. These genes often have an effect of inducing a malignant-like cellular 
phenotype of uncontrolled cell cycle and evasion of apoptotic pathways. 
60
 As the 
cancer cells are already in this state of unregulated growth, there is no requirement for 
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them to be virally induced, and can be safely deleted without detriment to viral 
replication in cancer cells. 
 
One such deletion is the thymidine kinase (TK) gene, which when deleted renders the 
virus dependent on cellular thymidine kinase which is transiently expressed during S 
phase in normal cells, but constitutively expressed at high levels in cancer cells. 
100
 
Vaccinia also expresses an EGF homologue (vaccinia growth factor; VGF) that binds 
EGFR. 
101-103
 VGF induces cell proliferation, but as many cancers already have an 
activated EGFR – Ras pathway, deletion of this gene does not interfere with viral 
replication in cancer cells. WR VV with deletions of TK and VGF, so-called double-
deleted virus (vvDD or WRDD) shows markedly enhanced tumour specificity 
compared to wild-type and single-deletion mutants. 
83
 Another tumour-selective 
deletion is the gene encoding an IFNγ receptor homologue. Interferons are key 
components of the innate immune response to viruses. Normally the virus produces a 
decoy receptor to sequester extracellular IFN. 
104,105
 However viruses that are unable to 
produce this decoy receptor have replication limited to cells that have lost the ability to 
produce or respond to IFN, and in particular cancer cells. 
106
 Other strategies include 
deleting serpins (SPI-1 and SPI-2) which inhibit apoptosis, 
107,108
 and an inhibitor of 
cytochrome c release. 
109
 
 
1.7.4. Immune evasion of vaccinia virus 
 
The oncolytic efficiency of vaccinia virus is critically dependent on its clearance by the 
host immune system. A too vigorous immune response will remove the virus 
prematurely and result in a weak anti-tumour response. Conversely, a powerful immune 
response can be triggered by vaccinia virus against both virally infected and uninfected 
tumour cells, resulting in robust anti-tumour potency. 
110
  The host immune response to 
viral infections is biphasic, comprising the immediate, non-specific and amnesic innate 
immune system, followed by the delayed onset, specific and memory-inducing adaptive 
immune responses, sub-divided into the humoural and cellular systems (the latter seems 
to be the more crucial for viral clearance). 
79
  
 
1.7.5. Host anti-viral innate immune response 
 
The innate response is the immediate immune response and relies on critical effectors, 
such as interferons (IFNs), natural killer (NK) cells, macrophages and neutrophils. IFNs 
are a group of secreted proteins produced in response to viral infections.  There are two 
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types of IFNs: type 1 IFNs include IFNα and IFNβ, and are secreted by leukocytes and 
fibroblasts. They offer resistance to virus infection, stimulate MHC class 1 expression 
and inhibit cellular proliferation. 
111
 Type 2 IFN (IFNγ) is secreted by NK cells and T 
cells. IFNγ recruits leukocytes to the site of the infection, stimulates the bactericidal 
activity of macrophages and regulates the Th2 response. 
112
 Both types of interferon 
have demonstrated a key role in limiting poxvirus infections; with mice deficient in IFN 
receptors abnormally susceptible to vaccinia infections. 
113
 
 
Macrophages phagocytose opsonised virus, but also have an important function as 
antigen presenting cells (APC) for the activation of T cells and initiation of a specific 
immune response. Mice depleted of macrophages are unable to control vaccinia 
infections due to impaired viral clearance and antigen presentation. 
114
 NK cells are 
attracted to the site of infection and kill virus-infected cells, especially those with 
reduced levels of MHC class 1 expression. 
115
 NK cells have a direct cytotoxic effect on 
vaccinia-infected cells in vitro. 
116
 NK cell depletion has also been associated with 
enhanced vaccinia virulence in vivo. 
117
 
 
The innate immune system also includes the complement system of proteins in the 
plasma that are able to destroy enveloped virions or infected cells via the formation of 
membrane attack complexes (MAC); through either the classic (antibody-dependent) or 
alternative (antibody-independent) pathways. Additional functions of the complement 
system include opsonisation, mediated by C3b, and attracting macrophages and 
neutrophils, via the C3a and C5a fragments. 
 
1.7.6. Host anti-viral cellular immune response 
 
The T cell response is the most important adaptive immune response against vaccinia 
infection.  In mouse models, the absence of a functional T cell population allowed 
vaccinia to express genes within tumour cells for greater durations than in an 
immunocompetent model. 
118
 Also progressive vaccinia infection (vaccinia necrosum) 
is known to correlate with defects in cell-mediated immunity. 
119
 Furthermore it has 
been demonstrated that vaccinia infection is capable of raising a cytotoxic T lymphocyte 
(CTL) or CD8+ T cell response not only against virus, but also against virally infected 
tumour cells. 
120
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CD4+ T helper cells may have a greater role in the immune response against vaccinia 
than CD8+ T cells.  Depletion of T helper cells has been shown to cause viral 
persistence, whereas CTL depletion fails to demonstrate a similar effect. 
114
 Moreover, 
most of the immunomodulatory proteins expressed by vaccinia virus also target the T 
helper cell induced immune response. 
121
 
 
1.7.7. Host anti-viral humoural immune response 
 
The smallpox vaccination programme has resulted in the majority of older patients 
being immunised to vaccinia, with patients born after the 1970s free from immunity. 
The presence of circulating antibodies against vaccinia has the potential to diminish the 
anti-tumour potency of vaccinia virus. However this appears not to be significant, with 
no effect on anti-tumour potency demonstrated in a recent clinical trial following IT 
vaccinia delivery. 
122
 Additionally, it is known that systemic spread occurs 1-2 weeks 
post-infection in humans despite rising antibody levels, and that re-infection is still 
possible. 
123
 The EEV form of vaccinia virus is resistant to antibody neutralisation and, 
as this form is responsible for the majority of long-range spread of vaccinia, represents a 
significant advantage to vaccinia use as a gene therapy vector and/or oncolytic virus. 
124
 
Mutations in vaccinia virus that increase the proportion of EEV released compared to 
CEV have been shown to increase viral spread through tumours, and to distant tumour 
sites in the face of neutralising antibodies.
125
 
 
 
1.7.8. Vaccinia virus immunomodulatory proteins 
 
 
Vaccinia virus has evolved a number of strategies to evade the host immune response 
that shall be considered in turn below. 
 
Firstly, as previously stated, the EEV form of vaccinia virus is resistant to antibody 
neutralisation, in contradistinction to the IMV forms. 
88,113,126
 The EEV form mediates 
distant spread of vaccinia following inoculation and therefore represents a promising 
systemic treatment for metastatic cancer. 
 
The vaccinia genome encodes a number of immunomodulatory proteins that block the 
innate and cellular immune systems, through inhibition of cytokines (Interferons, TNF, 
Interleukins), chemokines, complement and Toll-like receptors. 
127
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Interferons are important mediators of the host anti-viral response and vaccinia 
produces interferon decoy receptors (B8R, B18R) 
128,129
 and also blocks interferon-
induced apoptosis (E3L), 
130
 and protein translation shut-down (K3L). 
131
 TNF are 
critical cytokines in the early defence against viruses, and vaccinia genes A53R   and 
B28R encode TNF decoy receptors preventing TNF action. 
132
 
 
Toll-like receptors (TLR) are pattern recognition receptors (PRR) that recognise 
pathogen-associated molecular patterns (PAMPs) and form an important sentinel 
function of the innate immune system. A52R and A46R vaccinia genes encode 
inhibitors TLR signalling, 
133
 thereby impairing the innate immune response to the 
invading virus. 
 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a 
transcription factor that regulates innate immune responses to cellular stresses including 
viral infection. N1L vaccinia protein has an immunomodulator action by blocking NF-
kB signalling pathways. 
134
 
 
Chemokines are small cytokines that direct chemotaxis during the immune response. 
B29R and A41L vaccinia genes have been identified as inhibiting chemokine activity. 
127,135
  More recently a 35kDa viral CC chemokine inhibitor (vCCI) has been identified 
as expressed by several strains of vaccinia, excluding WR strain. 
136
 Vaccinia genes 
B13R, B15R and C12L block IL-1β and IL18 proinflammatory cytokine function. 127 
 
Furthermore, vaccinia expresses several genes that inhibit serpins, 
137
 cytochrome c 
release, 
109
 and complement activation, 
138
 enhancing the persistence of the virus in the 
face of the host immune response. 
 
Other studies have examined the role of certain cytokines in changing the balance of 
Th1 (IFNγ, IL12) and Th2 (IL4, IL10) immune responses. Viral replication was 
enhanced in IL12 and IFNγ knockout mice, whereas IL4 and IL10 knockout mice 
exhibited increased viral clearance. 
139
 This suggests that the Th1 response is most 
important in vaccinia virus clearance. 
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1.7.9. Development of vaccinia virus as an oncolytic agent 
 
Preclinical evidence suggests that wild-type vaccinia virus strains are naturally tumour-
targeting following systemic delivery.
140
 Several trials in the 1970s and 1990s using 
wild-type viruses, mainly in melanoma patients intratumourally, have demonstrated 
only mild, transient, flu-like symptoms with objective tumour regression rates (>50% 
reduction in volume) in over 50% of cases; and complete regression in 25% of cases. 
123,141-143
 A further phase I/II trial, evaluating intravesical instillation of virus in bladder 
cancer patients showed the treatment was again well tolerated, and evidence of 
intratumoural viral replication and tumour destruction was recorded. 
144
 Despite these 
promising early results research over the intervening years has focused on improving 
tumour targeting, raising the possibility of a systemically delivered therapy that could 
treat both primary and metastatic disease, and enhancing anti-tumour potency of the 
wild-type virus through genetic modification. 
 
1. Tumour targeting 
 
Viruses endeavour to induce a cellular state in their host cell very much like the cellular 
state of cancer cells. They express a number of genes that result in the host cells 
inability to arrest cell cycle and enter apoptosis, and consequently undergo uncontrolled 
proliferation. This cellular state is often present in cancer cells and therefore 
preferentially supports viral replication compared to non-cancer cells. Specifically for 
vaccinia virus, cells with activation of the epidermal growth factor receptor (EGFR) – 
Ras signalling pathway support vaccinia replication and spread. 
145
 Activation of this 
pathway is seen in most cancers; 
7
 suggesting vaccinia has a broad tropism for tumours. 
Therefore when viruses infect cancer cells the viral genes that are required to induce the 
optimal cellular state for viral replication in non-cancer cells are not needed. Deleting 
these genes from the viral genome consequently restricts viral replication to cancer 
cells. 
 
The most successful gene deletions to restrict viral replication to cancer cells are 
thymidine kinase (TK) and vaccinia growth factor (VGF). TK insertional inactivation 
leads to viral dependence on host cell sources of TK; 
146
 which are only transient in 
normal cells, but constitutively high in the majority of cancer cells. 
100
 It has been 
shown in biodistribution experiments that viral replication of TK-deleted vaccinia virus 
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is much higher in tumours compared to other organs. 
118
 Most cancer gene therapy trials 
have used TK-deleted viruses. 
79
 
 
Vaccinia also expresses an EGF homologue (vaccinia growth factor; VGF) that binds 
EGFR, 
101-103
 and induces a proliferative state optimal for viral replication.  Double 
deleted virus has demonstrated tumour-restricted replication and tumour regression in 
vivo.
83
 Further cancer selectivity deletions include anti-apoptotic serpin genes SP-1/SP-
2, 
147
 and IFNγ receptor homologues. 148 
 
2. Arming vaccinia virus 
 
Insertion of foreign genes into the vaccinia backbone has been attempted to further 
improve anti-tumour efficacy of the recombinant virus. Vaccinia represents a good virus 
for transgene expression given its large cloning capacity (25kbp) and promoters that 
direct high-level late gene expression. 
149
 Ideal transgenes should not have a direct anti-
viral action, which would limit the viral anti-tumour efficacy, and should achieve a 
bystander effect, whereby non-virally infected cells are also influenced. Transgenes can 
the categorised into: immunomodulatory, anti-angiogenic, pro-drug converting 
enzymes, and imaging mediators. 
 
Researched immunomodulatory transgenes include co-stimulatory molecules to increase 
the immune response against tumour cells, which themselves attempt to reduce their 
immunogenicity to evade the host immune system.  Recombinant vaccinia virus 
expressing polymorphic epithelial mucin (MUC-1) and IL2 has been used in breast and 
prostate cancer. 
150,151
 Another vaccinia virus construct expressing carcinoembryonic 
antigen (CEA), and a triad of co-stimulatory molecules (TRICOM; B7.1, intracellular 
adhesion molecule-1 (ICAM-1), leukocyte function associated molecule-3 (LFA-3)) has 
been trialled in melanoma patients. 
152
 
 
Inflammatory mediating cytokines can be used as transgenes causing local expression in 
the tumour milieu to modulate the immune response against the cancer and infecting 
virus. The Th1 T cell mediated immune response is thought to be the most important in 
clearing vaccinia virus by the host, principally mediated by IFNγ, TNFβ, and IL12 
cytokines; 
139
 as well as the most critical in the host immune response to cancer. 
153
 
Promotion of the Th2 response, mediated by IL10 and IL4 cytokines, is therefore 
thought to be anti-inflammatory and virus promoting. The most successful cytokine 
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researched so far is using granulocyte-macrophage-colony-stimulating-factor (GM-
CSF); which acts as a growth factor for white blood cells including neutrophils, 
macrophages and dendritic cells.  This construct has demonstrated clinical anti-tumour 
efficacy in patients with recurrent and/or refractory melanoma, 
123
 and refractory 
primary or metastatic liver cancer following IT delivery. 
122
 IL2 is classically associated 
with the Th1 response and vaccinia-expressed IL2 has been assessed in the patients in 
patients with refractory malignant pleural mesothelioma. 
154
 Vaccinia-mediated IFNβ 
and IL2 expression have also shown promising results in pre-clinical testing. 
106,155
 A 
converse approach is to promote an anti-inflammatory response through the transgene 
expression of Th2 cytokines to reduce viral clearance. There is pre-clinical evidence of 
anti-tumour efficacy of recombinant vaccinia-mediated IL4 expression. 
156
 IL10 
transgene expression has also been shown to reduce peritoneal growth of MKN45 
gastric cancer in a mouse model following intraperitoneal injection. 
157
  Such strategies 
to reduce viral clearance by the immune system do, however, pose safety concerns, in 
that treatment may cause overwhelming viral infection that cannot be controlled by the 
host immune system. 
79
 
 
Another approach is to use a toxic or pro-drug converting enzyme to improve 
therapeutic efficacy. Gene-directed enzyme pro-drug therapy (GDEPT) involves 
cloning an enzyme into a virus that is able to convert a systemically administered non-
toxic pro-drug into a cytotoxic drug within the tumour microenvironment. The gene 
encoding cytosine deaminase (CD) has been the most extensively investigated. 
158
 It 
converts 5-fluorocytosine (5-FC) into the toxic metabolite 5-fluorouracil (5-FU).  
Improved animal survival and tumour responses were demonstrated in mice treated with 
5-FC and low dose vaccinia virus compared to virus alone. 
158
 
 
Finally, transgenes can be used to mediate tracking of the virus following administration 
in conjunction with imaging technology. This is useful to both monitor the 
biodistribution of viruses as well as their therapeutic action. Genes employed include 
human somatostatin receptor type 2 (SSTR2) in conjunction with a radiolabelled long-
acting somatostatin analogue, 
159
 luciferase and/or fluorescent proteins, 
140
 and 
transferrin receptors which can be detected on MRI. 
160
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1.7.10. Current State of Oncolytic Vaccinia Virus Clinical Trials 
 
The first use of vaccinia as an oncolytic virus was based on the administration of IT 
wild-type virus in patients with malignant melanoma in the 1960s and 1970s. These 
studies showed reasonable responses and lack of adverse side effects. 
141,142
 A 
subsequent clinical trial again investigated patients with melanoma, but this time used a 
recombinant vaccinia virus expressing granulocyte macrophage-colony stimulating 
factor (GM-CSF). 
123
 Of the seven patients, four had partial responses and one had a 
complete response.  More recently, a Wyeth GM-CSF expressing and TK deleted virus - 
JX-594, was investigated by IT delivery to 22 patients with primary or metastatic liver 
tumours refractory to conventional treatment. 
122
 Three partial responses, six stable 
disease, and one progressive disease were demonstrated based on Response Evaluation 
Criteria in Solid Tumours (RECIST). Interestingly, responsive patients included those 
who had anti-vaccinia antibodies following previous smallpox vaccination. Also virus 
was found replicating in distant (non-injected) tumour sites with resultant reduction in 
tumour volume. Further phase I trials are investigating JX-594 in application to 
refractory melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck 
squamous cell carcinoma, colorectal cancer and a selection of paediatric cancers. A 
phase II dose-finding trial of JX-594 in 30 patients with advanced hepatocellular 
carcinoma has recently demonstrated  radiological and survival advantages at the higher 
10
9 
PFU virus dose. 
161
 
 
GL-ONC1/GLV-1h68 is a Lister strain-based virus with insertional mutations of TK 
and A56R haemagglutinin loci with three reporter genes including a renilla luciferase-
green fluorescent protein (Ruc-GFP) allowing, in addition to oncolysis, diagnosis of 
metastatic disease and monitoring of treatment. 
162
 A phase I trial in patients with a 
heterogeneous group of advanced solid organ tumours has very recently completed; 
with the results of primary outcome analysis, as yet, unpublished. 
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1.8. IL10 and cancer 
 
1.8.1. IL10 
 
Interleukin-10 (IL10) was first described as a cytokine synthesis inhibitor factor 
secreted by murine T-helper 2 (Th2) cells, which suppressed cytokine production by T-
helper 1 (Th1) cells. 
163
  IL10 has broad anti-inflammatory properties through 
suppression of the antigen-presenting cell function and pro-inflammatory cytokine 
production of macrophages and dendritic cells. 
164
  This anti-inflammatory action has 
led to research to investigate the use of IL10 in the treatment of chronic inflammatory 
diseases, such as Crohn’s disease, rheumatoid arthritis and psoriasis. More recently a 
role for IL10 in cancer treatment has been researched with evidence of anti-tumour 
efficacy, 
157
 and suppression of angiogenesis. 
165-167
 This study will establish the effect 
of an IL10-expressing recombinant Lister strain vaccinia virus on a number of types of 
cancer in vitro and in vivo; and investigate the hypothesis that IL10 suppresses viral 
host clearance, thus enhancing anti-tumour potency. 
 
1.8.2. IL10 and IL10 receptor gene and protein structure  
 
The human IL10 gene is located on chromosome 1, encoding for 5 exons (5.1kb). 
168
 
Human IL10 is a homodimer, with each monomer consisting of 160 amino acids with a 
molecular mass of 18.5kDa 
169
. Murine and human IL10 exhibit 80% homology; and 
there are several viral homologues, with the EBV-derived BCRF1 being the most 
extensively studied. Additionally five human structurally related molecules have been 
discovered and are considered to belong to the IL10 family: IL19, IL20, IL22, IL24 
(mda-7) and IL26 (AK155). The elucidation of the function of these accessory IL10 
family members is incomplete. The x-ray crystal structure of IL10 (Figure 6.) shows 
two intertwining polypeptide chains, each consisting of six helices, arranged in a V-
shaped structure. 
168,170 
 
IL10 production has been demonstrated in various cell types including Th2 cells, 
monoctyes, B cells, eosinophils, mast cells and dendritic cells; however the major 
source appears to be macrophages. 
168
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Figure 6. Three-dimensional structure of human IL10. 
169
 
 
1.8.3. IL10 secretion, receptor and signalling 
 
The IL10 promoter is highly polymorphic and contains several transcription factor-
responsive elements, 
171
 that are stimulated by several endogenous and exogenous 
factors such as endotoxin (via Toll-like receptor 4, NF-κB-dependent), tumour necrosis 
factor (TNF)-α (via TNF receptor p55, NF-κB-dependent), catecholamines and cAMP-
elevating drugs. 
172-177
 Of particular significance is the role of the stress axis in affecting 
IL10 expression. 
169
 
 
 
Figure 7. IL10 receptor and signalling. 
178
 
IL10 activity is mediated through binding to a specific cell surface receptor (IL10R) 
which is expressed predominantly in immune cells (Figure 7.). IL10R expression has 
been shown to be increased by endotoxin, 
179
 and decreased by T cell stimulation, 
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glucocorticoids, vitamin D3 and calcipotriol. 
180,181
 IL10R is composed of α chain (or 
IL10R1) 
182
 and β chain (CRFB4 or IL10R2); 178 and is a member of the class II 
cytokine receptor (CRF2) family. CRF2 are transmembrane glycoproteins, with 
extracellular domains consisting of 210 amino acids with several conserved areas 
important for secondary structure. 
169
 IL10 and IL10R1/2 interaction causes 
transcription of hundreds of genes through activation of tyrosine kinases Jak1 and Tyk2, 
170
 and subsequent stimulation of STAT 1,3 and 5 transcription factors. 
183
 
 
 
1.8.4. IL10 function and immunology 
 
The human IL10 gene was first cloned from a T-cell clone that secreted IL10 and IFNγ 
amongst other cytokines. 
184
 Further research has demonstrated IL10 production by Th1 
cells in human and murine systems, 
164
 and has been shown to be required for murine 
immune regulation against Toxoplasma gondii and Leishmania major infections. 
185,186
 
This is suggestive of a regulatory role for IL10 and IFNγ in the equilibrium between 
pathogen clearance and persistence,
187,188
 – resulting in either chronic infection or 
immunopathology. In this immuno-regulatory role, IL10’s actions are generally 
considered immunosuppressive; with inhibition of macrophage and dendritic cell 
function, including production of pro-inflammatory cytokines, expression of co-
stimulators and  major histocompatibility complex (MHC) class II molecules. 
164
 This 
immunosuppressive function is supported by evidence from IL10-deficient mice, which 
develop colitis in the absence of a pathogenic stimulus,
189,190
 and sometimes fatal 
immunopathology in the presence of pathogens. 
164
  Therefore, IL10 acts to protect the 
host from an unrestrained immune system, but at high levels can prevent adequate 
pathogen clearance leading to chronic infection. Conversely it has also been 
demonstrated that IL10 can exert a pro-inflammatory role by activating humoural 
immune responses by promoting MHC class II B cell expression and inducing 
immunoglobulin production. 
182,191-194
 Additionally IL10 has been show to activate mast 
cells,
195,196
 CD8+ and NK cell action. 
197-200
 Intracellularly, IL10 inhibition of immune 
function is thought to be mediated through blocking nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB); which is a key regulator of the immune response 
to infection and is implicated in autoimmune/inflammatory diseases and cancer. 
201
 
Other anti-inflammatory mechanisms of IL10 include inhibition of interferon-induced 
gene transcription, 
170,202,203
 induction of the suppressor of cytokine synthesis (SOCS) – 
3, 
202
 and heme oxygenase-1 (HO-1). 
204
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1.8.5. IL10 applications to inflammatory diseases 
 
Given the anti-inflammatory actions of IL10, a number of studies have examined the 
effect of IL10 on the treatment of immune-mediated inflammatory diseases such as 
psoriasis, Crohn’s disease (CD) or rheumatoid arthritis (RA). Phase I and II trials have 
demonstrated efficacy of systemically administered recombinant IL10 in patients with 
psoriasis and CD; the results in RA were less convincing. 
205,206
 Later studies in larger 
blinded studies showed only limited beneficial effects. 
169
 
IL10 has also been investigated for its effects of CNS autoimmune inflammatory 
disease using an animal model of human multiple sclerosis - experimental autoimmune 
encephalomyelitis (EAE). It has been demonstrated that IL10 null mice are unable to 
recover from acute CNS inflammation, 
207-209
 and intracerebral administration of an 
IL10-expressing replication-deficient adenovirus (rAdV) rendered mice EAE-resistant. 
210
 
 
 
 
1.8.6. IL10 applications to cancer 
 
 
Growth of cancer cells depends on an appropriately tolerant tumour microenvironment, 
where the tumour escapes the host immune system. This achieved through a number of 
immunosuppressive mechanisms that subvert tumour recognition and rejection. Anti-
tumour responses depend on activation of cytotoxic CD8+ T cells, macrophages, NK 
cells and Th1-derived cytokines. 
211-213
 Moreover a number of tumours have 
demonstrated pronounced Th2 responses and suppressed CTL responses. A pro-tumour 
environment is further supported by Th2 cytokine driven macrophages. 
214,215
 IL10 is an 
important Th2 cytokine that inhibits macrophage antigen presenting capabilities and 
encourages tumour tolerance. 
170
 Furthermore, as a rationale for an immunosuppressive 
strategy to enhance viral oncolysis, the use of systemic immunosuppressive agents, such 
as cyclophosphamide, has been shown to enhance viral replication and hence anti-
tumour potency. 
216
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IL10 has been found to be expressed by a variety of malignant tumour cell types, 
including breast, colorectal and lung, 
164
 and is correlated with poor prognosis. It has 
also been shown that IL10 contributes to tumour survival by generating a 
microenvironment conducive to tumour growth and metastasis. 
217-220
 The majority of 
tumour-associated macrophages (TAMs) in solid tumours express higher levels of IL10 
and lower levels of IL12 and TNFα; 221-224 resulting in suppression of anti-tumour T cell 
responses. In addition to TAMs, DC are critical to the host cellular anti-tumour 
response. Increased numbers of IL10 producing DC and Tregs have been demonstrated 
within many human cancers. 
225-230
 IL10-producing Tregs suppress CD8+ T cells and 
DC maturation. 
 
Further evidence for the role of IL10 in tumour-associated immunosuppression comes 
from research using IL10 transgenics, IL10 knockouts and IL10 transfectants. For 
example, IL10 knockout mice are resistant to UV-induced skin cancer, which has been 
related to a potent Th1 response; not seen in wild-type mice. 
231
 However the effects of 
IL10 on tumour growth in vivo are conflicting in the literature; with some studies 
showing increased tumour growth, consistent with tumour immuno-tolerance; whilst 
some other studies show decreased tumour growth, suggesting immune system 
activation and tumour rejection. 
164
 A possible explanation for these contradictory 
findings relates to the actual level of IL10 expression; with the suggestion that low level 
IL10 expression causing immunosuppression and tumour progression, and high levels 
resulting in tumour regression. 
164
 Evidence for high-dose IL10 anti-tumour efficacy is 
far from unequivocal at this stage; however recombinant IL10 anti-tumour efficacy has 
been demonstrated in some animal models of immune-sensitive tumours.
232-234
 
 
The anti-tumour function of IL10 may also be dependent on non-immune mechanisms, 
such as inhibition of angiogenesis and elevation of levels of nitric oxide. IL10 has been 
shown to inhibit angiogenesis in various cancers, including melanoma, Burkitt’s 
lymphoma, prostate and ovarian cancer. 
165-167
 In prostate cancer cells this effect has be 
demonstrated to be mediated by the stimulation of tissue inhibitors of metalloproteases 
and inhibition of matrix metalloproteases. 
235
 Another anti-tumour mechanism of IL10 
is mediated through nitric oxide. Nitric oxide is known to have potent anti-tumour 
activity, 
169
 and IL10 gene transfer in murine mammary tumour cells was associated 
with increased expression and activity of the inducible isoform of nitric-oxide synthase 
(iNOS), resulting in elevated levels of nitric oxide in transfected cancer cells. 
236 
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1.8.7. IL10 application to viral gene therapy 
 
The anti-tumour effects of IL10 are thought to be mediated through the cells of the 
immune system, angiogenesis and nitric oxide. However, an indirect effect of IL10 on 
cancer, in the context of viral gene therapy, relates to the effect of IL10 on the virus, 
either as a vector delivering therapeutic transgenes or as an inherently cancer-killing 
(oncolytic) virus. Again the T cell response is vital to clearing viruses, as it is for 
mounting a powerful anti-tumour response. Evidence from IL10-knockout mice 
infected with mutants of lymphocytic choriomeningitis virus (LCMV) demonstrated 
more rapid virus elimination and development of anti-viral memory T cells. 
237
 
Additionally administration of IL10 antibody in mice with wild-type IL10 gene restored 
T cell function and allowed virus elimination. 
237
 However, there is some conflicting 
evidence in the literature where IL10 was given after non-replicating vaccinia virus 
administration to mice bearing CT26 pulmonary metastases. 
59
 Although a reduction in 
pulmonary metastases was observed in mice receiving adjuvant IL10 12 hours after the 
virus was administered. An immunosuppressive mechanism was not seen with enhanced 
cytotoxic lymphocyte activity and lower viral titres from the lungs in the IL10 group 
compared to the no-IL10 groups, and higher titres from ovaries in the no-IL10 group. 
59
 
Further research using more sensitive techniques is required to definitively establish the 
effect of IL10 on viral persistence within the tumour. 
48 
 
1.9. Aims of this study 
 
1. To compare the anti-tumour potency and viral replication of Lister and WR strain 
tumour selective mutants in vitro. 
2. To assess the relative tumour selectivity of viral replication in cancer and normal 
cells of the Lister and WR strain vaccinia viruses in vitro. 
3. To establish the in vivo anti-tumour efficacy in nude and immunocompetent models 
of murine and human cancer. 
4. To determine the biodistribution of Lister and WR strain vaccinia viruses in nude 
and immunocompetent mouse models of murine and human cancer. 
5. To assess the effect of IL10 transgene expression on in vitro anti-tumour potency, 
viral replication, in vivo anti-tumour potency and biodistribution. 
6. To investigate mechanisms of action of IL10 for cancer treatment by examining 
changes in cytokine profiles. 
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2. Materials and Methods 
 
2.1. Cell lines  
All cell lines were maintained in their respective media at 37C in air supplemented 
with 5% carbon dioxide (CO2). Repeated experiments were performed using cells of 
similar passage. All cells were grown in media containing 0.06μg/l penicillin and 
0.1μg/l streptomycin obtained from Cancer Research UK Central Cell Services (CRUK 
CCS, Clare Hall, Hertfordshire, UK) unless otherwise stated and were regularly tested 
for mycoplasma. 
 
2.1.1. Human cell lines 
2.1.1.1. HNSCC 
The HNSCC cell lines SCC4 (tongue) and SCC25 (tongue) were obtained from the 
CRUK CCS and were maintained in 1:1 Dulbecco’s modified Eagle’s medium 
(DMEM) and Ham’s F12 supplemented with 10% heat-inactivated foetal calf serum 
(FCS) and 400ng/ml hydrocortisone (Sigma-Aldrich, MO, USA). The HNSCC cell lines 
TR126 (tongue) and TR138 (larynx) were obtained from the CRUK CCS and were 
maintained in DMEM and Ham’s F12 respectively, each with 10% FCS. FaDu was 
obtained from American Type Culture Collection (ATCC; VA, USA) and maintained in 
Earle’s minimal essential medium (EMEM) with 10% FCS. 
2.1.1.2. Pancreatic carcinoma 
The pancreatic carcinoma cell lines SUIT2, MiaPaCa2, PANC1, PT45 and Capan2 were 
obtained from CRUK CCS and maintained in DMEM with 10% FCS. 
2.1.1.3. Colorectal carcinoma 
The colorectal carcinoma cell lines HT29, HCT116, and SW620 were obtained from 
ATCC and maintained in DMEM with 10% FCS. 
2.1.1.4. Gastric carcinoma 
MKN45 gastric adenocarcinomas cell line was kindly provided by Professor Stephen 
Mather (Barts Cancer Institute, Queen Mary University of London, UK) and maintained 
in DMEM with 10% FCS. 
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2.1.1.5. Ovarian carcinoma 
The ovarian carcinoma cell line A2780 was kindly provided by Professor I. McNeish 
(Barts Cancer Institute, Queen Mary University of London, UK) and maintained in 
DMEM with 10% FCS. 
2.1.1.6. Primary cell line 
Normal human bronchial epithelial cells (NHBE) were obtained from Cambrex 
(Cambridge, UK) and maintained in Bronchial Epithelial Growth Medium (BEGM) 
(Cambrex). Cambrex obtained these cells from their patient donation programme 
following the acquisition of informed consent for use of cells in research. 
 
2.1.2. Murine cell lines 
The HNSCC cell line SCCVII was kindly provided by Dr. Osam Mazda (Department of 
Microbiology, Kyoto Prefectural University of Medicine, Japan) and maintained in 
DMEM supplemented with 10% FCS. The pancreatic carcinoma cell line PANC02 was 
obtained from the ATCC and maintained in DMEM with 10% FCS. The colorectal 
carcinoma cell lines CT26 and CMT93 was obtained from CRUK CSS and maintained 
in DMEM supplemented with 10% FCS. MOSEC ovarian carcinoma cell line was 
kindly provided by Professor I. McNeish (Barts Cancer Institute, Queen Mary 
University of London, UK) and maintained in DMEM with 1% Insulin-Transferrin-
Selenium supplement-G (GIBCO, Invitrogen) and 3% FCS.  
 
2.1.3. Monkey cell line 
CV1, the immortalised non-transformed African Green Monkey kidney cell line was 
obtained from ATCC and cultured in DMEM with 10% FCS. 
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2.2. Viruses 
2.2.1. Vaccinia viruses 
The highly attenuated Lister vaccine strain of vaccinia virus (VVLister) and all 
recombinant vaccinia viruses (VVIL10 and VVL15) were constructed and kindly 
provided by Professor Istvan Fodor (Loma Linda University Campus, CA, USA).  
 
2.2.2. Recombinant vaccinia virus construction 
Istvan Fodor used the highly attenuated Lister vaccine strain of vaccinia virus 
(VVLister) as the backbone for production of other engineered viruses. Vaccinia vector 
construction was performed by Istvan Fodor using an in vitro intracellular 
recombination technique previously described. 
238
 
 
VVL15 was constructed by the insertion of the lacZ reporter and the firefly luciferase 
genes into the TK region of VVLister under the control of the synthetic early/late and 
p7.5 promoters respectively. 
239
 Expression of firefly luciferase enables real-time 
luminescence imaging of viral location in vivo following the addition of the substrate D-
Luciferin. 
 
VVIL10 was constructed by the insertion of the LacZ reporter and murine IL10 genes 
into the TK region of VVLister under the control of the p7.5 and synthetic early/late 
promoters respectively. 
240
 
 
WR, TK deletion, and WRDD, double deletion (TK and VGF) viruses, were kindly 
provided by Dr Steve Thorne (University of Pittsburgh, Pittsburgh, USA) and Dr A. 
McCart (University of Toronto, Toronto, Canada) respectively. 
83,241
 
 
2.2.3. Vaccinia virus mass production 
CV1 cells were cultured until 90% confluent and infected with 20μl of purified virus to 
produce a primary expansion. This was harvested when significant cytopathic effect 
(CPE) was observed by cell detachment at 48-72 hours. A CF10 viral production 
factory (Nunc, NY, USA) was seeded with four 175cm
2
 flasks of CV1 cells at 90% 
confluence. After 72 hours, this was infected with the primary expansion in DMEM 
with 2% FCS until significant CPE was observed a further 72-96 hours later. 
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Cells harvested from the CF-10 were centrifuged in Sorvall centrifuge bottles (Sorvall, 
MA, USA) at 3,500 revolutions per minute (rpm) for 15 minutes at 4C. The cell pellet 
in each bottle was re-suspended in 30ml phosphate-buffered saline (PBS), transferred to 
a 50ml tube and centrifuged in the same manner. The supernatant was again discarded 
and each pellet of cells re-suspended in 7ml of 10mM Tris-HCl pH 9.0, then combined. 
Cell membranes were disrupted by 3 cycles of freezing in liquid nitrogen and thawing 
in a 37C water bath, prior to homogenisation by 60 strokes with a Dounce 
homogeniser. 
 
Cells were centrifuged at 900 rpm for 5 minutes at 4C and the supernatant removed 
and saved. The cell pellet was re-suspended in 3ml of 10mM Tris-HCl pH 9.0 prior to a 
second centrifugation. Both supernatants were combined and the pellet discarded. This 
was sonicated in an ultrasound ice bath for 20 seconds (Grant Instruments, 
Hertfordshire, England) and diluted to 30ml with 10mM Tris-HCl pH 9.0. 7.5ml was 
carefully layered onto 17ml of 36% sucrose (w/v) 10mM Tris-HCl pH 9.0 in each of 
four SW17 Beckman ultracentrifuge tubes (Beckman Coulter UK Ltd, Bucks, UK). 
After careful balancing by weight, these tubes were centrifuged at 13,500 rpm for 80 
minutes at 4C.  
 
Each supernatant was discarded and purified viral pellets re-suspended in 1ml of 1mM 
Tris-HCl pH 9.0 prior to combination and storage at -80C. The viral titre was 
determined by TCID50 plaque assay (See 2.4.2) 
 
2.3. Cell proliferation MTS assay of vaccinia virus in tumour 
cell lines. 
The potency of all viruses against a panel of cell lines was determined by CellTiter 96
®
 
AQueous Non-Radioactive Cell Proliferation (MTS) assay. Cells were infected with 9 
serial dilutions of virus in 96 well plates and the proportion of cells alive after 6 days at 
each viral concentration compared to a non-infected control following the addition of 
MTS reagents. The assay measures cell survival by dehydrogenase enzyme activity 
found in metabolically active cells, which reduces MTS into formazan in proportion to 
the number of living cells present. 
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Cells were cultured in 90l of media with 5% FCS in 96-well plates at a density of 
between 1x10
3
 and 1x10
4
 cells per well, depending on the rate of cell growth, to ensure 
that mock-infected wells were nearly confluent 6 days after infection. Plates were 
incubated at 37C and 16-18 hours later, infected in sextuplicate with 10l of 9 serial 
dilutions of viruses (range optimised for each cell line; typically MOI 100 or 1000 
PFU/ml) diluted in media with 5% FCS or mock-infected with media with 5% FCS 
alone. Six days following infection, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) was added to PMS 
(phenazine methosulfate; Promega, WI, USA) according to the manufacturer’s 
instructions in a ratio of 20MTS: 1PMS. 20l was added to each well and plates 
incubated for 1 to 3 hours. Cell viability was determined by measuring the absorbance 
or optical density (OD) at 490nm using an Opsys MR 96-well plate absorbance reader 
(Dynex, VA, USA). Cell viability was determined in infected cells in comparison to 
mock-infected cells (positive control) after correction for absorbance due to the media 
alone (negative control). All OD values in positive controls were greater than 1. The 
concentration of virus required to kill 50% of cells (half maximal effective 
concentration or EC50) was then calculated for each cell line (Section 2.15.1) and a 
dose-response curve created by non-linear regression using Prism
®
 (GraphPad 
Software, CA, USA). Experiments were repeated in sextuplicate. 
 
2.4. Viral replication of vaccinia virus in tumour and normal 
human bronchial epithelial cell lines. 
 
2.4.1. Viral Infection 
Cells were seeded in 3 wells of a 6-well plate in 2ml of media with 10% FCS at a 
density of between 2 and 4x10
5
 cells per well depending on the rate of cell growth. One 
plate was seeded for each virus at each time point (24, 48, 72 and 96 hours) with a 
further control plate. All plates were incubated overnight at 37C in air supplemented 
with 5% CO2.  
 
16 to 18 hours later, cells from the control plate were harvested, counted and the mean 
number of cells per well used to determine the amount of virus required to infect the 
other plates. Plates were infected by 2ml of media with 2% FCS containing vaccinia 
virus at a multiplicity of infection (MOI) of 1 PFU/cell. Cells and supernatant were 
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harvested together by scraping from each individual well to give samples in triplicate at 
every time point. Cell lysates were created by three cycles of freezing samples in liquid 
nitrogen and thawing in a 37C water bath. 
 
2.4.2. TCID50 viral titration assay 
The titres of purified viruses and the replication of viruses in cell lines were determined 
by measuring the 50% tissue culture infective dose (TCID50) of samples titrated onto 
indicator cells. 
 
1x10
4
 CV1 cells were seeded in 200μl of DMEM with 10% FCS into 96 well plates and 
incubated at 37C in air supplemented with 5%CO2. 16 to 18 hours later, plates were 
infected with purified virus or viral burst assay sample lysates diluted to 1x10
-5
 or 1x10
-
3
 respectively in DMEM supplemented with 10% FCS. 20μl was added with a multi-tip 
pipette to all 12 wells of the top row and mixed. Following a change of pipette tips, 
serial 1:10 dilutions were made to the next 7 consecutive rows of CV1 cells up to a 
dilution of 1x10
-11
 for purified virus or 1x10
-9
 for burst assay sample lysates. Row H 
was left uninfected as a negative control. 
 
The CPE of viruses on CV1 cells were determined by light microscopy 10 days after 
infection. Each well was scored 0 (no CPE) or 1 (any CPE) to make a score for each 
row out of 12. These were used to calculate the TCID50 using the established Reed-
Muench accumulate method (Section 2.15.2). TCID50 plates were performed in 
duplicate for each sample, with three samples at each time-point. Purified viral titres 
were converted to PFU/ml and viral burst titres to PFU/cell based on the number of cells 
present at viral infection. 
 
2.5. Anti-tumour efficacy of vaccinia virus in vivo. 
In vivo studies of viral efficacy in mouse tumour models were all designed by JH and 
performed at the Biological Services Unit at Clare Hall laboratories (Hertfordshire, UK) 
with the assistance of Gary Martin and Sandra Peak, and at the Sino-British Research 
Centre, Zhengzhou University, China with the assistance of Jiwei Wang, Donling Gao 
and Penju Wang, and the Biological Services Unit at The Barts Cancer Institute 
(London, UK). Mice at Clare Hall and The Barts Cancer Institute were kept in 
accordance with the UK co-ordinating committee on cancer research guidelines and the 
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Animals (Scientific Procedures) Act 1986 (Home Office, London). Mice at the Chinese 
Academy of Sciences were kept in accordance with the Regulations on the Management 
of Experimental Animals (Government of People’s Republic of China) and purchased 
from approved suppliers. The general health of mice was assessed daily and animals 
killed if judged to be terminally sick, tumour size reached 1.44cm
2
 or had been present 
for 3 months (See 2.5.3). Tumour volumes were estimated using (volume = (width x 
length
2
 x )/6) twice weekly from the start of treatment until the sacrifice or death of the 
first mouse in each treatment group.  
 
Anti-tumour efficacy was measured by the changes in tumour volumes over time until 
the death or sacrifice of the first mouse in each group, and the length of survival of each 
mouse until the tumour volume reached 1.44cm
2
 or tumour ulceration occurred.  
Kaplan-Meier curves (indicating percentage of animals without tumour progression) 
were created. Statistical analysis using log rank testing compared different viral 
treatments and PBS treated mice. 
 
2.5.1. Efficacy of IT vaccinia virus mutants against FaDu human 
HNSCC cancer xenograft model in nude mice.  
1x10
6 
FaDu cells were implanted subcutaneously into the right flank of 30 BALB/c 
nu/nu female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, tumour volumes were measured and mice were regrouped into 10 mice per 
group to ensure even spread of tumour sizes. Each group received 50μl IT injections of 
1x10
7
 PFU VVL15, WRDD or PBS on days 1, 3 and 5. Tumours were measured twice a 
week from first appearance until the mice were sacrificed.  
  
2.5.2. Efficacy of IT vaccinia virus mutants against PT45 human 
pancreatic cancer xenograft model in nude mice. 
5x10
6 
PT45 cells were implanted subcutaneously into the right flank of 40 BALB/c 
nu/nu female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, tumour volumes were measured and mice were regrouped into 10 mice per 
group to ensure even spread of tumour sizes. Each group received 50μl IT injections of 
1x10
7
 PFU VVL15, VVIL10, WRDD or PBS on days 1, 3 and 5. Tumours were 
measured twice a week from first appearance until the mice were sacrificed.  
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2.5.3. Efficacy of IT vaccinia virus mutants against CT26 murine 
tumour model in immunocompetent mice. 
1x10
6 
CT26 cells were implanted subcutaneously into the right flank of 40 BALB/c 
immunocompetent female 4-5 week old mice (Harlan UK Ltd). When tumours reached 
0.4-0.5cm in diameter, mice were regrouped into 10 mice per group to ensure even 
spread of tumour sizes. Each group received 50μl IT injections of 1x108 PFU VVL15, 
VVIL10, WRDD or PBS on days 1, 3 and 5. Tumours were measured twice a week 
from first appearance until the mice were sacrificed. 
 
2.5.4. Efficacy of IT vaccinia virus mutants against CMT93 murine 
colorectal tumour model in nude mice. 
5x10
6 
CMT93 cells were implanted subcutaneously into the right flank of 40 ICRF 
nu/nu female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, tumour volumes were measured and mice were regrouped into 10 mice per 
group to ensure even spread of tumour sizes. Each group received 50μl IT injections of 
1x10
7
 PFU VVL15, VVIL10, WRDD or PBS on days 1, 3 and 5. Tumours were 
measured twice a week from first appearance until the mice were sacrificed.  
 
2.5.5. Efficacy of IT vaccinia virus mutants (3 x injections) against 
CMT93 murine tumour model in immunocompetent mice. 
5x10
6 
CMT93 cells were implanted subcutaneously into the right flank of 40 C57BL/6 
immunocompetent mice female 4-5 week old mice (Harlan UK Ltd). When tumours 
reached 0.4-0.5cm in diameter, tumour volumes were measured and mice were 
regrouped into 10 mice per group to ensure even spread of tumour sizes. Each group 
received 50μl IT injections of 1x108 PFU VVL15, VVIL10, WRDD or PBS on days 1, 
3 and 5. Tumours were measured twice a week from first appearance until the mice 
were sacrificed.  
 
2.5.6. Efficacy of IT vaccinia virus mutants (5 x injections) against 
CMT93 murine tumour model in immunocompetent mice. 
5x10
6 
CMT93 cells were implanted subcutaneously into the right flank of 40 C57BL/6 
immunocompetent mice female 4-5 week old mice (Harlan UK Ltd). When tumours 
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reached 0.4-0.5cm in diameter, tumour volumes were measured and mice were 
regrouped into 10 mice per group to ensure even spread of tumour sizes. Each group 
received 50μl IT injections of 1x108 PFU VVL15, VVIL10, WRDD or PBS on days 1, 
2, 3, 4, 5. Tumours were measured twice a week from first appearance until the mice 
were sacrificed.  
 
 
2.6. Expression of IL10 in vitro by ELISA. 
2 x 10
5
 CMT93/ PT45 and 1 x 10
5
 SCC7 cells were seeded in 3 wells of a 6-well plate 
with 2ml of 10% DMEM. One plate was seeded for each virus (VVL15, WRDD, 
VVIL10) at each time point (6 and 24 hours) with 2 control plates representing mock 
infections at the same time points. All plates were incubated overnight at 37C in air 
supplemented with 5%CO2.  
 
16 to 18 hours later, cells from the control plate were harvested, counted and the mean 
number of cells per well used to determine the amount of virus required to infect the 
other plates. Plates were infected by 2ml of DMEM with 2% FCS containing vaccinia 
virus at a multiplicity of infection (MOI) of 5 PFU/cell. Cells and supernatant were 
harvested together by scraping from each individual well to give samples in triplicate at 
every time point. Cell lysates were created by three cycles of freezing samples in liquid 
nitrogen and thawing in a 37C water bath. 
 
IL10 concentration in the lysates was determined using the Quantikine Mouse IL10 kit 
(R&D Systems, Abingdon, UK) according to the manufacturer’s instructions. Cell 
lysate samples were prepared into undiluted, ½ diluted, 1/5 diluted, 1/10 and 1/20 
diluted triplicates with the provided calibrator diluents. 
 
The OD of each well was determined using a microplate reader at 450 nm and OD 
values at 540 nm subtracted to correct for optical plate imperfections. Mean OD values 
were used to create a standard curve, which was used to obtain IL10 levels for each 
sample. 
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2.7. Biodistribution of vaccinia virus in ICRF nude mice 
bearing murine CMT93 flank tumours. 
5 x 10
6 
CMT93 cells were implanted subcutaneously into the right flank of 60 ICRF 
nude female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, mice were regrouped into 12 mice per group to ensure even spread of tumour 
sizes. Each group received a single 100μl IV tail vein injections of 1x107 PFU VVL15, 
WRDD, or PBS. On days 2, 6, 8 and 12 four mice were sacrificed from each group and 
the tumours and other tissues (ovary, bone marrow, liver, lungs, brain and spleen) were 
harvested and snap frozen in liquid nitrogen for further processing. 
 
2.8. Biodistribution of vaccinia virus in C57BL/6 
immunocompetent mice bearing murine CMT93 flank 
tumours. 
5 x 10
6 
CMT93 cells were implanted subcutaneously into the right flank of 36 C57BL/6 
female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, mice were regrouped into 9 mice per group to ensure even spread of tumour 
sizes. Each group received 100μl IV tail vein injections of 2x108 PFU VVL15, VVIL10, 
WRDD or PBS. On days 4, 8 and 12 three mice were sacrificed from each group and 
the tumours and other tissues (ovary, bone marrow, liver, lungs, brain, blood and 
spleen) were harvested and snap-frozen in liquid nitrogen for further processing. Blood 
collected in serum separator tubes, allowed to stand for 10 minutes to clot, then 
centrifuged at 1100rpm and the serum pipetted off and snap frozen in liquid nitrogen for 
further processing. 
 
2.9. Biological time-points of vaccinia virus in C57BL/6 
immunocompetent mice bearing murine CMT93 flank 
tumours. 
5 x 10
6 
CMT93 cells were implanted subcutaneously into the right flank of 48 C57BL/6 
female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, mice were regrouped into 12 mice per group to ensure even spread of tumour 
sizes. Each group received 50μl IT injections of 1x108 PFU VVL15, VVIL10, WRDD 
or PBS on days 1, 3, 5. On days 5, 10, 15 and 20 three mice were sacrificed from each 
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group, and the tumours and ovaries were harvested and snap-frozen in liquid nitrogen 
for further processing. Blood samples were collected in heparinised tubes prior to 
freezing. 
 
2.10. Biodistribution of vaccinia virus in ICRF nude mice 
bearing human PT45 flank tumours. 
5 x 10
6 
PT45 cells were implanted subcutaneously into the right flank of 36 ICRF nude 
female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, mice were regrouped into 9 mice per group to ensure even spread of tumour 
sizes. Each group received a single 100μl IV tail vein injections of 1x107 PFU WRDD, 
VVL15, VVIL10 or PBS. On days 8, 12 and 18 four mice were sacrificed from each 
group, and the tumours were harvested and snap-frozen in liquid nitrogen for further 
processing. Blood samples were collected in heparinised tubes prior to freezing. 
 
2.11. Biological time-points of vaccinia virus mutants in ICRF 
nude mice bearing human PT45 flank tumours. 
5 x 10
6 
PT45 cells were implanted subcutaneously into the right flank of 36 ICRF nude 
female 4-5 week old mice (Harlan UK Ltd). When tumours reached 0.4-0.5cm in 
diameter, mice were regrouped into 9 mice per group to ensure even spread of tumour 
sizes. Each group received 50μl IT injections of 1x107 PFU VVL15, VVIL10, WRDD 
or PBS on days 1, 3, 5.  On days 7, 12 and 20 four mice were sacrificed from each 
group, and the tumours were harvested and snap frozen in liquid nitrogen for further 
processing. Blood samples were collected in heparinised tubes prior to freezing. 
 
2.12. Histology and immunohistochemistry for vaccinia virus 
coat protein. 
All histology and IHC was kindly performed by Mohammed Ikram and Keyur Trivedi 
(Pathology department, Barts Cancer Institute, Queen Mary University of London, UK) 
and all slides reviewed by JH and YW. The biodistribution of VVL15 and WRDD in 
vivo was determined by vaccinia coat protein staining of tumours and organs (optimised 
for frozen sections of tumours and paraffin sections of organs) of vaccinia-treated 
animals compared to PBS-treated controls.  
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2.12.1. Sample processing 
4μm frozen sections were cut from blocks of tumours from all experiments using a 
Leica CM1900 cryostat (Leica Microsystems, Wetzlar, Germany). All other organs 
were fixed in 10% formaldehyde and then processed, paraffin embedded and cut into 
4μm sections using Leica EG1160. Slides were stained with hematoxylin and eosin 
(H&E) according to standard protocols using a Leica autostainer XL. Further sections 
were cut for IHC, which was performed using the Ventana
®
 Discovery staining module 
(Ventana, Tucson, USA). This system used biotin-free secondary antibodies, which 
were already conjugated to streptavidin-HRP. These were visualised with a hydrogen 
peroxide (H2O2) substrate and 3,3’-diaminobenzidine tetrahydrochloride (DAB) 
chromogen, which produced a dark brown substrate on light microscopy.  
 
2.12.2. Optimisation of IHC in frozen sections 
Optimisation of vaccinia coat protein primary antibody (MorphoSys UK Ltd, Bath, UK) 
for use in frozen sections was performed by IHC on positive controls at a range of 
antibody dilutions. Primary antibody was applied to slides for 1 hour and then washed 
before Omnimap anti-rabbit secondary antibodies were applied to the slides for 16 
minutes. Slides were washed, visualised with DAB and H2O2 and reviewed by JH and 
YW. Primary antibody dilutions that produced strong signals and weak background 
were chosen and validated on negative and positive controls for use on all further slides 
( 1:2000). 
 
2.12.3. Optimisation of IHC in paraffin embedded sections 
Optimisation of vaccinia coat protein IHC in paraffin sections was performed in stages. 
Slides were deparaffinised using EZ Prep (Ventana) at 75C for 8 minutes. A range of 
reagents were tried in order to break the covalent bonds between the aldehyde and 
amino groups that form when tissues are formalin-fixed. Trypsin resulted in high 
background activity; therefore slides were heated to 95C for 8 minutes in the presence 
of conditioning solution 1 (CC1; Tris-EDTA based buffer), CC2 (citrate based buffer) 
or protease 1 (All Ventana). CC1 resulted in the least background. Various dilutions of 
the primary antibody were tried with Omnimap anti-Rabbit HRP secondary antibody. 
The least background was seen after a 1:200 dilution of primary antibody. The protocol 
was finalised with washes after every stage: 
1. Deparaffinisation with EZ Prep at 75C for 8 minutes  
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2. CC1 at 95C for 8 minutes 
3. 1:200 anti-vaccinia virus antibody for 60 minutes at 37C 
4. Omnimap anti-Rabbit HRP for 16 minutes 
5. DAB and H2O2 for 8 minutes 
6. Haematoxylin (nucleus) counterstain for 2 minutes 
7. Bluing agent (counterstaining background) for 2 minutes 
 
2.13. Homogenisation of animal tissues for in vitro studies. 
Mouse tissues from in vivo experiments for use in viral titre determination (qRT-PCR 
and TCID50) and ELISA were processed according to the following protocol. Mouse 
tissue was weighed and any hair was removed from the sample using a scalpel under 
sterile conditions. The tissue was homogenised using an Omni TissueMaster hand-held 
homogeniser to a total volume of 2 ml in DMEM, then frozen and thawed three times in 
liquid nitrogen and in a water bath at 37 ºC. 100 μl of the resultant lysate was used for 
DNA extraction using the DNeasy 96 blood and tissue kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s instructions, and eluted in 100 μl of Buffer AE. DNA 
concentration was determined using the NanoDrop ND-1000 Spectrophotometer 
(Nanodrop Technologies, Delaware, USA) and a fixed amount of DNA was used for 
quantitative real-time polymerase chain reaction (qRT-PCR) (see 2.14). DNA was 
accepted as adequately pure where the ratio of absorbance at 260 and 280nm was ~1.8. 
DNA copies were against total DNA and the results are displayed as arbitrary units. The 
results are displayed as PFU/ml/g, normalised against the weight of the tissue sample. 
 
2.14. Vaccinia virus DNA quantification in mouse tissues by 
qRT-PCR. 
2.14.1 Primers and probes 
Primers and probes for VVLister were designed manually by James Tysome using 
Primer Express
®
 v3.0 software (Applied Biosystems, New Jersey, USA) and 
constructed by Sigma-Aldrich and Applied Biosystems respectively. Briefly, the 
vaccinia genome was imported from NCRI Corenucleotide database and the vaccinia 
late gene transcription factor-1 
242
 (VLTF-1) sequences identified from their open 
reading frames as List107 (103385 to 105298bp) and List082 (77898 to 78680bp) 
243
. 
Primers and probes (Table 1.) were chosen for optimum PCR efficiency with minimal 
62 
 
secondary structures with probe length 17-20bp, Tm (Melting temperature) 68-70C, 
GC content 40-60% with repeats minimised. Primers were chosen to be 20-26bp in 
length either side of the probe with Tm 58-60C and GC content 40-60%.  
 
Table 1. Primers and probes used for qRT-PCR. 
S = sense; AS = antisense 
Gene Primer or 
Probe 
Sequence 
VVLister 
VLTF-1 
Probe ATTTTAGAACAGAAATACCC 
Primers S 5’-AACCATAGAAGCCAACGAATCC 
AS 5’-TGAGACATACAAGGGTGGTGAAGT 
 
2.14.2. Quantitative Real-Time PCR (qRT-PCR) 
Samples, control (RNAse free water) and nine 10-fold serial dilutions of standards 
(5x10
8
 to 5 viral genome copies diluted in 5μl RNAse free water) were tested in 
triplicate in each plate by quantitative real-time polymerase chain reaction (qRT-PCR). 
A 25μl reaction volume consisted of 5μl sample or standard and 20μl of Master mix 
(0.9μM forward primer, 0.9μM reverse primer, 0.2μM probe in TaqMan® Universal 
PCR Master Mix). Reactions were performed in MicroAmp optical 96-well reaction 
plates sealed with optical adhesive covers and amplified using the 7500 Real-time PCR 
System (1 cycle of 48C for 30min, 95C for 10min then 40 cycles of 95C for 15s, 
60C for 1min). Cycle thresholds (CT) were determined using 7500 System SBS 
software (All Applied Biosystems, New Jersey, USA). 
 
Standard and sample triplicates were accepted for analysis where their standard 
deviation was <0.3. Standard curves were created using mean cycle thresholds in 
Prism® and sample genome copy number determined accordingly. Standard curves 
were accepted as valid where R
2
  0.99 with a slope of –3.30 to-3.32. Results were 
corrected for weight for harvested tumours and organs, and expressed in arbitrary units. 
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2.15. Quantification of vaccinia virus in tumour and organ 
homogenates using TCID50 (see 2.4.2 TCID50 viral titration 
assay). 
Vaccinia virus titration of in vivo homogenised mouse tumour and organ samples using 
a TCID50 technique as previously described (see 2.4.2 TCID50 viral titration assay). As 
with the in vitro samples, 20µl of homogenised tissue was added to the first row of 
seeded CV1 cells and following a change of pipette tips, serial 1:10 dilutions were made 
to the next 7 consecutive rows. Viral titres were corrected for the initial weight of the 
sample. 
 
2.16. Effect of Recombinant IL10 alone, and in conjunction 
with VVL15 compared to VVIL10 on cell proliferation as 
measured by MTS assay. 
The effect of recombinant murine unconjugated IL10 (R&D Systems, Abingdon, UK) 
on tissue culture cell proliferation was investigated. Firstly recombinant IL10 was 
applied on its own to CMT93 cells and a cytopathic response was investigated. As per 
previous MTS cell proliferation protocol (2.3 Cell proliferation (MTS) assay) 5000 
CMT93 cells were seeded in 90l of media with 5% FCS in 96-well plates. The 10µl 
aliquot of 9 serial dilutions in media with 5% FCS recombinant IL10 (1x10
6
pg/ml) was 
applied; resulting in a maximum initial concentration of 1x10
5
pg/ml. Following three 
days of incubation under standard conditions, the plates were read as previously 
described. 
 
To assess the effect of recombinant IL10 on VVL15 in vitro cytotoxicity, the previously 
described cell proliferation (MTS) assay was further adjusted. CMT93 cells were seeded 
in 90µl of media with 5% FCS in 96-well plates at a density of 5000 cells per well. 16-
18 hours later the cells were infected with VVL15 and VVIL10 viruses (MOI=1000 
PFU/ml). Immediately prior to the virus application 10µl of media was removed from 
half the VVL15 infected plates and replaced with 10µl of recombinant IL10 
(1x10
6
pg/ml) in 5% FCS media (i.e. no recombinant IL10 serial dilution). 10µl of 
serially diluted viruses were applied as previously described; yielding the following 
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experimental combinations: VVL15 alone, VVIL10 alone, and VVL15 + recombinant 
IL10. The plates were read as previously described at 3 days post-infection. 
 
2.17. Assessment of pro-inflammatory cytokines in CMT93 
tissue culture supernatants following infection with different 
vaccinia virus mutants. 
CMT93 cells were seeded and infected with vaccinia virus as previously described (see 
2.4. Viral replication of vaccinia virus mutants in solid tumour and normal human 
bronchial epithelial cell lines). Cytokine concentration was determined for several pro-
inflammatory cytokines using a Meso Scale Discovery multi-spot assay system mouse 
pro-inflammatory 7-plex ultra-sensitive kit (MSD Gaithersburg, Maryland, USA). The 
manufacturer’s instructions were followed and a series 1:5 dilutions were used, with 
samples tested in triplicate. 
 
Further testing of selected cytokines (IL10, IL12 and IFNγ) was conducted using 
Quantikine Mouse IL10/IL12/IFNγ kits (R&D Systems, Abingdon, UK) according to 
the manufacturer’s instructions. Undiluted, 1:5 and 1:20 dilutions were used. 
Experiments were repeated twice in triplicate. 
 
2.18. Assessment of pro-inflammatory cytokines in 
immunocompetent mouse CMT93 flank tumours and serum 
following IT treatment with different vaccinia virus mutants. 
Tumour and serum samples were generated and processed as previously described (see 
2.9 Biological time points of Vaccinia virus mutants in C57BL/6 immunocompetent 
mice bearing murine CMT93 flank tumours; 2.10. Homogenisation of animal tissues for 
in vitro studies). Cytokine concentration was determined for several pro-inflammatory 
cytokines using a Meso Scale Discovery multi-spot assay system mouse pro-
inflammatory 7-plex ultra-sensitive kit (MSD Gaithersburg, Maryland, USA). The 
manufacturer’s instructions were followed and 1:2 dilutions were used, with samples 
tested in triplicate. 
 
Further testing of selected cytokines (IL10, IL12 and IFNγ) was conducted using 
Quantikine Mouse IL10/IL12/IFNγ kits (R&D Systems, Abingdon, UK) according to 
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the manufacturer’s instructions. Undiluted, 1:5 and 1:20 dilutions were used. 
Experiments were repeated twice in triplicate. 
 
2.19. Analysis of tumour homogenate and serum IL10 
concentrations in nude mice bearing PT45 flank tumours 
following IT vaccinia virus treatment. 
Biological specimens were generated and processed as previously described (see 2.11. 
Biological time points of Vaccinia virus mutants in ICRF nude mice bearing human 
PT45 flank tumours; 2.10. Homogenisation of animal tissues for in vitro studies). IL10 
concentrations were determined using a Quantikine Mouse IL10 kit (R&D Systems, 
Abingdon, UK) according to the manufacturer’s instructions. Samples were diluted 1:2 
and 1:20. Experiments were repeated twice in triplicate. 
 
2.20. Data handling and statistical analysis 
 
2.20.1. EC50 and variable slope non-linear regression 
EC50 = ((X where Y=top) – (X where Y= bottom))*0.5 
Y= Bottom +   ____(Top-Bottom)____ 
(1+10
((LogEC50-X)*HillSlope)
) 
X = log[virus] ;Y =  %cells alive; Hillslope = steepness of curve 
Top/Bottom = Maximum/Minimum Y value (or cell death) 
 
2.20.2. TCID50 
The Reed-Muench method of TCID50 calculation is based on the adding the 
proportionate distance between CPE scores of rows above and below 6 out of 12 to the 
log of the viral dilution where CPE is 6 or less. Viral dilutions range from 10
-5
 to 10
-11
 
for purified virus and 10
-3
 to 10
-9
 for viral replication samples.  
 
log TCID50 = log (viral dilu
n
 at row above 50% CPE) - (% CPE next above  50%) - 50%      
                          (% CPE next above 50%) - (% CPE next below or equal to 50%) 
 
This is converted to PFU/ml for purified viral titres:  
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Since volume of sample inoculated into the first row = 0.02ml 
TCID50/ml = (1/ TCID50)*(1/0.02) 
TCID50 PFU/ml = TCID50/ml*0.69  
This is then converted into PFU/cell for viral replication titres. 
TCID50 (PFU/cell) = ____TCID50 PFU/ml___ 
number of cells at infection 
 
2.20.3. Statistical analysis 
Unpaired t-tests were used to compare peak viral replication in vitro and tumour sizes in 
vivo. 
Log rank testing was used to compare the percentage of animals free of tumour 
progression in vivo. 
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3. Results: Comparison of the anti-tumour 
potency of vaccinia virus mutants in vitro and in 
vivo. 
 
Wild-type Western Reserve (WR) vaccinia virus has been reported to have superior 
anti-tumour potency compared to other wild-type strains of vaccinia virus. 
82
 However, 
the WR strain is a laboratory, non-vaccine strain and there are very limited data on its 
behaviour in humans. Also the experiments demonstrating this superior potency used 
only two human cancer cell lines (A2780 and HCT116) in vitro to make this assertion. 
Furthermore, we know from early Phase I/II trials in the 1970s and 1990s that wild-type 
vaccinia viruses demonstrate limited anti-tumour potency. 
141-143,244
 Tumour-selective 
viruses have been developed since that time to improve tumour targeting and reduce 
side-effects. Despite these shortcomings, a double-deleted mutant (TK-, VGF-) of the 
WR strain (WRDD) shows great promise as an anti-cancer therapeutic with marked 
tumour selectivity and anti-tumour potency. 
83
 Single deleted WR strain (TK-, WRLuc) 
shows less favourable tumour selectivity compared to WRDD, with significant titres of 
virus recovered from brain, testicular and bone marrow tissue in mice following 
intraperitoneal injection; and was included initially in this study as a control. 
83
 
 
An alternative vaccinia strain, Lister, is a European vaccine strain and has been used in 
millions of humans safely. A Lister strain TK-deleted virus, VVL15, has recently been 
shown to have favourable anti-tumour potency compared to adenovirus, with 
cytotoxicity even demonstrated against adenovirus insensitive cancer cell lines. 
245
 
These initial experiments will compare the in anti-tumour potency of tumour-selective 
WR and Lister vaccinia viruses in several cancer cell lines from multiple organs in vitro 
and in vivo. 
 
3.1. Anti-tumour potency of Lister and Western Reserve strain 
vaccinia virus mutants in a panel of murine and human cancer cell 
lines in vitro. 
 
The hypothesis that Lister strain vaccinia virus is a better alternative to Western Reserve 
as an oncolytic virus shall be investigated by comparing the potency of TK-deleted 
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Lister strain (VVL15) to TK-deleted WR strain (WRLuc), and TK and VGF double-
deleted WR strain (WRDD) in a panel of solid tumour cell lines from multiple 
anatomical sites, including head and neck, pancreatic, gastrointestinal and ovarian, 
using the MTS cell proliferation assay. 
 
Tumour 
type 
Cell line VVL15 WRLuc WRDD 
Mean EC50 
(PFU/cell) 
SEM Mean EC50 
(PFU/cell) 
SEM Mean EC50 
(PFU/cell) 
SEM 
HNSCC 
FaDu 0.056 0.0022 0.16 0.011 0.66 0.089 
SCC4 0.00081 
6.38 
x10-5 
0.0026 
4.87 
x10-4 
0.0035 
2.78 
x10-4 
SCC25 0.003 
0.0006
3 
0.0013 
3.54 
x10-4 
0.014 0.0029 
TR138 0.015 
0.0020
8 
0.0061 
0.0007
9 
0.029 0.0018 
SCCVII 81.16 12.16 3.06 0.72 6.35 1.31 
Pancreatic 
PANC1 0.26 0.034 0.25 0.0108 0.98 0.070 
Capan2 0.0091 
0.0008
4 
0.0062 
0.0005
8 
0.023 0.0023 
PT45 5.53 1.39 11.37 0.919 18.42 1.88 
SUIT2 2.63 0.499 10.65 1.58 11.85 1.84 
MiaPaCa2 9.79 1.047 19.51 1.25 27.03 2.74 
Panc02 842.9 45.9 481.5 22.37 50.58 5.80 
Gastro 
intestinal 
HCT116 9.42 1.124 2.16 0.262 2.78 0.148 
HT29 0.408 0.051 0.443 0.027 1.195 0.113 
SW620 6.37 0.592 2.83 0.138 9.14 0.4004 
MKN45 2.62 0.114 1.61 0.129 2.42 0.145 
CMT93 25.17 1.575 0.048 0.013 0.189 0.0322 
CT26 1.70 0.148 0.046 0.0054 0.065 0.0114 
Ovary 
A2780 0.412 0.103 0.035 0.0069 0.0602 0.0092 
MOSEC 0.121 0.014 0.0137 0.0011 0.049 0.0015 
Table 2. Potency of the Lister and Western Reserve strain of vaccinia virus in a 
panel of human and murine tumour cell lines. Comparison of mean EC50 values ± 
SEM generated from sextuplicate MTS cell proliferation assays 6 days after infection; 
1000 cells per well were infected with different VV at a series of  MOI (highest MOI of 
1000 PFU/cell). Statistical analysis was performed using the unpaired T-test. Grey 
shaded cells are murine cell lines; white cells are human cell lines. Bold figures 
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represent the most potent virus overall; underlined figures represent the most potent 
virus comparing VVL15 and WRDD. Where two viruses are highlighted, they are 
jointly most potent statistically (i.e. no statistically significant difference). 
 
Therefore when comparing the mean EC50 values from sextuplicate MTS assays VVL15 
showed greater cytotoxicity compared to WRDD in 11 of the 14 human cancer cell lines 
tested. MKN45 human gastric cancer cell line showed equivalent EC50 values for 
VVL15 and WRDD treated cells. Two human cancer cell lines, A2780 and HCT116, 
demonstrated greater anti-tumour potency with WRDD compared to VVL15. All five of 
the murine cancer cell lines showed greater cytotoxicity with WRDD compared to 
VVL15 treatment. 
 
WRLuc showed a more mixed picture compared to WRDD, with superior potency 
(compared to VVL15 and WRDD) in two mouse cancer cell lines and six out of the 14 
human cancer cell lines. 
 
3.2. Viral replication of Lister and Western Reserve strain vaccinia 
virus mutants in a panel of murine and human cancer cell lines in vitro. 
A number of cell lines used in the cell proliferation studies (MTS assay) were selected 
for further investigation to determine the ability of Lister and WR strain vaccinia virus 
mutants to replicate in these cell lines using a viral burst assay technique. These 
experiments were designed to provide corroborating evidence to the MTS data in 
assessing in vitro anti-tumour potency of the respective viruses. 
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Tumour 
type 
Cell line VVL15 WRLuc WRDD 
Viral 
Replication 
(PFU/cell) 
SEM Viral 
Replication 
 (PFU/cell) 
SEM Viral 
Replication 
 (PFU/cell) 
SEM 
HNSCC FaDu 17.15 0.70 9.17 2.54 8.45 2.29 
SCCVII 28.81 4.67 634.48 47.11 392.94 5.57 
Pancreatic PANC1 133.89 24.74 140.68 0.001 56.75 5.00 
PT45 25.16 5.01 19.40 0.65 7.29 0.42 
SUIT2 121.08 8.67 52.43 7.73 56.01 4.16 
MiaPaCa2 127.20 17.00 38.35 3.50 19.59 0.034 
Panc02 51.04 2.66 2861.96 132.03 1711.86 413.96 
Gastro 
intestinal 
CMT93 142.41 31.56 1627.42 309.48 618.91 225.25 
CT26 147.75 34.17 1057.85 77.28 2534.72 388.33 
Table 3. Viral Replication of the Lister and Western Reserve strain of vaccinia 
virus in a panel of human and murine tumour cell lines. Burst assays were infected 
with 1 PFU/cell of virus (2x10
5
 cells per well). Cell lysates were harvested at 24 hour 
intervals typically up to 96 hours. Mean viral replication at 72 hours ± SEM was 
determined by TCID50 assay on CV1 cells are tabulated. Statistical analysis was 
performed using the unpaired T-test.  Grey shaded cells are murine cell lines; white 
cells are human cell lines. Bold figures represent the most potent virus overall; 
underlined figures represent the most potent virus comparing VVL15 and WRDD. 
Where two viruses are highlighted, they are jointly most potent statistically (i.e. no 
statistically significant difference). 
 
 
All cancer cell lines supported replication of Lister and WR strain viruses. The Lister 
strain virus demonstrated inferior replication in murine cancer cell lines (CMT93, 
CT26, SCCVII and Panc02) compared to WR strain; in keeping with the MTS cell 
proliferation study findings. VVL15 replication was superior to WRDD in human cell 
lines (PT45, SUIT2, PANC1, MiaPaCa2, FaDu); again in congruence with the cell 
proliferation studies. 
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3.3. Tumour selectivity of viral replication of Lister and Western 
Reserve strain vaccinia virus mutants. 
 
To assess the tumour selectivity of Lister and WR strain viruses in vitro, viral 
replication was determined in non-malignant Normal Human Bronchial Epithelial cells 
(NHBE). Ratios for viral replication in cancer cells over normal cells were then 
calculated. 
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Figure 8. Replication of Lister and WR vaccinia virus mutants in Normal Human 
Bronchial Epithelial cells. Burst assays were infected with 1 PFU/cell of virus (2x10
5
 
cells per well). Cell lysates were harvested at 24 hour intervals typically up to 96 hours. 
Mean viral replication ± SEM was determined by TCID50 assay on CV1 cells. Statistical 
analysis was performed using the unpaired T-test with * representing statistical 
significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
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Figure 9. Relative replication of WR and Lister strain viruses in cancer cells 
compared to normal human cells (NHBE). Viral titres were compared at 96 hours 
post-infection. Mean viral replication ± SEM was determined by TCID50 assay on CV1 
cells. A ratio greater than 1 indicates superior viral replication in the respective cancer 
cells compared to non-malignant cells (NHBE). Statistical analysis was performed using 
the unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
 
Both WR and Lister strain vaccinia viruses showed higher replication in all cancer cells 
compared to non-malignant cells, except FaDu. Interestingly WRDD replicated better in 
NHBE cells compared to FaDu. This perhaps relates to the slow doubling time of the 
FaDu tumour cells in vitro. Again a distinction between human and murine cancer cells 
is apparent. VVL15 demonstrates higher ratios compared to WRDD in human cancer 
cell lines (FaDu, MiaPaCa2, PT45, PANC1, SUIT2) suggesting greater tumour 
selectivity for human tumours. Whereas the pattern was reversed in murine cancer cells; 
with WRDD showing higher ratios compared to VVL15. 
 
To further investigate the relative potency of Lister and WR strain vaccinia viruses, 
experimentation in vivo using nude and immunocompetent mouse models of solid 
tumours was performed. Based upon the above in vitro results and findings from the 
literature, VVL15 and WRDD were selected for investigation of in vivo efficacy in a 
number of nude and immunocompetent mouse models. WRLuc has been shown to 
demonstrate poor tumour-selectivity in biodistribution experiments in C57BL/6 
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immunocompetent mice bearing MC38 tumours compared to WRDD. 
83
 Furthermore 
marked cytotoxicity following intra-peritoneal injection into nude and 
immunocompetent C57BL/6 mice (non-tumour bearing) at 1 x10
8
 and 1x10
9
 PFU was 
shown. 
83
 Experience in our laboratory has demonstrated significant in vivo cytotoxicity 
demonstrated in nude mice bearing CMT93 flank tumours following 3 x 1x10
7
 PFU 
intra-tumoural injection. 
 
 
3.4. Anti-tumour efficacy of Lister and Western Reserve vaccinia virus 
mutants in a human HNSCC (FaDu) nude mouse (BALB/c) model. 
 
Having established a general pattern of superior anti-tumour potency, viral replication 
and tumour selectivity for the Lister vaccinia virus strain over the WR in human cancer 
cell lines in vitro; the potency in vivo was investigated. The effect on tumour growth 
and the percentage of animals without tumour progression was examined following 
repeated IT viral treatments. 
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Figure 10a. Growth of established human HNSCC tumours in nude mice after 
treatment with different vaccinia virus mutants. 1x10
6
 FaDu cells were seeded by 
subcutaneous injection into the right flank of 30 BALB/c nude mice. When tumours 
reached 4-5mm in diameter, 10 mice each received IT injections of PBS, WRDD or 
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VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Tumours were measured twice weekly. Mean 
tumour sizes ± SEM are displayed.  
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Figure 10b. Animal survival of nude mice bearing established human HNSCC 
tumours after treatment with different vaccinia virus mutants.1x10
6
 FaDu cells 
were seeded by subcutaneous injection into the right flank of 30 BALB/c nude mice. 
When tumours reached 4-5mm in diameter, 10 mice each received IT injections of PBS, 
WRDD or VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Kaplan-Meier curves are shown. 
Log-rank test statistical analysis showed significant differences at the 0.1% level 
between PBS and WRDD data sets, and at the 1% level between VVL15 and WRDD 
data sets. 
 
Reduced tumour growth was demonstrated in the treatment group receiving VVL15 
compared to WRDD and PBS. This result is in keeping with in vitro data, which 
showed better viral replication and cytotoxicity with VVL15 in the FaDu human cancer 
cell line. 
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3.5. Anti-tumour potency of Lister and Western Reserve vaccinia virus 
mutants in a human pancreatic carcinoma (PT45) nude mouse model 
(ICRF nu/nu). 
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Figure 11a. Growth of established human pancreatic tumours in nude mice after 
treatment with different vaccinia virus mutants. 5x10
6
 PT45 cells were seeded by 
subcutaneous injection into the right flank of 30 ICRF nude mice. When tumours 
reached 4-5mm in diameter, 10 mice each received IT injections of PBS, WRDD or 
VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Tumours were measured twice weekly. Mean 
tumour sizes ± SEM are displayed. Statistical analysis of tumour sizes at stated time-
points was performed using the unpaired T-test with * representing statistical 
significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
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Figure 11b. Animal survival of nude mice bearing established human pancreatic 
tumours after treatment with different vaccinia virus mutants. 5x10
6
 PT45 cells 
were seeded by subcutaneous injection into the right flank of 30 ICRF nude mice. When 
tumours reached 4-5mm in diameter, 10 mice each received IT injections of PBS, 
WRDD or VVL15 on days 1,3,5 (3 x 1x10
7 
PFU).  Kaplan-Meier curves are shown. 
Log-rank test statistical analysis showed significant differences at the 0.1% level 
between PBS and VVL15 & WRDD data sets. 
 
Significant tumour regression was demonstrated in the treatment group receiving 
VVL15 compared to WRDD and PBS. This result is in keeping with in vitro data, 
which showed better viral replication and cytotoxicity with VVL15 in the PT45 human 
cancer cell line. 
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3.6. Anti-tumour potency of Lister and Western Reserve vaccinia virus 
mutants in a mouse colorectal carcinoma (CMT93) nude mouse model 
(ICRF nu/nu). 
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Figure 12a. Growth of established murine colorectal tumours in nude mice after 
treatment with different vaccinia virus mutants. 5x10
6
 CMT93 cells were seeded by 
subcutaneous injection into the right flank of 30 ICRF nu/nu mice. When tumours 
reached 4-5mm in diameter, 10 mice each received IT injections of PBS, WRDD or 
VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Tumours were measured twice weekly. Mean 
tumour sizes ± SEM are displayed. Statistical analysis of tumour sizes at stated time-
points was performed using the unpaired T-test with * representing statistical 
significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
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Figure 12b. Animal survival of nude mice bearing established murine colorectal 
tumours after treatment with different vaccinia virus mutants. 5x10
6
 CMT93 cells 
were seeded by subcutaneous injection into the right flank of 30 ICRF nu/nu mice. 
When tumours reached 4-5mm in diameter, 10 mice each received IT injections of PBS, 
WRDD or VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Kaplan-Meier curves are shown. 
Log-rank test statistical analysis showed no significant difference between the treatment 
groups. 
 
Reduced tumour progression was demonstrated in the treatment group receiving WRDD 
compared to VVL15 and PBS. This result is in keeping with in vitro data, which 
showed better viral replication and cytotoxicity with WRDD in the CMT93 murine 
cancer cell line. Interestingly there was no statistical difference in tumour growth 
between PBS and VVL15 treatment. The EC50 value for VVL15 was 133x that of 
WRDD and the viral replication of WRDD was four times the VVL15 value.  The only 
cell lines with two orders of magnitude difference in EC50 between VVL15 and WRDD 
was the murine colorectal cell lines CMT93 and CT26. Clearly the CMT93 cell line is 
relatively insensitive to VVL15 in vitro and in a nude in vivo model. 
 
79 
 
3.7. Anti-tumour potency of Lister and Western Reserve vaccinia virus 
mutants in a mouse colorectal carcinoma (CMT93) immunocompetent 
mouse model (C57BL/6).  
 
To assess the anti-tumour potency efficacy studies were performed using a C57BL/6 
immunocompetent mouse model. This immunocompetent model would allow 
assessment of the behaviour of the different vaccinia virus strain mutants in the 
presence of an intact host immune system.  CMT93 flank tumours were grown and IT 
viruses administered at 1x10
8
 PFU on a three-day (days 1,3,5) and five-day (1,2,3,4,5) 
injections regime. Our hypothesis was that the anti-tumour effect of the viruses in an 
immunocompetent model may be different to the in vitro and nude in vivo models; and 
that any effect would be enhanced with a five day injection regime, whilst maintaining 
safety. 
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Figure 13a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants.  
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, WRDD or VVL15 (3 x 1x10
8 
PFU) on days 1,3,5. Tumours were 
measured twice weekly. Mean tumour sizes ± SEM are displayed. Statistical analysis of 
tumour sizes at stated time-points was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
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Figure 13b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus mutants. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, WRDD or VVL15 (3 x 1x10
8 
PFU) on days 1,3,5.  Kaplan-Meier 
survival curves are shown. Log-rank test survival curve statistical analysis showed no 
significance between all 3 data sets. 
 
Interestingly in the immunocompetent model the pattern is reversed compared to the 
nude CMT93 murine cancer model. Here tumour progression is slower in the VVL15-
treated mice compared to WRDD. The presence of an intact host immune system 
completely reverses the potency of the viruses against CMT93 tumours. 
 
The experiment was then repeated using a five-day regime of IT injections (5 x 1x10
8 
PFU) to determine if the anti-tumour effect could be enhanced without compromising 
the side-effects profile. 
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Figure 14a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants.  
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, WRDD or VVL15 (5 x 1x10
8 
PFU) on days 1,2,3,4,5. Tumours were 
measured twice weekly. Mean tumour sizes ± SEM are displayed. Statistical analysis of 
tumour sizes at stated time-points was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
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Figure 14b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus mutants. 
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5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, WRDD or VVL15 (5 x 1x10
8 
PFU) on days 1,2,3,4,5. Tumours were 
measured twice weekly.  Kaplan-Meier survival curves are shown. Log-rank test 
survival curve statistical analysis showed no significance between all 3 data sets. 
 
The reduced tumour progression with VVL15 compared to WRDD was enhanced when 
the virus was administered for five days rather than three days. The five-day viral 
injection regime was well tolerated by the mice.  No difference was found between the 
groups in animal survival. 
 
3.8. Anti-tumour potency of Lister and Western Reserve vaccinia virus 
mutants in a mouse colorectal carcinoma (CT26) immunocompetent 
mouse model (BALB/c). 
 
Having demonstrated reduced tumour progression with VVL15-treated mice in the nude 
FaDu, nude PT45, and immunocompetent CMT93 models compared to WRDD, 
vaccinia virus behaviour in a further immunocompetent model was investigated. CT26 
cell line, like CMT93, demonstrated relatively poor sensitivity to VVL15 (EC50 26x) 
and significantly reduced viral replication (17x less). Given the reversal of potency of 
the two viruses in the CMT93 immunocompetent model, corroborating evidence of 
VVL15’s superior anti-tumour potency in mice with intact immune systems was sort. 
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Figure 15a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants.   
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1x10
6
 CT26 cells were seeded by subcutaneous injection into the right flank of 30 
BALB/c immunocompetent mice. When tumours reached 4-5mm in diameter, 10 mice 
each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU).  
Tumours were measured twice weekly. Mean tumour sizes ± SEM are displayed. 
Statistical analysis of tumour sizes at stated time-points was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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Figure 15b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus mutants. 
1x10
6
 CT26 cells were seeded by subcutaneous injection into the right flank of 30 
BALB/c immunocompetent mice. When tumours reached 4-5mm in diameter, 10 mice 
each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU). 
Kaplan-Meier survival curves are show. Log-rank test survival curve statistical analysis 
showed significance at the 0.1% level between VVL15 and WRDD treated mice, and at 
the 5% level between VVL15 and PBS. 
 
Reduced tumour progression was demonstrated in the treatment group receiving VVL15 
compared to WRDD. Statistically significant differences were demonstrated in the 
animal survival between the WRDD- and VVL15-treated mice. Interestingly in both of 
these immunocompetent murine colorectal models there is no significant difference 
between the PBS- and WRDD –treated mice, in terms of tumour growth and animal 
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survival. The host immune system is able to overcome the anti-tumour potency 
demonstrated in vitro and in the nude cancer models. 
 
To explain why Lister and WR demonstrated different anti-tumour potencies in 
different cell lines, investigation was made into the genetic changes of the different cell 
lines used. A distinction between the sensitivities of murine and human origin cell lines 
was apparent and is possibly explained by the development of the WR parent strain, 
Wyeth, by repeated passage in mice brains. 
246
 
 
Differences in status of tumour suppressor genes and oncogenes in the cell lines used in 
my experiments were established through a literature search and presented in Table 4. 
 
Sensitivities of cell lines to radiotherapy and/or chemotherapy dependent of p53 and 
other genetic changes has been investigated elsewhere, with wild-type status conferring 
greater sensitivity to treatments. 
247,248
 Furthermore adenovirus-mediated restoration of 
p53 function to p53-deficient tumours was a key cancer gene therapy strategy. 
4
 
 
However differences in cell line sensitivities to different vaccinia viruses dependent on 
their p53 and other tumour suppressor or oncogene status has not been reported.  It is 
impossible to conclude definitively relationships between genetic changes of the 
infected cell line and WRDD vs VVL15 sensitivity. However there is a suggestion that 
WR strain may be more potent in cell lines with wild-type p53; as is the case with 
SCCVII, Capan2, Panc02, HCT116, MKN45 and CMT93 (but not SW620 and SCC25). 
VVL15 appears to be more potent in the cell lines with mutated p53, such as FaDu, 
SCC4, PT45, SUIT2, MiaPaCa. This suggestion requires further investigation to 
demonstrate that virus sensitivity can be reversed in individual cell lines with wild-type 
and mutated p53 function. 
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Tumour 
type 
Cell line 
(Human/Murine) 
K-
ras 
p53 p16/ 
CDKN2A 
DPC4 
smad4 
BRAF PIK3CA PTEN 
HNSCC 
FaDu 249  
Mut 
(pm) 
Mut (pm)     
SCC4 249  
Mut 
(pm) 
Mut (pm)     
SCC25 249  
Mut 
(pm) 
Mut (pm) 
Mut 
(pm) 
   
TR138 No data found 
SCCVII 
250
   Mut (pm)     
Pancreatic 
PANC1 251 
Mut 
(pm) 
Mut 
(pm) 
Mut (hd) WT    
Capan2 
251
 
Mut 
(pm) 
WT 
 
Mut (ins) 
 
low 
protein 
expression 
   
PT45 251 
Mut 
(pm) 
Mut 
(pm) 
Mut (hd) WT    
SUIT2 252 
Mut 
(pm) 
Mut 
(pm) 
Mut (pm) WT    
MiaPaCa2251 
Mut 
(pm) 
Mut 
(pm) 
Mut (hd) WT    
Panc02 
253
 SNP WT WT 
Mut 
(pm) 
   
Gastro 
intestinal 
HCT116 254 
Mut 
(pm) 
WT   WT 
Mut 
(pm) 
WT 
HT29 254 WT WT WT WT Mut Mut WT 
SW620 249 
Mut 
(pm) 
Mut 
(pm) 
  WT WT WT 
MKN45 
255,256
  WT Mut Mut    
CMT93 
257
 WT WT   WT Mut  
CT26 
258
 Mut       
Ovary 
A2780 259 WT     WT Mut 
MOSEC No data found 
Table 4. Genetic profile of cancer cell lines and sensitivity to different Vaccinia 
virus strains. Dark grey = VVL15 most potent; dark blue = WR most potent; light blue 
= WRLuc most potent; white = WR = VVL15.  Mut = Mutation; WT = Wild Type; pm 
= point mutation; hd= homozygous deletion; SNP = Single-nucleotide polymorphism. 
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3.9 Chapter Conclusions 
 
 VVL15 > WRDD 11/14 human cancer cell lines in vitro. 
 A2780 and HCT116 are outliers showing a reverse in sensitivity. 
 WRDD > VVL15 5/5 murine cancer cell lines in vitro 
 WRLuc (single deleted) more potent than WRDD (double deleted) except in 
Panc02. 
 Viral replication studies supported cell proliferation study findings, with 
higher viral titres in cell lines with lowest EC50. 
 WR Luc toxic in vivo. 
 Nude in vivo models of cancer evidenced superior anti-tumour potency of 
VVL15 in human (FaDu and PT45) cancer s; in keeping with in vitro data. A 
nude murine model of cancer (CMT93) demonstrated identical findings to in 
vitro data, with superior WRDD potency. 
 Immunocompetent murine models of cancer (CMT93 and CT26) conversely 
showed superior anti-tumour of VVL15 compared to WRDD. 
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4. Results: Comparison of the biodistribution of vaccinia virus 
mutants in mouse models of solid tumours in nude and 
immunocompetent mice.  
 
Investigation of the biodistribution of vaccinia virus mutants in nude and 
immunocompetent solid tumour mouse models following systemic (IV) delivery was 
carried out to establish relative in vivo tumour selectivity and viral clearance by the host 
immune system. Viruses were injected into the tail vein of mice bearing CMT93 flank 
tumours and then at set time-points the mice were sacrificed, and tumours and organs of 
interest were harvested for determination of viral titre by TCID50, qRT-PCR and 
immunohistochemistry. 
 
4.1 Biodistribution of vaccinia virus mutants in ICRF nu/nu mice 
bearing CMT93 flank tumours determined by TCID50. 
 
Tumour 
Site 
PBS VVL15 WRDD 
Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM 
Tumour 
0 0 6235153.00 4116647.00 
6.912245x
10
8 
4.26328
4 x10
8
 
Ovary 
0 0 95789.840 36684.390 
4.716238 
x10
8
 
3.07291
1 x10
8
 
Lung 
0 0 21652.690 7162.151 81952.930 
8212.01
5 
Liver 
0 0 13435.280 4988.430 61266.930 
29240.2
90 
Spleen 
0 0 0 0 91273.190 
26757.4
80 
Brain 
0 0 0 0 0 0 
Bone 
Marrow 
0 0 0 0 0 0 
Table 5.  Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
CMT93 flank tumours determined by TCID50. 5x10
6
 CMT93 cells were seeded by 
subcutaneous injection into the right flank of 36 ICRF nude mice. When tumours 
reached 4-5mm in diameter, 12 mice each received single IV injections of PBS, WRDD 
or VVL15 (1 x 1x107 PFU). On days 2, 6, 8 and 12 four mice from each group were 
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sacrificed and ovaries were harvested and frozen. Samples were then homogenised and 
repeatedly freeze-thawed. Mean viral recovery at 8 days post injection ± SEM was 
determined by TCID50 assay on CV1 cells are tabulated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
CMT93 flank tumours determined by TCID50. Viral titre of harvested tumours and 
other organs in ICRF nu/nu mice bearing CMT93 flank tumours following IV vaccinia 
virus treatment. 5x106 CMT93 cells were seeded by subcutaneous injection into the 
right flank of 36 ICRF nude mice. When tumours reached 4-5mm in diameter, 12 mice 
each received single IV injections of PBS, WRDD or VVL15 (1 x 1x107 PFU). On days 
2, 6, 8 and 12 four mice from each group were sacrificed and ovaries were harvested 
and frozen. Samples were then homogenised and repeatedly freeze-thawed. Mean viral 
recovery at 8 days post injection ± SEM was determined by TCID50 assay on CV1 cells 
are shown. Statistical analysis of tumour sizes at stated time-points was performed using 
the unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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WRDD vaccinia virus demonstrated higher viral titres from tumour, ovary, liver, and 
spleen samples compared to VVL15. There was no recoverable virus from splenic 
samples other than WRDD at 6 and 8 days. Therefore, although WRDD had higher viral 
titres in the tumour samples, there was less tumour selectivity with higher titres in other 
organs. 
 
4.2. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice 
bearing CMT93 flank tumours determined by qRT-PCR. 
 
To confirm the TCID50 findings, homogenised tumour and organ samples underwent 
DNA extraction, total DNA quantification and qRT-PCR of vaccinia genomes using 
vaccinia late primers to assess vaccinia genome copy number. 
 
Tumour 
Site 
PBS VVL15 WRDD 
Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM 
Tumour 
0 0 9289.081 2516.674 
212877.50
0 
97294.85
0 
Ovary 
0 0 188.7133 22.18592 
103459.10
0 
28499.39
0 
Lung 0 0 93.55778 14.54905 189.7389 46.71809 
Liver 0 0 31.515 5.440252 95.19625 32.46453 
Spleen 0 0 83.18188 23.75478 247.6278 32.77229 
Brain 0 0 28.61928 1.259999 244.9778 41.50741 
Bone 
Marrow 
0 0 233.1237 59.31355 774.6817 69.85658 
Table 6. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
CMT93 flank tumours determined by qRT-PCR. 5x10
6
 CMT93 cells were seeded 
by subcutaneous injection into the right flank of 36 ICRF nude mice. When tumours 
reached 4-5mm in diameter, 12 mice each received single IV injections of PBS, WRDD 
or VVL15 (1 x 1x10
7
 PFU). On days 2, 6, 8 and 12 four mice from each group were 
sacrificed and ovaries were harvested and frozen. Samples were then homogenised and 
repeatedly freeze-thawed. Mean viral recovery at 8 days post injection ± SEM was 
determined by TCID50 assay on CV1 cells are tabulated.  
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Figure 17. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
CMT93 flank tumours determined by qRT-PCR.   5x10
6
 CMT93 cells were seeded 
by subcutaneous injection into the right flank of 36 ICRF nude mice. When tumours 
reached 4-5mm in diameter, 12 mice each received single IV injections of PBS, WRDD 
or VVL15 (1 x 1x107 PFU). On days 2, 6, 8 and 12 four mice from each group were 
sacrificed and ovaries were harvested and frozen. Samples were then homogenised and 
repeatedly freeze-thawed. Mean viral recovery at 8 days post injection ± SEM was 
determined by TCID50 assay on CV1 cells are shown. Statistical analysis of tumour 
sizes at stated time-points was performed using the unpaired T-test with * representing 
statistical significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
qRT-PCR findings are similar to the TCID50 findings. The increased sensitivity of qRT-
PCR compared to TCID50 allowed fuller assessment of splenic distribution, and an 
assessment of bone marrow and brain tissue. Again the pattern is confirmed with 
WRDD showing higher copy numbers in tumour and non-tumour tissues, especially 
ovary and bone marrow, compared to VVL15. 
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4.3. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice 
bearing CMT93 flank tumours determined by immunohistochemistry. 
 
To confirm the TCID50 and qRT-PCR findings, the frozen sections of tumour and organ 
samples were stained with vaccinia coat protein antibody. Only tumour and ovary 
tissues stained positive. 
 
4.3.1. Optimisation of anti vaccinia virus antibody for immunohistochemistry. 
The anti-Lister vaccinia virus antibody was optimised for immunohistochemistry in 
frozens sections using several dilutions (Figure 18), with 1:2000 chosen since there was 
no background staining and clear positive staining of vaccinia virus infected tissue.  
 
1:200    1:400    1:1000 
   
1:2000    1:3000    No primary antibody 
   
Figure 18. Optimisation of anti-Lister vaccinia virus coat protein antibody for 
immunohistochemistry in frozen sections. Immunohistochemistry was performed on 
frozen sections of CMT93 tumours infected IT with VVLister (+ve control) or PBS (-ve 
control) using different dilutions  (1:200, 1:400, 1:1000, 1:2000, 1:3000 and no 
primary) of anti-Lister vaccinia virus coat protein antibody. Representative images are 
shown at x200 magnification. 
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 PBS 200x 
 
  VVL15 200x 
 
  WRDD 200x (a) 
 
 WRDD100x (b) 
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Figure 19. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
flank CMT93 tumours, as determined by immunohistochemistry of tumour 
samples. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right flank 
of 36 ICRF nude mice. When tumours reached 4-5mm in diameter, 12 mice each 
received single IV injections of PBS, WRDD or VVL15 (1 x 1x10
7 
PFU). On days 2, 6, 
8 and 12 four mice from each group were sacrificed and tumours were harvested and 
frozen. IHC for vaccinia coat protein was performed and representative images at day 8 
are shown at 100-200x magnification; images were taken with a Zeiss Axioplan 
microscope fitted with a Zeiss AxioCam MRc camera. 
 
WRDD-infected mice showed more VCP staining compared to VVL15. The WRDD 
tumour sections featured multiple necrotic centres (WRDD b). No necrotic centres were 
seen with VVL15 infected tumours nor PBS controls. 
 
 PBS 100x 
 
 WRDD 100x 
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 VVL15 100x 
 
Figure 20. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice bearing 
flank CMT93 tumours, as determined by immunohistochemistry of ovary samples. 
5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right flank of 60 
ICRF nude mice. When tumours reached 4-5mm in diameter, 12 mice each received 
single IV injections of PBS, WRDD or VVL15 (1 x 1x10
7 
PFU). On days 2, 6, 8 and 12 
four mice from each group were sacrificed and ovaries were harvested and frozen. IHC 
for vaccinia coat protein was performed and representative images at day 12 are shown 
at 200x magnification; images were taken with a Zeiss Axioplan microscope fitted with 
a Zeiss AxioCam MRc camera. 
 
The immunoreactivity was more convincing in the ovary than in the tumour slides. 
Marked VCP staining was seen with the WRDD-infected ovarian tissue; with prominent 
necrotic follicles seen. 
 
The immunohistochemistry staining evidenced similar patterns to the TCID50 and qRT-
PCR data, with greater WRDD replication in the tumours, but also the ovaries. Vaccinia 
coat staining was too weak to be visible in the other organs tested using TCID50 and 
qRT-PCR virus quantification techniques, despite repeat optimisation of anti vaccinia 
virus antibody as outlined above. 
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4.4. Biodistribution of vaccinia virus mutants in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours determined by 
qRT-PCR. 
 
To further assess the biodistribution of vaccinia virus mutants, systemic treatment of 
immunocompetent mice was investigated. This will evaluate the role of the host 
immune system in clearance of the viral oncolytic agents. The samples for this 
experiment were assessed using TCID50 and qRT-PCR; however only qRT-PCR was 
sensitive enough to detect the virus. More DNA extraction lysate from the tissue 
homogenates had to be used for the PCR reaction (20ng DNA nude mice biodistribution 
versus 100ng DNA for immunocompetent mice biodistribution) to detect and quantify 
the virus. 
 
Tumour 
Site 
PBS VVL15 WRDD 
Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM 
Tumour 
0 0 23237.070 8439.108 358.8244 96.51902 
Ovary 
0 0 26.13517 2.398122 24654.400 
10801.60
0 
Lung 
0 0 4292.671 691.9373 981.1987 175.5599 
Liver 
0 0 166.9944 34.23967 69.62366 17.23177 
Spleen 
0 0 78.040 18.0735 67.440 14.0419 
Brain 
0 0 0 0 0 0 
Bone 
Marrow 
0 0 130.9678 51.81752 173.180 55.06757 
Table 7. Vaccinia virus genome copy number of harvested CMT93 tumours and 
other organs in immunocompetent C57BL/6 mice following IV vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received single IV injections of PBS, WRDD or VVL15 (2 x 
1x10
8 
PFU). On days 4, 8, and 12 four mice from each group were sacrificed and 
tumours were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
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SEM at day 8 were determined by qRT-PCR using the vaccinia late gene (VLTF-1) and 
tabulated above.   
 
 
 
Figure 21. Vaccinia virus genome copy number of harvested CMT93 tumours and 
other organs in immunocompetent C57BL/6 mice following IV vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received single IV injections of PBS, WRDD or VVL15 (2 x 
1x10
8 
PFU). On days 4, 8, and 12 four mice from each group were sacrificed and 
tumours were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
SEM at day 8 were determined by qRT-PCR using the vaccinia late gene (VLTF-1) and 
shown above.  Statistical analysis of viral titres at stated time-points was performed 
using the unpaired T-test with * representing statistical significance at p<0.05, ** 
representing statistical significance at p<0.01, *** representing statistical significance at 
p<0.001 and ns indicating no statistical significance. 
 
In the immunocompetent model VVL15 demonstrated higher tumour viral genome copy 
numbers compared to WRDD at the day 8 and 12 time-points. As before, the ovary viral 
genome copy number for WRDD was much higher than VVL15. For the liver, lungs 
and spleen samples there was no statistically significant difference between VVL15 and 
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WRDD copy numbers. The bone marrow data shows higher WRDD copy numbers at 
the late time point (day 12). 
 
 
4.5. Biological time-points of vaccinia virus mutants in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours determined by 
qRT-PCR. 
 
Following assessment of VVL15 and WRDD biodistribution in nude and 
immunocompetent murine tumour models, investigation into the behaviour of IT-
delivered virus was undertaken. 
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Figure 22. Vaccinia virus genome copy number of harvested tumours in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours following IT vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received three IT  injections of PBS, WRDD or VVL15 (3 x 
1x10
8 
PFU). On days 5, 10, 15 and 20 three mice from each group were sacrificed and 
tumours were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
SEM were determined by qRT-PCR using the vaccinia late gene (VLTF-1). Statistical 
analysis of viral titres at stated time-points was performed using the unpaired T-test 
with * representing statistical significance at p<0.05, ** representing statistical 
significance at p<0.01, *** representing statistical significance at p<0.001 and ns 
indicating no statistical significance. 
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Figure 23. Vaccinia virus genome copy number of harvested ovaries in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours following IT vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received three IT  injections of PBS, WRDD or VVL15 (3 x 
1x10
8 
PFU). On days 5, 10, 15 and 20 three mice from each group were sacrificed and 
ovaries were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
SEM were determined by qRT-PCR using the vaccinia late gene (VLTF-1). Statistical 
analysis of viral titres at stated time-points was performed using the unpaired T-test 
with * representing statistical significance at p<0.05, ** representing statistical 
significance at p<0.01, *** representing statistical significance at p<0.001 and ns 
indicating no statistical significance. 
 
 
Biological time-points studies showed that VVL15 delivered to IT replicated better in 
the immunocompetent model compared to WRDD. This would explain the better anti-
tumour efficacy was demonstrated in vivo. WRDD virus delivered IT, and to a lesser 
extent VVL15, was able to spread to and replicate within the mouse ovaries. 
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4.6. Biodistribution of vaccinia virus mutants in ICRF nu/nu mice 
bearing PT45 flank tumours determined by qRT-PCR. 
 
Following assessment of VVL15 and WRDD biodistribution in nude and 
immunocompetent murine tumour models, investigation into the biodistribution of the 
viruses in a model of human cancer was undertaken. The human pancreatic tumour 
PT45 was chosen and flank tumours in ICRF nu/nu mice were grown. 
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Figure 24. Vaccinia virus genome copy number in harvested tumours of ICRF 
nu/nu mice bearing PT45 flank tumours following IV vaccinia virus treatment. 
5x10
6 
PT45 cells were seeded by subcutaneous injection into the right flank of 27 ICRF 
nu/nu mice. When tumours reached 4-5mm in diameter, 9 mice each received single IV  
injections of PBS, WRDD or VVL15 (1x10
7 
PFU). On days 8, 12 and 18 three mice 
from each group were sacrificed and tumours were harvested and frozen. Samples were 
then homogenised and repeatedly freeze-thawed. Lysates underwent DNA extraction. 
Mean viral genome copy numbers ± SEM were determined by qRT-PCR using the 
vaccinia late gene (VLTF-1). Statistical analysis of viral titres at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
The biodistribution results are in keeping with the PT45 in vitro cell proliferation and 
viral replication assays, which showed superior anti-tumour potency and viral 
replication of VVL15 over WRDD; and the PT45 in vivo efficacy studies, where 
100 
 
reduced tumour growth and disease progression was recorded in an ICRF nu/nu model. 
Good VVL15 replication was demonstrated with greater viral titres at two time-points, 
compared to WRDD which exhibited poor viral replication. 
 
 
4.7. Biological time-points of vaccinia virus mutants in ICRF nu/nu 
mice bearing PT45 flank tumours determined by qRT-PCR. 
 
Assessment of IT delivered viruses was also made in the mouse ICRF nu/nu PT45 
human pancreatic cancer model. 
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Figure 25. Vaccinia virus genome copy number in harvested tumours of ICRF 
nu/nu mice bearing PT45 flank tumours following IT vaccinia virus treatment. 
5x10
6 
PT45 cells were seeded by subcutaneous injection into the right flank of 30 ICRF 
nu/nu  mice. When tumours reached 4-5mm in diameter, 12 mice each received three IT  
injections of PBS, WRDD or VVL15 (3 x 1x10
7 
PFU). On days 7, 12 and 20 three mice 
from each group were sacrificed and tumours were harvested and frozen. Samples were 
then homogenised and repeatedly freeze-thawed. Lysates underwent DNA extraction. 
Mean viral genome copy numbers ± SEM were determined by qRT-PCR using the 
vaccinia late gene (VLTF-1). Statistical analysis of viral titres at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
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Higher viral titres for VVL15 were recovered following IT delivery compared to 
WRDD; indicating that VVL15 is better able to replicate in cancer cells in vivo. These 
results are in keeping with the in vitro cytotoxicity and viral replication studies; and 
additionally congruent with the in vivo PT45 efficacy study. 
 
4.8 Chapter Conclusions 
 
 WRDD demonstrates higher tumour viral titres compared to VVL15 following 
systemic delivery in a nude CMT93 biodistribution model, however the virus 
demonstrated less tumour selectivity with higher levels of WRDD found in off-
target sites, including ovary, lung, liver, spleen, brain and bone marrow. 
 Corroboration of qRT-PCR findings with TCID50; with the former proving to be a 
more sensitive technique. 
 Immunohistochemistry demonstrated superior vaccinia coat protein staining of 
tumour and ovarian tissues following systemic virus delivery of WRDD compared 
to VVL15. 
 VVL15 demonstrated higher copy numbers compared to WRDD in a systemically 
delivered CMT93 immunocompetent model with a similar off target profile between 
the two viruses, except for the ovary tissue which showed high WRDD virus copy 
numbers. 
 VVL15 when delivered IT to CMT93 flank tumours in nude mice achieved  higher 
copy numbers than WRDD. 
 Higher VVL15 copy numbers were achieved following systemic and IT virus 
delivery to nude mice bearing flank tumours compared to WRDD. 
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5.  Results: Investigation into the host immune response to 
Western Reserve and Lister strain viruses 
 
The reduced tumour viral clearance and superior anti-tumour potency of the Lister strain 
virus, VVL15, compared to the Western Reserve strain virus, WRDD, in 
immunocompetent, but not nude, models is suggestive of immunologically related 
differences between the two virus strain mutants. To characterise these potential 
differences I performed an investigation into the profile of multiple cytokines in serum 
and tumour murine samples (following IT delivery of virus to CMT93 flank tumours in 
C57BL/6 immunocompetent mice), as well as in vitro infection of CMT93 cells. Our 
hypothesis was that superior anti-tumour potency was related to reduced viral clearance; 
and that differences in the pro-inflammatory cytokine profile might exist following 
Lister infection, compared to WR. 
 
5.1. Analysis of multiple pro-inflammatory cytokines in serum of 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours 
following intratumoural viral injection. 
 
To assess the differences in pro-inflammatory cytokines in the serum of C57BL/6 
immunocompetent mice bearing CMT93 flank tumours, serum was sampled at various 
time-points following different IT viral treatments. Serum samples were subjected to 
cytokine quantification using a mouse pro-inflammatory ultra-sensitive kit for the Meso 
Scale Discovery multi-spot assay system.  
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Cytokine PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL1β 0.000 0.000 0.0415 
0.041
5 0.666 
0.045
1 
TNFα 0.000 0.000 1.0058 0.355 0.915 0.471 
IFNγ 1.409 0.090 2.39 0.324 12.0186 1.449 
IL10 14.97 1.881 84.6 5.74 29.25 6.017 
IL12 0.000 0.000 0.000 0.000 19.55 3.077 
IL6 11.387 1.228 29.93 4.157 53.34 2.409 
IL8 189.83 6.495 204.74 11.96 462.68 
28.69
6 
Table 8. Concentration of multiple pro-inflammatory cytokines in the serum of 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 36 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15 (day 5 samples not analysed here), 3 animals 
from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using a mouse pro-inflammatory 7-plex ultra-sensitive kit 
for the Meso Scale Discovery multi-spot assay system (2 animals per group in sample 
duplicate). Mean serum cytokine concentrations at day 10 ± SEM are shown. 
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Figure 26. Concentration of multiple pro-inflammatory cytokines in the serum of 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 36 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15 (day 5 samples not analysed here), 3 animals 
from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using a mouse pro-inflammatory 7-plex ultra-sensitive kit 
for the Meso Scale Discovery multi-spot assay system (2 animals per group in sample 
duplicate). Mean serum cytokine concentrations at day 10 ± SEM are shown. Statistical 
analysis was performed using the unpaired T-test with * representing statistical 
significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
The results revealed higher levels of pro-inflammatory in animals treated with WRDD 
compared to VVL15; with the exception of IL10, which is considered an anti-
inflammatory cytokine. This is highly suggestive of WR infections inducing a more 
potent host anti-viral immune response, with resultant enhanced viral clearance and, 
hence reduced anti-tumour potency in immunocompetent in vivo models of cancer. 
There is also evidence of cytokine production in response to what appears to be PBS 
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treatment. However this represents cytokines released into the tumour 
microenvironment by the tumour cells and the host immune cells in a battle of survival 
of the host and cancer cells.
260
 
 
5.2. Analysis of multiple pro-inflammatory cytokines in tumour 
homogenates of C57BL/6 immunocompetent mice bearing CMT93 
flank tumours following intratumoural viral injection. 
 
To assess the differences in pro-inflammatory cytokines in the tumour 
microenvironment CMT93 flank tumours were grown in C57BL/6 immunocompetent 
mice and different viral treatments were applied intratumourally. Tumours harvested 
from sacrificed mice were weighed, homogenised and subjected to cytokine 
quantification using a mouse pro-inflammatory ultra-sensitive kit for the Meso Scale 
Discovery multi-spot assay system.  
 
Cytokine PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM 
IL1β 374.89 41.03 2105.35 347.6 442.02 27.08 
TNFα 8.359 0.8107 15.344 1.407 25.99 2.340 
IFNγ 37.730 5.974 76.372 9.292 102.66 22.943 
IL10 60.25 10.931 132.54 13.59 20.75 5.132 
IL12 4.574 0.380 59.294 16.04 26.597 8.855 
IL6 360.82 8.625 370.64 66.40 699.40 27.55 
IL8 83.357 9.717 1509.981 261.9 8396.20 397.24 
Table 9. Concentration of multiple pro-inflammatory cytokines in CMT93 flank 
tumour samples following IT viral infection of C57BL/6 immunocompetent mice. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 36 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 9 mice each received IT 
injections of PBS, WRDD or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU). At days 5, 10 and 
15 (day 15 samples not analysed here), 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using a mouse pro-inflammatory ultra-sensitive kit for the Meso 
Scale Discovery multi-spot assay system (2 animals per group in sample duplicate). 
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Mean serum concentrations at day 10 ± SEM are shown. Cytokine concentration was 
corrected for tumour weight.  
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Figure 27. Concentration of multiple pro-inflammatory cytokines in CMT93 flank 
tumour samples following IT viral infection of C57BL/6 immunocompetent mice. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 36 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 9 mice each received IT 
injections of PBS, WRDD or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU). At days 5, 10 and 
15 (day 15 samples not analysed here), 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using a mouse pro-inflammatory ultra-sensitive kit for the Meso 
Scale Discovery multi-spot assay system (2 animals per group in sample duplicate). 
Mean cytokine concentration at day 10 ± SEM are shown. Cytokine concentration was 
corrected for tumour weight. Statistical analysis was performed using the unpaired T-
test with * representing statistical significance at p<0.05, ** representing statistical 
significance at p<0.01, *** representing statistical significance at p<0.001 and ns 
indicating no statistical significance. 
 
When considering the cytokine levels found within tumours the cytokine profile is more 
complicated with a less apparent overall pattern. WRDD infection resulted in higher 
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levels of TNFα, IL8 and IL6; but lower IL12, and IL1β and IL10 samples (differences 
in IFNγ levels were not significant). In contrast to the ideal host response in the serum, 
where a limited inflammatory response is favourable for the persistence and efficacy of 
oncolytic virotherapy, in the tumour a pro-inflammatory response can be beneficial in 
tumour lysis. However as I have demonstrated greater viral persistence together with 
superior in vivo anti-tumour potency with IT-delivered VVL15 compared to WRDD, a 
reduced host intra-tumoural anti-viral inflammatory response following VVL15 
treatment is the most likely overall effect of this cytokine profile. Although the 
elevation of some pro-inflammatory cytokines (IL12 in particular) may contribute to the 
superior anti-tumour potency of VVL15 independent of this viral persistence 
mechanism. 
 
5.3. Analysis of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection. 
 
To investigate further the observed differences in anti-tumour potency between VVL15 
and WRDD an analysis of multiple pro-inflammatory cytokines was performed using a 
mouse pro-inflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot 
assay system. Samples were analysed from tissue culture supernatants of CMT93 cells 
infected with viruses. 
 
 
Cytokine PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL1β 0.000 0.000 5.081 0.0940 4.1803 0.272 
TNFα 0.000 0.000 0.000 0.000 1.677 0.194 
IFNγ 0.000 0.000 0.000 0.000 4.242 0.187 
IL10 4.795 4.795 337.72 32.75 4.494 3.882 
IL12 11.270 5.687 48.633 4.555 121.9 9.310 
IL6 14.355 2.346 0.000 0.000 40.132 3.217 
IL8 55.253 7.221 266.48 9.017 398.15 32.64 
Table 10. Concentration of multiple pro-inflammatory cytokines in CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
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with 1 PFU/cell of virus. Cell lysates were harvested at 6 and 24 hour intervals. 
Cytokine concentrations were quantified in triplicate using a mouse pro-inflammatory 
ultra-sensitive kit for the Meso Scale Discovery multi-spot assay system. Mean cytokine 
concentrations at 24 hours ± SEM are shown.  
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Figure 28. Concentration of multiple pro-inflammatory cytokines in CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6 and 24 hour intervals. 
Cytokine concentrations were quantified in triplicate using a mouse pro-inflammatory 
ultra-sensitive kit for the Meso Scale Discovery multi-spot assay system. Mean cytokine 
concentrations at 24 hours ± SEM are shown. Statistical analysis was performed using 
the unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
  
 
The tissue culture cytokine profiles for VVL15 and WRDD show a similar pattern to  
those found in the serum samples, with elevated pro-inflammatory cytokines IFNγ, 
IL12, IL6, IL8 and TNFα; IL1β levels were not significantly different between the two 
groups. As before, IL10 was elevated in the VVL15-infected cells compared to WRDD. 
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Having reviewed the different cytokines and virus combinations, the cytokines that 
showed most promise as to explain the different anti-tumour potencies in vitro and in 
vivo were IL10, IL12 and IFN γ. More samples from an additional time-point and in 
sample triplicate were analysed. 
 
5.4. Analysis of IL10, IL12 and Interferon γ cytokine concentrations in 
serum of C57BL/6 immunocompetent mice bearing CMT93 flank 
tumours following intratumoural viral injection. 
 
IL10, IL12 and IFNγ cytokine concentrations in the serum of C57BL/6 
immunocompetent mice bearing CMT93 flank tumours was quantified at various time-
points following different IT viral treatments using R&D Systems Quantikine Mouse 
ELISA kits. 
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PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml) 
SEM 
Cytokine 
concentration 
(pg/ml) 
SEM 
Cytokine 
concentration 
(pg/ml) 
SEM 
IL12 
 
5 0.000 0.000 0.000 0.000 1.859 0.1034 
10 0.622 0.073 0.000 0.000 1.745 0.1369 
15 0.897 0.103 0.129 0.0451 5.148 0.3509 
IFNγ 
5 0.337 0.023 0.518 0.0235 3.271 0.2001 
10 0.354 0.016 0.576 0.0429 3.037 0.2653 
15 0.906 0.035 0.425 0.0263 3.152 0.4395 
IL10 
 
5 0.099 0.062 23.74 2.882 3.607 0.344 
10 0.000 0.000 10.09 0.8861 1.535 0.1887 
15 0.000 0.000 3.002 0.395 0.502 0.1525 
Table 11. Concentration of multiple pro-inflammatory cytokines in the serum of 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the serum was sampled. The cytokine concentration was quantified using R&D Systems 
Quantikine Mouse IL10, IL12 and Interferon γ ELISA kits (3 animals per group in 
sample duplicate). Mean cytokine concentrations ± SEM are shown. Statistical analysis 
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was performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
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Figure 29. Concentration of multiple pro-inflammatory cytokines in the serum of 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the serum was sampled. The cytokine concentration was quantified using R&D Systems 
Quantikine Mouse IL10, IL12 and Interferon γ ELISA kits (3 animals per group in 
sample duplicate). Mean cytokine concentrations ± SEM are shown. Statistical analysis 
was performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
These data over three time-points confirm the previous findings over two time-points 
using the Meso Scale Discovery multi-spot assay system. The pro-inflammatory 
cytokines were raised following WRDD IT treatment of mice bearing CMT93 flank 
tumours, whereas the anti-inflammatory cytokine IL10 was reduced compared to 
VVL15. 
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5.5. Analysis of IL10, IL12 and Interferon γ cytokine concentrations in 
CMT93 flank tumour homogenates following intratumoural viral 
injection of C57BL/6 immunocompetent mice. 
 
In order to assess IL10, IL12 and Interferon γ cytokine concentrations in the tumour 
microenvironment, CMT93 flank tumours were grown in C57BL/6 immunocompetent 
mice and different viral treatments were applied intratumourally. Harvested tumours 
from sacrificed mice were weighed, homogenised and subjected to cytokine 
quantification using R&D Systems Quantikine Mouse IL10, IL12 and IFN γ ELISA 
kits. 
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PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM 
IL12 
 
5 0.922 0.070 18.070 2.640 0.223 0.111 
10 1.169 0.055 19.830 2.552 6.43 0.837 
15 0.892 0.114 20.33 1.963 7.818 0.805 
IFNγ 
5 14.419 0.700 30.88 2.092 55.27 6.079 
10 10.487 0.960 19.10 1.329 25.60 2.898 
15 14.249 0.599 15.942 0.713 29.72 4.894 
IL10 
 
5 11.737 1.611 82.545 7.448 17.015 1.933 
10 12.44 1.40 43.028 3.14 5.087 0.498 
15 9.081 0.778 47.060 4.460 5.098 0.767 
Table 12. Concentration of multiple pro-inflammatory cytokines in harvested and 
homogenised CMT93 flank tumour samples following IT viral infection of 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using R&D Systems Quantikine Mouse IL10, IL12 and 
Interferon γ ELISA kits (3 animals per group in sample duplicate). Mean cytokine 
concentrations ± SEM are shown. Cytokine concentration was corrected for tumour 
weight.  
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Figure 30. Concentration of multiple pro-inflammatory cytokines in harvested and 
homogenised CMT93 flank tumour samples following IT viral infection of 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD or VVL15 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using R&D Systems Quantikine Mouse IL10, IL12 and 
Interferon γ ELISA kits (3 animals per group in sample duplicate). Mean cytokine 
concentrations ± SEM are shown. Cytokine concentration was corrected for tumour 
weight. Statistical analysis was performed using the unpaired T-test with * representing 
statistical significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
These data over three-time points are similar to the previous findings over two time-
points using the Meso Scale Discovery multi-spot assay system. However now there are 
significant differences in IFNγ levels whereas previously no significant differences were 
found between the two virus-treated groups. Again this is suggestive of a more powerful 
inflammatory reaction elicited locally in response to the WRDD virus, resulting in 
accelerated viral clearance and reduced anti-tumour potency in vivo. 
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5.6. Analysis of IL10, IL12 and Interferon γ cytokine concentration of 
CMT93 tissue culture samples following viral infection. 
 
IL10, IL12 and Interferon γ cytokine concentrations of CMT93 tissue culture 
supernatants at 6, 24 and 48 hours following WRDD, VVL15 and mock infection were 
quantified using R&D Systems Quantikine Mouse IL10, IL12 and Interferon γ ELISA 
kits. 
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PBS VVL15 WRDD 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL12 
 
6 3.259 0.358 20.70 1.651 36.44 3.211 
24 4.019 0.293 14.25 1.473 40.90 3.352 
48 3.217 0.243 11.91 1.176 36.01 3.4703 
IFNγ 
6 0.000 0.000 0.000 0.000 0.371 0.0508 
24 0.000 0.000 0.000 0.000 1.336 0.0731 
48 0.000 0.000 0.159 0.057 1.569 0.1500 
IL10 
 
6 0.000 0.000 22.76 3.183 0.875 0.3665 
24 1.291 0.636 91.08 4.954 1.767 0.6233 
48 1.486 0.620 138.24 4.816 1.699 0.5983 
Table 13. Concentration of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6, 24 and 48 hour intervals. 
Cytokine concentration was quantified in triplicate using R&D Systems Quantikine 
Mouse IL10, IL12 and Interferon γ ELISA kits. Mean cytokine concentrations ± SEM 
are shown.  
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Figure 31. Concentration of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6, 24 and 48 hour intervals. 
Cytokine concentration was quantified in triplicate using R&D Systems Quantikine 
Mouse IL10, IL12 and Interferon γ ELISA kits. Mean cytokine concentrations ± SEM 
are shown. Statistical analysis was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
 
The above findings confirm the data using the Meso Scale Discovery multi-spot assay 
system. Raised pro-inflammatory IL12 and IFNγ levels with WRDD infection; and 
elevated anti-inflammatory IL10 levels with VVL15 infection. Again this is suggestive 
of a greater pro-inflammatory response as a result of the WRDD infection leading to 
increased viral clearance and diminished anti-tumour potency. 
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5.7 Chapter Conclusions 
 
 Assessment of several pro-inflammatory cytokines, including IL12, IFNγ, and 
TNFα, demonstrated a greater pro-inflammatory response to WRDD treatment both 
locally and systemically in an immunocompetent CMT93flank tumour model 
following IT virus delivery compared to VVL15. 
 Assessment of the anti-inflammatory cytokine IL10 showed higher levels locally 
and systemically with VVL15 treatment in an immunocompetent CMT93flank 
tumour model following IT virus delivery compared to WRDD. 
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6.  Results: Effect of IL10 expression on Lister strain anti-
tumour efficacy and biodistribution. 
 
The above data are suggestive of reduced induction of a pro-inflammatory response 
following Lister strain vaccinia virus treatment compared to Western Reserve. The 
consequences are reduced viral clearance and improved anti-tumour efficacy in vivo, as 
demonstrated by biodistribution, biological time-points and efficacy studies. Therefore 
to further improve Lister strain anti-tumour efficacy it was proposed to insert a murine 
IL10 gene into the VVL15 genome. It has been shown elsewhere that IL10 expressed by 
an adenovirus can inhibit peritoneal gastric cancer spread. 
157
 
 
Therefore a TK-deleted Lister strain vaccinia virus expressing murine IL10 (VVIL10), 
already demonstrated to reduce the incidence of auto-immune diabetes in a mouse 
model, 
240
 was provided by a collaborator. 
 
6.1. Confirmation of expression of the IL10 transgene in VVIL10 and 
determination of IL10 expression by VVL15 infection using ELISA. 
 
Firstly expression of the IL10 transgene by VVIL10 was confirmed by ELISA of 
CMT93, PT45 and SCCCVII tissue culture lysates infected with VVIL10, VVL15 and 
mock infection as controls. WRDD was also included to confirm that no endogenous 
IL10 was produced by this strain. 
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Figure 32. IL10 expression of CMT93 cells infected with VVL15 and VVIL10 at 6, 
24 and 48 hours post-infection. 2 x10
5 
CMT93 cells per 2ml well were infected with 
MOI 5 PFU/ml of VVL15, WRDD or VVIL10. Cells and supernatants were harvested 
at 6, 24 and 48 hours post-infection. Samples were repeatedly freeze-thawed and IL10 
expression was quantified using a murine IL10 ELISA. Mean IL10 concentration ± 
SEM are shown. Statistical analysis of IL10 concentration at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
 
Expression of the IL10 transgene in VVIL10 and to a lesser extent VVL15 was 
confirmed in the CMT93 cell line. No endogenous IL10 expression by uninfected 
CMT93 cells was found; nor following WRDD treatment. 
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Figure 33. IL10 expression of PT45 cells infected with VVL15 and VVIL10 at 6, 24 
and 48 hours post-infection. 2 x10
5 
PT45 cells per 2ml well were infected with MOI 5 
PFU/ml of VVL15, WRDD or VVIL10. Cells and supernatants were harvested at 6, 24 
and 48 hours post-infection. Samples were repeatedly freeze-thawed and IL10 
expression was quantified using a murine IL10 ELISA. Mean IL10 concentration ± 
SEM are shown. Statistical analysis of IL10 concentration at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
This experiment measured murine IL10 expression in a human pancreatic cancer cell 
line. The antibody against murine IL10 detected a signal from samples infected with 
VVIL10 and to a lesser extent those infected with VVL15. Therefore the measured IL10 
was made by the virus rather than the cancer cells themselves in response to the virus. 
VVIL10 has a murine IL10 gene and therefore would be expected to be detected by a 
murine-specific ELISA. VVL15 must encode an IL10 homologue that shows sufficient 
homology to murine IL10 to be detected by the ELISA. This viral IL10 homologue was 
absent from WRDD vaccinia virus. 
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Figure 34. IL10 expression of SCCVII infected with VVL15 and VVIL10 at 6, 24 
and 48 hours post-infection. 1 x10
5 
SCCVII cells per 2ml well were infected with 
MOI 5 PFU/ml of VVL15, WRDD or VVIL10. Cells and supernatants were harvested 
at 6, 24 and 48 hours post infection. Samples were repeatedly freeze-thawed and IL10 
expression was quantified using a murine IL10 ELISA. Mean IL10 concentration ± 
SEM are shown. Statistical analysis of IL10 concentration at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
IL10 expression was further confirmed in the murine HNSCC cancer cell line SCCVII 
after infection with VVL15 and VVIL10. 
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6.2. Anti-tumour potency of VVL15 and VVIL10 Lister strain vaccinia 
virus mutants in a selection of cancer cell lines. 
 
The effect of IL10 expression on in vitro cytotoxicity was determined using the MTS 
cell proliferation assay, as before, in a number of murine cancer cell lines and two 
human cancer cell lines (PT45, MKN45) from multiple organ sites. 
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Figure 35. Anti-tumour potency of VVL15 and VVIL10 in panel of cancer cell 
lines. Comparison of mean EC50 values ± SEM generated from sextuplicate MTS cell 
proliferation assays 6 days after infection; 1000 cells per well and an MOI of 1000 
PFU/cell. Statistical analysis was using the unpaired T-test with * representing 
statistical significance at p<0.05, ** representing statistical significance at p<0.01, * 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
Of the seven cell lines tested, all of which are murine except MKN45 and PT45, 
VVIL10 demonstrated greater or equivalent antitumour potency to VVL15. 
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6.3. Comparison of the viral replication of VVL15 and VVIL10 in a 
selection of cancer cell lines. 
As before when comparing the anti-tumour potency of VVL15 and WRDD, MTS cell 
proliferation data was compared with viral replication data. 
 
 
Tumour 
type 
Cell line 
VVL15 VVIL10 
Viral 
Replication 
(PFU/cell) 
SEM 
Viral 
Replication 
(PFU/cell) 
SEM 
HNSCC SCCVII 201.30 70.87 23.70 5.68 
Pancreatic 
PT45 1042.95 242.83 229.81 56.87 
Panc02 60.11 7.08 84.52 7.40 
Gastro 
intestinal 
CMT93 142.43 31.56 80.04 23.74 
CT26 94.21 23.73 20.55 6.40 
Table 14. Viral replication of VVL15 and VVIL10 vaccinia virus in a panel of 
human and murine tumour cell lines. Burst assays were infected with 1 PFU/cell of 
virus (2x10
5
 cells per well). Cell lysates were harvested at 24 hour intervals typically up 
to 96 hours. Mean viral replication at 72 hours ± SEM was determined by TCID50 assay 
on CV1 cells are tabulated. Grey shaded cells are murine cell lines; white cells are 
human cell lines. Bold figures represent the most potent virus overall; underlined 
figures represent the most potent virus comparing VVL15 and WRDD. Where two 
viruses are highlighted, they are jointly most potent statistically (i.e. no statistically 
significant difference). 
 
 
With the exception of Panc02, VVIL10 demonstrated inferior viral replication 
compared to VVL15. Panc02 is a very aggressive cancer cell line with a short doubling 
time. Microscopy of the six well plates following viral infection of PT45 and Panc02 
cells prior to cell scraping and cell lysis, showed increased cell death in the VVIL10-
treated wells compared to those treated VVL15 (Figures 36. and 37.). Reduced numbers 
of viable cells results in reduced viral replication as the virus life cycle is dependent on 
living cells. In cancer cell lines with very high multiplication rate, such as Panc02, cell 
death does not limit viral replication as there is a plentiful supply of viable cells to 
support virus progeny. 
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Figure 36. Microscopy of PT45 viral replication 6-well plates infected with VVIL10 
and VVL15. 2x10
5
 PT45 cells were seeded in 2ml 6-well plates and infected with 
VVL15 and VVIL10 (MOI = 1 PFU/ml). Microscopy of plates was performed at 48, 72 
and 96 hours post infection. Representative micrographs are shown at 40x 
magnification. 
 
 
 
 
Figure 37. Microscopy of Panc02 viral replication 6-well plates infected with 
VVIL10 and VVL15. 2x10
5
 Panc02 cells were seeded in 2ml 6-well plates and infected 
with VVL15 and VVIL10 (MOI = 1 PFU/ml). Microscopy of plates was performed at 
48, 72 and 96 hours post infection. Representative micrographs are shown at 40x 
magnification. 
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6.4. Anti-tumour potency of VVL15 and VVIL10 vaccinia virus 
mutants in a mouse colorectal carcinoma CMT93 nude mouse model.  
 
Having established enhanced anti-tumour potency of VVIL10 over VVL15 in vitro, 
potency was assessed in nude and immunocompetent mouse tumour models. 
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Figure 38a. Growth of established murine colorectal tumours in nude mice after 
treatment with different vaccinia virus mutants. 5x10
6
 CMT93 cells were seeded by 
subcutaneous injection into the right flank of 30 ICRF nu/nu mice. When tumours 
reached 4-5mm in diameter, 10 mice each received IT injections of PBS, VVL15 or 
VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). Tumours were measured twice weekly. Mean 
tumour sizes ± SEM are displayed until the death of the first mouse in each group. 
Statistical analysis of tumour sizes at stated time-points was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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Figure 38b. Animal survival of nude mice bearing established murine colorectal 
tumours after treatment with different vaccinia virus mutants. 5x10
6
 CMT93 cells 
were seeded by subcutaneous injection into the right flank of 30 ICRF nu/nu mice. 
When tumours reached 4-5mm in diameter, 10 mice each received IT injections of PBS, 
VVL15 or VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). Kaplan-Meier curves are shown. 
Log-rank test curve statistical analysis showed no significance between all 3 data sets. 
 
In the nude mouse CMT93 model no difference in animal survival or tumour 
progression was noted between the virus-treated animals and those subjected to mock 
infections with PBS. 
 
6.5. Anti-tumour potency of VVL15 and VVIL10 vaccinia virus 
mutants in a mouse colorectal carcinoma CMT93 immunocompetent 
mouse model. 
 
To assess the anti-tumour potency efficacy studies were performed using a C57BL/6 
immunocompetent mouse model. CMT93 flank tumours were grown and viruses 
(1x10
8
) were administered IT on a 3 day (days 1,3,5) and 5 day (1,2,3,4,5) injection 
regime. Our hypothesis was that the anti-tumour effect would be enhanced with the 5 
day injection regime; whilst being well tolerated by the mice. 
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Figure 39a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, VVL15 or VVIL10 (3 x 1x10
8 
PFU) on days 1,3,5. Tumours were 
measured twice weekly. Mean tumour sizes ± SEM are displayed until the death of the 
first mouse in each group. Statistical analysis of tumour sizes at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
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Figure 39b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus mutants.   
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5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, VVL15 or VVIL10 (3 x 1x10
8 
PFU) on days 1,3,5. Tumours were 
measured twice weekly.  Kaplan-Meier curves are shown. Log-rank test curve statistical 
analysis showed significance at the 0.1% level between PBS and VVL15 data sets; and 
at the 5% level between VVL15 and VVIL10. 
 
In the immunocompetent model, statistically significant differences in tumour growth 
were noted between the PBS, VVL15 and VVIL10 treatment regimes. The VVIL10 
treated mice showed reduced tumour progression and enhanced survival compared to 
PBS and VVL15. 
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Figure 40a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, VVL15 or VVIL10 (5 x 1x10
8 
PFU) on days 1,2,3,4,5. Tumours were 
measured twice weekly. Mean tumour sizes ± SEM are displayed until the death of the 
first mouse in each group. Statistical analysis of tumour sizes at stated time-points was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
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Figure 40b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus mutants. 
5x10
6
 CMT93 cells were seeded by subcutaneous injection into the right flank of 30 
C57BL/6 mice. When tumours reached 4-5mm in diameter, 10 mice each received IT 
injections of PBS, VVL15 or VVIL10 (5 x 1x10
8 
PFU) on days 1,2,3,4,5. Kaplan-Meier 
curves are shown. Log-rank test curve statistical analysis showed significance at the 5% 
level between VVL15 vs PBS and at the 1% level between VVL15 and VVIL10 data 
sets. 
 
With the five-day regime of injections reduced tumour progression was again noted 
with the VVIL10-treated group; indeed 6/10 animals showed complete tumour 
regression.  
 
 
6.6. Anti-tumour potency of VVL15 and VVIL10 vaccinia virus 
mutants in a mouse colorectal carcinoma CT26 immunocompetent 
mouse model. 
 
Having demonstrated reduced tumour progression with VVIL10-treated mice in the 
immunocompetent CMT93 models compared to VVL15, virus anti-tumour efficacy was 
investigated in a further immunocompetent model. 
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Figure 41a. Growth of established murine colorectal tumours in 
immunocompetent mice after treatment with different vaccinia virus mutants. 
1x10
6
 CT26 cells were seeded by subcutaneous injection into the right flank of 30 
BALB/c immunocompetent mice. When tumours reached 4-5mm in diameter, 10 mice 
each received IT injections of PBS, VVIL10 or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU). 
Tumours were measured twice weekly. Mean tumour sizes ± SEM are displayed until 
the death of the first mouse in each group. Statistical analysis of tumour sizes at stated 
time-points was performed using the unpaired T-test with * representing statistical 
significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
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Figure 41b. Animal survival of immunocompetent mice bearing established 
murine colorectal tumours after treatment with different vaccinia virus 
mutants.1x10
6
 CT26 cells were seeded by subcutaneous injection into the right flank of 
30 BALB/c immunocompetent mice. When tumours reached 4-5mm in diameter, 10 
mice each received IT injections of PBS, VVIL10 or VVL15 on days 1,3,5 (3 x 1x10
8 
PFU). Kaplan-Meier curves are shown. . Log-rank test curve statistical analysis showed 
significance at the 0.1% level between VVL15 and VVIL10 treated mice, and at the 1% 
level between VVL15 and PBS. 
 
In a different immunocompetent model, CT26 colorectal carcinoma, statistically 
significant differences in tumour progression between VVL15- and VVIL10-treated 
mice were again recorded. VVIL10 treated m ice showed marked tumour regression and 
prolonged animal survival. 
 
6.7. Anti-tumour potency of VVL15 and VVIL10 vaccinia virus 
mutants in a human pancreatic carcinoma PT45 nude mouse model. 
 
VVIL10 anti-tumour potency was further investigated in the model of human pancreatic 
PT45 flank tumours in ICRF nu/nu mice. 
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Figure 42a. Growth of established human pancreatic tumours in nude mice after 
treatment with different vaccinia virus mutants. 5x10
6
 PT45 cells were seeded by 
130 
 
subcutaneous injection into the right flank of 30 ICRF nude mice. When tumours 
reached 4-5mm in diameter, 10 mice each received IT injections of PBS, VVIL10 or 
VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Tumours were measured twice weekly. Mean 
tumour sizes ± SEM are displayed until the death of the first mouse in each group. 
Statistical analysis of tumour sizes at stated time-points was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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Figure 42b. Animal survival of nude mice bearing established human pancreatic 
tumours after treatment with different vaccinia virus mutants. 5x10
6
 PT45 cells 
were seeded by subcutaneous injection into the right flank of 30 ICRF nude mice. When 
tumours reached 4-5mm in diameter, 10 mice each received IT injections of PBS, 
VVIL10 and VVL15 on days 1,3,5 (3 x 1x10
7 
PFU). Kaplan-Meier curves are shown. 
Log-rank test curve statistical analysis showed significance at the 0.1% level between 
PBS and VVL15 & VVIL10 data sets. 
 
Marked tumour regression was demonstrated in the virus treated groups; with all 
tumours becoming virtually undetectable after 17 days. VVIL10 treated mice showed 
more enhanced tumour regression compared to VVL15 treated mice during the first 17 
days of the experiment. 
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6.8. Biodistribution of VVL15 and VVIL10 vaccinia virus mutants in 
immunocompetent C57BL/6 mice bearing flank CMT93 tumours, as 
determined by qRT-PCR. 
 
As before the behaviour of the virus in a mouse model was assessed through 
biodistribution studies in immunocompetent mice bearing CMT93 flank tumours. A 
single tail vein injection was used to deliver the viruses and control. Tumours and 
organs were harvested at specific time-points and subjected to virus quantification using 
qRT-PCR; which I have previously validated as an accurate method of virus 
measurement. 
 
Tumour 
Site 
PBS VVL15 VVIL10 
Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM Viral 
Recovery 
(PFU/ml/g) 
SEM 
Tumour 
0 0 23237.07 8439.10 282895.700 129522.5 
Ovary 
0 0 26.13 2.398 33.361 7.319 
Lung 
0 0 4292.67 691.937 285.553 47.499 
Liver 
0 0 166.99 34.239 126.608 28.974 
Spleen 
0 0 78.04 18.0735 19.363 1.9812 
Brain 
0 0 0 0 0 0 
Bone 
Marrow 
0 0 130.96 51.817 5.402 5.402 
Table 15. Vaccinia virus genome copy number of harvested CMT93 tumours in 
C57BL/6 immunocompetent mice following IV vaccinia virus treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right flank of 36 C57BL/6 
immunocompetent mice. When tumours reached 4-5mm in diameter, 12 mice each 
received single IV injections of PBS, VVIL10 or VVL15 (2 x 10
8 
PFU). On days 4, 8, 
and 12 four mice from each group were sacrificed and the tumours were harvested and 
frozen. Samples were then homogenised and repeatedly freeze-thawed. Lysates 
underwent DNA extraction. Mean viral genome copy numbers ± SEM were determined 
by qRT-PCR using the vaccinia late gene (VLTF-1); data for day 8 are tabulated.  
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Figure 43. Vaccinia virus genome copy number of harvested CMT93 tumours in 
C57BL/6 immunocompetent mice following IV vaccinia virus treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right flank of 36 C57BL/6 
immunocompetent mice. When tumours reached 4-5mm in diameter, 12 mice each 
received single IV injections of PBS, VVIL10 or VVL15 (2 x 10
8 
PFU). On days 4, 8, 
and 12 four mice from each group were sacrificed and the tumours were harvested and 
frozen. Samples were then homogenised and repeatedly freeze-thawed. Lysates 
underwent DNA extraction. Mean viral genome copy numbers ± SEM were determined 
by qRT-PCR using the vaccinia late gene (VLTF-1); data for day 8 are shown. 
Statistical analysis of viral genome copy number at stated time-points was performed 
using the unpaired T-test with * representing statistical significance at p<0.05, ** 
representing statistical significance at p<0.01, *** representing statistical significance at 
p<0.001 and ns indicating no statistical significance.
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VVIL10 biodistribution in a CMT93 flank tumour immunocompetent model 
demonstrated significantly higher viral replication in the tumours, with equivalent levels 
in the ovaries and liver, and reduced levels in the bone marrow, lungs and spleen. 
Therefore not only is VVIL10 likely to be more efficacious than VVL15 due to higher 
achieved tumour concentrations following systemic delivery, the side effect profile is 
likely to be better due to reduced viral titres in the bone marrow, lungs and spleen. 
 
6.9. Biological time-points of vaccinia virus mutants in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours determined by 
qRT-PCR. 
 
Following assessment of VVL15 and VVIL10 biodistribution in an immunocompetent 
murine tumour model, investigation into the behaviour of IT delivered viruses was 
examined. 
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Figure 44. Vaccinia virus genome copy number of harvested tumours in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours following IT vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received single IT  injections of PBS, VVIL10 or VVL15 (3 x 
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1x10
8 
PFU). On days 5, 10, 15 and 20 three mice from each group were sacrificed and 
the tumours were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
SEM were determined by qRT-PCR using the vaccinia late gene (VLTF-1). Statistical 
analysis of viral genome copy number at stated time-points was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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Figure 45. Vaccinia virus genome copy number of harvested ovaries in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours following IT vaccinia virus 
treatment. 5x10
6 
CMT93 cells were seeded by subcutaneous injection into the right 
flank of 36 C57BL/6 immunocompetent mice. When tumours reached 4-5mm in 
diameter, 12 mice each received single IT  injections of PBS, VVIL10 or VVL15 (3 x 
1x10
8 
PFU). On days 5, 10, 15 and 20 three mice from each group were sacrificed and 
the ovaries were harvested and frozen. Samples were then homogenised and repeatedly 
freeze-thawed. Lysates underwent DNA extraction. Mean viral genome copy numbers ± 
SEM were determined by qRT-PCR using the vaccinia late gene (VLTF-1). Statistical 
analysis of viral genome copy number at stated time-points was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
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statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
 
 
Biological time-points studies showed that VVIL10 delivered IT replicated better than 
VVL15 in the flank tumours of immunocompetent mouse. This would explain why 
better anti-tumour efficacy was demonstrated in vivo. VVL15 delivered IT, and to a 
much lesser extent VVIL10, was able to spread to and replicate within the mouse 
ovaries. 
 
 
 
6.10. Biodistribution of vaccinia virus mutants in nude mice bearing 
human pancreatic carcinoma PT45 flank tumours determined by qRT-
PCR. 
 
Following assessment of VVL15 and VVIL10 biodistribution in immunocompetent 
murine tumour models, investigation into the biodistribution of the viruses in a model of 
human cancer was undertaken. The human pancreatic tumour PT45 was chosen and 
flank tumours in ICRF nu/nu mice were grown. 
 
0 5 10 15 20
0
500 000
1 000 000
1.5100 6
VVL15
PBS
VVIL10
*
*
Days post injection
A
rb
it
a
ry
 u
n
it
s
(2
0
n
g
 D
N
A
 p
e
r 
re
a
c
ti
o
n
)
 
 
Figure 46. Vaccinia virus genome copy number of harvested tumours in ICRF 
nu/nu mice bearing PT45 flank tumours following IV vaccinia virus treatment. 
5x10
6 
PT45 cells were seeded by subcutaneous injection into the right flank of 27 ICRF 
nu/nu mice. When tumours reached 4-5mm in diameter, 9 mice each received single IV  
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injections of PBS, VVIL10 or VVL15 (1x10
7 
PFU). On days 8, 12 and 18 three mice 
from each group were sacrificed and the tumours were harvested and frozen. Samples 
were then homogenised and repeatedly freeze-thawed. Lysates underwent DNA 
extraction. Mean viral genome copy numbers ± SEM were determined by qRT-PCR 
using the vaccinia late gene (VLTF-1). 
 
The biodistribution results are in keeping with the PT45 in vitro cell proliferation 
assays, which showed superior anti-tumour potency of VVIL10 over VVL15; and the in 
vivo efficacy studies, where reduced tumour growth and improved animal survival was 
recorded in a nude model of human pancreatic cancer. 
 
6.11. Biological time-points of vaccinia virus mutants in ICRF nu/nu 
mice bearing PT45 flank tumours determined by qRT-PCR. 
 
Assessment of viruses delivered IT was also made in the mouse ICRF nu/nu PT45 
human pancreatic cancer model. 
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Figure 47. Vaccinia virus genome copy number of harvested tumours in ICRF 
nu/nu mice bearing PT45 flank tumours following IT vaccinia virus treatment. 
5x10
6 
PT45 cells were seeded by subcutaneous injection into the right flank of 30 ICRF 
nu/nu mice. When tumours reached 4-5mm in diameter, 12 mice each received single IT  
injections of PBS, VVIL10 or VVL15 (3 x 1x10
7 
PFU). On days 7, 12 and 20 three 
mice from each group were sacrificed and the tumours were harvested and frozen. 
Samples were then homogenised and repeatedly freeze-thawed. Lysates underwent 
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DNA extraction. Mean viral genome copy numbers ± SEM were determined by qRT-
PCR using the vaccinia late gene (VLTF-1). 
 
Higher viral titres for VVIL10 were recovered compared to VVL15; indicating that 
VVIL10 is better able to replicate in cancer cells in vivo. This result is in keeping with 
the in vitro cytotoxicity studies, as well as the PT45 efficacy study. 
 
6.12 Chapter Conclusions 
 
 IL10 is expressed at high levels when CMT93. PT45, SCCVII cells are infected 
with  VVIL10, a TK-deleted Lister mutant encoding a murine IL10 gene. 
 A lower level of IL10 expression was demonstrated following VVL15 infection of 
the same cell lines. 
 No IL10 expression was demonstrated by WRDD infection of the same cell lines. 
 Higher levels of VVL15 were found in cell lines following viral infection compared 
to VVIL10, except Panc02. 
 No differences in tumour progression and animal survival were demonstrated in a 
nude CMT93 cancer model following IT virus delivery to flank tumours. 
 In the immunocompetent model VVIL10 IT treated mice demonstrated reduced 
tumour progression and improved animal survival compared to VVL15 treated mice 
bearing CMT93 tumours. This effect was enhanced with five consecutive days of 
injections  (5 x 1x10
8 
PFU)  compared to three (3 x 1x10
8 
PFU). 
 Biodistribution data in an immunocompetent murine CMT93 flank tumour model 
shows higher levels of virus following VVIL10 treatment within the tumours with 
less off-target virus, compared to VVL15 treated  mice. This was also the case with 
the human PT45nude model following systemic delivery of both viruses.. 
 Local delivery of viruses to nude and immunocompetent mice bearing PT45 and 
CMT93 flank tumours respectively, demonstrated higher levels of VVIL10 
compared to VVL15 within harvested tumours. 
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7. Results: Investigation into the mechanism of enhanced 
VVIL10 anti-tumour potency over VVL15. 
 
Having demonstrated that VVIL10 has greater anti-tumour potency over VVL15 in 
vitro and in vivo, possible mechanisms for this observation were then investigated.  
 
7.1. Anti-tumour potency of recombinant IL10 on CMT93 colorectal 
cancer cell line in vitro. 
 
Firstly investigation was made into whether the effect of IL10 on cancer cells was a 
direct action, independent of the virus.  To determine this, CMT93 cells were exposed 
to murine unconjugated recombinant IL10 (rIL10) at a range of concentrations in an 
MTS cell proliferation assay.   
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Figure 48. Effect of recombinant IL10 on CMT93 cancer cells. 5000 cells were 
seeded per well and serial dilutions of recombinant IL10 were applied, with a starting 
concentration of 1x10
5
pg/ml. Following 3 days of incubation, the viable cells were 
assayed with MTS reagent and graphed as a dose-response curve using non-linear 
regression analysis. 
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No cytopathic effect of recombinant IL10 was demonstrated on CMT93 cells in a 
concentration range 0.001 - 1x10
5
pg/ml. This corroborates data from another group that 
used rIL10 directly applied to CT26 cells, with a concentration range from 800 – 
3x10
6
pg/ml, with no effect on cell proliferation. 
59
 
 
7.2. Anti-tumour potency of recombinant IL10 in conjunction with 
VVL15 compared to VVL15 and VVIL10 alone infected CMT93 
colorectal cancer cells. 
 
As no cytopathic effect was observed with recombinant IL10 directly applied to cancer 
cells, it was investigated whether an effect would be demonstrated in conjunction with 
viruses. Specifically I sought to determine if rIL10 and VVL15 was able to result in 
equivalent cytotoxicity to VVIL10. 
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Figure 49. Anti-tumour potency of recombinant IL10 in conjunction with VVL15 
compared to VVL15 and VVIL0 alone infected CMT93 colorectal cancer cells. 
5000 CMT93 cells were seeded per well and infected with vaccinia virus at a series of 
increasing MOI (highest MOI of 1000 PFU/cell). Recombinant IL10 (1x10
6
pg/ml) was 
added to the VVL15 + rIL10 group wells immediately prior to infection. Following 3 
days of incubation, cell proliferation MTS assays were performed and the results 
graphed as a dose-response curve. 
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Figure 50. Anti-tumour potency of VVL15 + rIL10, VVL15 and VVIL10 infected 
CMT93 colorectal cancer cells. Comparison of mean EC50 values ± SEM generated 
from sextuplicate. 5000 CMT93 cells were seeded per well and infected with vaccinia 
virus at a series of increasing MOI (highest MOI of 1000 PFU/cell). MTS cell 
proliferation assays were performed 3 days after infection. Statistical analysis was 
performed using the unpaired T-test with * representing statistical significance at 
p<0.05, ** representing statistical significance at p<0.01, *** representing statistical 
significance at p<0.001 and ns indicating no statistical significance. 
 
As demonstrated before VVIL10 exhibited superior cytotoxicity in vitro compared to 
VVL15. However VVL15 with rIL10 showed an intermediate level potency. Therefore, 
to a degree the rIL10, was able to improve VVL15 potency; partially compensating for 
the lack of IL10 expression compared to VVIL10. This may suggest the concentration 
of rIL10 on its own was insufficient in the previous experiment to exert a direct, non-
virally mediated, cytotoxic effect; or further unknown factors produced by the vaccinia 
virus work in conjunction with IL10 to induce an elevated cytotoxic effect compared to 
VVL15. 
 
7.3. Analysis of multiple pro-inflammatory cytokines of the serum in 
C57BL/6 immunocompetent mice bearing CMT93 flank tumours 
following intratumoural viral injection. 
 
To assess the differences in pro-inflammatory cytokines of the serum in C57BL/6 
immunocompetent mice bearing CMT93 flank tumours, serum was sampled at various 
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time-points following different IT viral treatments. Serum samples were subjected to 
cytokine quantification using a mouse proinflammatory ultra-sensitive kit for the Meso 
Scale Discovery multi-spot assay system.  
 
Cytokine PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL1β 0.000 0.000 0.04157703 
0.041
57703 2.793901 
0.3649
448 
TNFα 0.000 0.000 1.005828 
0.355
4596 8.915852 
0.9564
027 
IFNγ 1.409787 
0.090
03938 2.398584 
0.324
78 58.30131 
12.671
54 
IL10 14.97578 
1.881
992 84.60355 
5.741
311 165.0063 
6.7918
69 
IL12 0.000 0.000 0.000 0.000 35.9429 
4.2524
29 
IL6 11.38702 
1.228
3 29.93359 
4.157
31 159.2583 
5.4131
41 
IL8 189.8381 
6.495
094 204.7455 
11.96
176 85.29649 
5.4744
84 
Table 16. Concentration of multiple pro-inflammatory cytokines of sampled serum 
in C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the serum was sampled. The cytokine concentration was quantified using a mouse pro-
inflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot assay system 
(2 animals per group in sample duplicate). Mean cytokine concentrations at day 10 ± 
SEM are shown.  
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Figure 51. Concentration of multiple pro-inflammatory cytokines of sampled 
serum in C57BL/6 immunocompetent mice bearing CMT93 flank tumours 
following intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by 
subcutaneous injection into the right flank of 27 C57BL/6 mice. When tumours reached 
4-5mm in diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on 
days 1,3,5 (3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were 
sacrificed and the serum was sampled. The cytokine concentration was quantified using 
a mouse pro-inflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot 
assay system (2 animals per group in sample duplicate). Mean cytokine concentrations 
at day 10 ± SEM are shown. Statistical analysis was performed using the unpaired T-
test with * representing statistical significance at p<0.05, ** representing statistical 
significance at p<0.01, *** representing statistical significance at p<0.001 and ns 
indicating no statistical significance. 
 
The serum cytokine levels reveal higher pro-inflammatory levels for VVIL10 compared 
to VVL15, with the exception of IL8. This is difficult to explain given the greater 
tumour biodistribution and superior anti-tumour efficacy of VVIL10 over VVL15. 
However in contrast to the previous experiments comparing cytokine responses 
following VVL15 and WRDD treatment, these high pro-inflammatory cytokines levels 
now occur in conjunction with high IL10 levels. Although this may explain why the 
viral titres of VVIL10 were less than VVL15 in the highly vascular bone marrow, 
143 
 
spleen and lungs; with the induction of a pro-inflammatory response clearing the virus 
from the circulation. Again the relative levels and combinations of cytokines may be 
important in explaining viral persistence and anti-tumour potency of the viruses tested. 
 
 
7.4. Analysis of multiple pro-inflammatory cytokines in CMT93 flank 
tumour homogenates following intratumoural viral injection of 
C57BL/6 immunocompetent mice. 
 
To assess the differences in pro-inflammatory cytokines in the tumour 
microenvironment, CMT93 flank tumours were grown in C57BL/6 immunocompetent 
mice and different viral treatments were applied intratumourally. Harvested tumours 
from sacrificed mice were weighed, homogenised and subjected to cytokine 
quantification using a Meso Scale Discovery multi-spot assay system mouse pro-
inflammatory ultra-sensitive kit.  
 
Cytokine PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM Cytokine 
concentration 
(pg/ml/g) 
SEM 
IL1β 374.89 41.03 2105.35 347.6 2121.22 102.27 
TNFα 8.359 0.810 15.34 1.407 1.458 0.3791 
IFNγ 37.73 5.974 76.37 9.292 239.15 19.800 
IL10 60.25 10.93 132.54 13.59 426.90 80.919 
IL12 4.574 0.380 59.29 16.04 87.998 17.980 
IL6 360.82 8.625 370.64 66.40 215.97 40.302 
IL8 83.35 9.717 1509.98 261.9 510.93 61.936 
Table 17. Concentration of multiple pro-inflammatory cytokines of harvested and 
homogenised CMT93 flank tumour samples following IT viral infection in 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15 (day 15 samples not analysed here), 3 animals 
from each group were sacrificed and the tumours were harvested. The tumours were 
weighed, homogenised and subjected to cytokine quantification using a mouse 
proinflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot assay 
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system (2 animals per group in sample duplicate). Mean cytokine concentrations at day 
10 ± SEM are shown. Cytokine concentration was corrected for tumour weight.  
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Figure 52. Concentration of multiple pro-inflammatory cytokines of harvested and 
homogenised CMT93 flank tumour samples following IT viral infection in 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15 (day 15 samples not analysed here), 3 animals 
from each group were sacrificed and the tumours were harvested. The tumours were 
weighed, homogenised and subjected to cytokine quantification using a mouse 
proinflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot assay 
system (2 animals per group in sample duplicate). Mean cytokine concentrations at day 
10 ± SEM are shown. Cytokine concentration was corrected for tumour weight. 
Statistical analysis was performed using the unpaired T-test with * representing 
statistical significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
When considering the cytokine levels found within tumours the cytokine profile is more 
complicated, as it was with WRDD and VVL15. VVIL10-treated tumours exhibited 
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higher levels of IL10 and IFNγ; whilst VVL15-infected tumours resulted in higher IL8 
and TNFα. Insignificant differences were found between the two virus treatments for 
IL12, IL1β and IL6. Both IFNγ and TNFα have anti-tumour and anti-viral functions; 
but, as discussed before, cytokines are considered part of a “cytokine network”, and 
therefore the relative levels and combinations of cytokines may be important in 
explaining viral persistence and anti-tumour potency of the viruses tested. 
 
 
7.5. Analysis of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection. 
 
To further investigate the observed differences in anti-tumour potency between VVL15 
and VVIL10 an analysis of multiple pro-inflammatory cytokines was performed using a 
mouse pro-inflammatory ultra-sensitive kit for the Meso Scale Discovery multi-spot 
assay system. Samples were analysed from supernatants of tissue cultured CMT93 cells 
infected with viruses. 
 
Cytokine PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL1β 0.000 0.000 5.081 0.094 16.790 0.408 
TNFα 0.000 0.000 0.000 0.000 0.000 0.000 
IFNγ 0.000 0.000 0.000 0.000 8.1655 0.309 
IL10 4.795 4.795 337.7298 32.75 7250.18 855.46 
IL12 11.270 5.687 48.63353 4.555 219.63 6.961 
IL6 14.355 2.346 0.000 0.000 241.40 8.880 
IL8 55.253 7.221 266.4881 9.017 193.39 9.361 
Table 18. Concentration of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6 and 24 hour intervals. 
Cytokine concentration was quantified in triplicate using a Meso Scale Discovery multi-
spot assay system mouse proinflammatory 7-plex ultra-sensitive kit. Mean cytokine 
concentrations at 24 hours ± SEM are shown. 
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Figure 53. Concentration of multiple pro-inflammatory cytokines of CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6 and 24 hour intervals. 
Cytokine concentration was quantified in triplicate using a Meso Scale Discovery multi-
spot assay system mouse proinflammatory 7-plex ultra-sensitive kit. Mean cytokine 
concentrations at 24 hours ± SEM are shown. Statistical analysis was performed using 
the unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
 
 
Comparing VVIL10 to VVL15 higher levels of IFNγ, IL10, IL12, IL1β and IL6 were 
demonstrated with VVIL10 infected cells. VVL15-infected cultures had higher levels of 
IL8, and no TNFα was detected. This pattern was similar to the serum pattern. 
 
Having reviewed the different cytokines and virus combinations, the cytokines that 
showed most promise as to explain the different anti-tumour potencies between VVL15 
and VVIL10 in vitro and in vivo were IL10, IL12 and Interferon γ. More samples from 
an additional time-points and in sample triplicate were analysed. 
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7.6. Analysis of IL10, IL12 and Interferon γ cytokine concentrations of 
the serum in C57BL/6 immunocompetent mice bearing CMT93 flank 
tumours following intratumoural viral injection. 
 
IL10, IL12 and Interferon γ cytokine concentrations in the serum of C57BL/6 
immunocompetent mice bearing CMT93 flank tumours following different IT viral 
treatments were quantified using R&D Systems Quantikine ELISA kits. 
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PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL12 
 
5 0.000 0.000 0.000 0.000 9.079 0.416 
10 0.6228 0.0736 0.000 0.000 10.901 1.283 
15 0.8979 0.1031 0.1299 0.045 21.547 1.371 
IFNγ 
5 0.3376 0.0230 0.5186 0.023 15.356 1.682 
10 0.3543 0.0169 0.5765 0.042 16.393 1.932 
15 0.9062 0.0357 0.4263 0.026 20.915 1.419 
IL10 
 
5 0.0993 0.0628 23.746 2.882 50.240 3.170 
10 0.000 0.000 10.099 0.886 48.025 2.987 
15 0.000 0.000 3.0025 0.395 29.596 3.717 
Table 19. Concentration of multiple pro-inflammatory cytokines of sampled serum 
in C57BL/6 immunocompetent mice bearing CMT93 flank tumours following 
intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, WRDD, VVL15 or VVIL10 on 
days 1,3,5 (3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were 
sacrificed and the serum was sampled. The cytokine concentration was quantified using 
R&D Systems Quantikine Mouse IL10, IL12 and Interferon γ ELISA kits (3 animals 
per group in sample duplicate). Mean cytokine concentrations ± SEM are shown. 
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Figure 54. Concentration of multiple pro-inflammatory cytokines of sampled 
serum in C57BL/6 immunocompetent mice bearing CMT93 flank tumours 
following intratumoural viral injection. 5x10
6
 CMT93 cells were seeded by 
subcutaneous injection into the right flank of 27 C57BL/6 mice. When tumours reached 
4-5mm in diameter, 9 mice each received IT injections of PBS, WRDD, VVL15 or 
VVIL10 on days 1,3,5 (3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each 
group were sacrificed and the serum was sampled. The cytokine concentration was 
quantified using R&D Systems Quantikine Mouse IL10, IL12 and Interferon γ ELISA 
kits (3 animals per group in sample duplicate). Mean cytokine concentrations ± SEM 
are shown. Statistical analysis was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
 
The above data confirm the previous pattern of multiple cytokine data over two time-
points. 
 
7.7. Analysis of IL10, IL12 and Interferon γ cytokine concentrations 
from CMT93 flank tumour homogenates following intratumoural viral 
injection in C57BL/6 immunocompetent mice. 
 
In order to assess IL10, IL12 and Interferon γ cytokine concentrations in the tumour 
microenvironment, CMT93 flank tumours were grown in C57BL/6 immunocompetent 
mice and different viral treatments were applied intratumourally. Harvested tumours 
from sacrificed mice were weighed, homogenised and subjected to cytokine 
quantification using R&D Systems Quantikine ELISA kits. 
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C
y
to
k
in
e 
D
a
y
 
PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL12 
 
5 0.9225 0.070 18.07 2.640 54.527 10.02 
10 1.1699 0.055 19.83 2.552 41.733 4.631 
15 0.892 0.114 20.33 1.963 48.382 4.393 
IFNγ 
5 14.419 0.700 30.88 2.092 73.486 8.780 
10 10.487 0.960 19.10 1.329 109.01 9.824 
15 14.249 0.599 15.94 0.713 91.810 5.929 
IL10 
 
5 11.737 1.611 82.54 7.448 244.30 27.33 
10 12.442 1.404 43.02 3.140 214.76 15.7 
15 9.081 0.778 47.06 4.460 96.206 8.946 
Table 20. Concentration of multiple pro-inflammatory cytokines of harvested and 
homogenised CMT93 flank tumour samples following IT viral infection in 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using R&D Systems Quantikine Mouse IL10, IL12 and 
Interferon γ ELISA kits (3 animals per group in sample duplicate). Cytokine 
concentration was corrected for tumour weight. Mean cytokine concentrations ± SEM 
are shown. 
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Figure 55. Concentration of multiple pro-inflammatory cytokines of harvested and 
homogenised CMT93 flank tumour samples following IT viral infection in 
C57BL/6 immunocompetent mice. 5x10
6
 CMT93 cells were seeded by subcutaneous 
injection into the right flank of 27 C57BL/6 mice. When tumours reached 4-5mm in 
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diameter, 9 mice each received IT injections of PBS, VVL15 or VVIL10 on days 1,3,5 
(3 x 1x10
8 
PFU). At days 5, 10 and 15, 3 animals from each group were sacrificed and 
the tumours were harvested. The tumours were weighed, homogenised and subjected to 
cytokine quantification using R&D Systems Quantikine Mouse IL10, IL12 and 
Interferon γ ELISA kits (3 animals per group in sample duplicate). Cytokine 
concentration was corrected for tumour weight. Mean cytokine concentrations ± SEM 
are shown. Statistical analysis was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
 
These data compared to the multiple cytokine data over two time-points show the same 
pattern for IL10 and IFNγ; with VVIL10 inducing higher levels of these cytokines. 
However now there are significant differences in IL12 levels, with VVIL10 inducing 
higher levels. 
 
7.8. Analysis of IL10, IL12 and Interferon γ cytokine concentrations in 
CMT93 tissue culture supernatants following viral infection. 
 
IL10, IL12 and Interferon γ cytokine concentrations of CMT93 tissue culture 
supernatants infected 6, 24 and 48 hours following mock, VVL15 and VVIL10 
infection were quantified using R&D Systems Quantikine ELISA kits. 
 
C
y
to
k
in
e 
H
o
u
rs
 
PBS VVL15 VVIL10 
Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM Cytokine 
concentration 
(pg/ml) 
SEM 
IL12 
 
6 3.259 0.358 20.700 1.651 55.623 1.9947 
24 4.019 0.293 14.251 1.473 62.156 5.1402 
48 3.217 0.243 11.911 1.176 68.847 4.5780 
IFNγ 
6 0.000 0.000 0.000 0.000 1.378 0.1332 
24 0.000 0.000 0.000 0.000 3.323 0.3093 
48 0.000 0.000 0.159 0.057 4.698 0.2195 
IL10 
 
6 0.000 0.000 22.769 3.183 548.350 28.919 
24 1.291 0.636 91.082 4.954 2433.62 296.10 
48 1.486 0.620 138.249 4.816 3225.154 155.32 
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Table 21. Concentration of multiple pro-inflammatory cytokines in CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6, 24 and 48 hour intervals. 
Cytokine concentration was quantified in triplicate using R&D Systems Quantikine 
Mouse IL10, IL12 and Interferon γ ELISA kits. Mean cytokine concentrations ± SEM 
are shown. 
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Figure 56. Concentration of multiple pro-inflammatory cytokines in CMT93 tissue 
culture samples following viral infection in vitro. 2x10
5
 cells per well were infected 
with 1 PFU/cell of virus. Cell lysates were harvested at 6, 24 and 48 hour intervals. 
Cytokine concentration was quantified in triplicate using R&D Systems Quantikine 
Mouse IL10, IL12 and Interferon γ ELISA kits. Mean cytokine concentrations ± SEM 
are shown. Statistical analysis was performed using the unpaired T-test with * 
representing statistical significance at p<0.05, ** representing statistical significance at 
p<0.01, *** representing statistical significance at p<0.001 and ns indicating no 
statistical significance. 
 
These data compared to the multiple cytokine data over two time-points show the same 
pattern for VVL15- and VVIL10-treated mice. 
 
7.9. Analysis of tumour homogenate IL10 concentrations in nude 
mouse bearing PT45 flank tumours following IT vaccinia virus 
treatment. 
 
Having assessed IL10 expression in vitro and in vivo in a murine colorectal CMT93 
immunocompetent tumour model following IT virus injection, expression was analysed 
in a human cancer model in nude mice. As employed before a PT45 human pancreatic 
152 
 
flank tumour model was used and harvested tumours and serum were subjected to IL10 
quantification using an R&D Systems Quantikine Mouse IL10 ELISA kit, following 
homogenisation. 
 
D
a
y
 
PBS WRDD VVL15 VVIL10 
Cytokine 
concent- 
ration  
(pg/ml/g) 
SEM Cytokine 
concent- 
ration  
(pg/ml) 
SEM Cytokine 
concent- 
ration  
(pg/ml) 
SEM Cytokine 
concent- 
ration  
(pg/ml) 
SEM 
7 214.8 21.55 894.5 216.2 4869 450.6 743.9 743.9 
12 1016 72.90 386.8 43.78 6680 330.4 1006 1006 
20 708.3 133.7 409.4 189.0 1446 226.5 87.19 87.19 
Table 22. Concentration of IL10 in harvested tumours from ICRF nu/nu mice 
bearing PT45 flank tumours following intratumoural viral injection. 5x10
6
 PT45 
cells were seeded by subcutaneous injection into the right flank of 36 ICRF nu/nu mice. 
When tumours reached 4-5mm in diameter, 9 mice each received IT injections of PBS, 
WRDD, VVL15 or VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). At days 7, 12 and 20, 3 
animals from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using R&D Systems Quantikine Mouse IL10 ELISA kit (3 
animals per group in sample duplicate). Mean cytokine concentrations ± SEM are 
shown. 
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Figure 57. Concentration of IL10 in harvested tumours from ICRF nu/nu mice 
bearing PT45 flank tumours following intratumoural viral injection. 5x10
6
 PT45 
cells were seeded by subcutaneous injection into the right flank of 36 ICRF nu/nu mice. 
When tumours reached 4-5mm in diameter, 9 mice each received IT injections of PBS, 
WRDD, VVL15 or VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). At days 7, 12 and 20, 3 
animals from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using R&D Systems Quantikine Mouse IL10 ELISA kit (3 
animals per group in sample duplicate). Mean cytokine concentrations ± SEM are 
shown. Statistical analysis was performed using the unpaired T-test with * representing 
statistical significance at p<0.05, ** representing statistical significance at p<0.01, *** 
representing statistical significance at p<0.001 and ns indicating no statistical 
significance. 
 
These data show the same pattern as in the CMT93 model data, with high IL10 levels in 
VVIL10-treated tumours and moderate levels in VVL15-treated tumours. Negligible 
levels were found with WRDD and mock infection. This again suggests the IL10 
detected in VVIL10-treated mice is virally encoded and not produced by the host cell in 
response to the viral infection. Furthermore, it is likely Lister strain vaccinia virus 
produces an IL10 homologue able to react with the murine IL10 antibody. 
 
7.10. Analysis of serum IL10 concentrations in nude mouse bearing 
PT45 flank tumours following IT vaccinia virus treatment  
 
IL10 expression in the serum of nude mice bearing PT45 tumours was also assessed 
following IT vaccinia virus administration. 
 
D
a
y
 
PBS WRDD VVL15 VVIL10 
Cytokine 
concent-
ration 
(pg/ml) 
SEM Cytokine 
concent-
ration 
 (pg/ml) 
SEM Cytokine 
concent-
ration  
(pg/ml) 
SEM Cytokine 
concent-
ration 
(pg/ml) 
SEM 
7 103.8 24.46 94.91 15.14 1081 130.8 3220 314.8 
12 194.4 21.73 195.2 61.78 1115 85.07 4247 172.7 
20 131.3 23.05 157.7 29.59 574.0 108.2 1891 235.3 
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Table 23. Concentration of IL10 in sampled serum of ICRF nu/nu mice bearing 
PT45 flank tumours following intratumoural viral injection. 5x10
6
 PT45 cells were 
seeded by subcutaneous injection into the right flank of 36 ICRF nu/nu mice. When 
tumours reached 4-5mm in diameter, 9 mice each received IT injections of PBS, 
WRDD, VVL15 or VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). At days 7, 12 and 20, 3 
animals from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using R&D Systems Quantikine Mouse IL10 ELISA kit (3 
animals per group in sample duplicate). Mean cytokine concentrations ± SEM are 
shown.  
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Figure 58. Concentration of IL10 in sampled serum of ICRF nu/nu mice bearing 
PT45 flank tumours following intratumoural viral injection. 5x10
6
 PT45 cells were 
seeded by subcutaneous injection into the right flank of 36 ICRF nu/nu mice. When 
tumours reached 4-5mm in diameter, 9 mice each received IT injections of PBS, 
WRDD, VVL15 or VVIL10 on days 1,3,5 (3 x 1x10
7 
PFU). At days 7, 12 and 20, 3 
animals from each group were sacrificed and the serum was sampled. The cytokine 
concentration was quantified using R&D Systems Quantikine Mouse IL10 ELISA kit (3 
animals per group in sample duplicate). Statistical analysis was performed using the 
unpaired T-test with * representing statistical significance at p<0.05, ** representing 
statistical significance at p<0.01, *** representing statistical significance at p<0.001 and 
ns indicating no statistical significance. 
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This finding is the same as found in the CMT93 immunocompetent mouse model. High 
IL10 levels are found with VVIL10 infection, albeit lower than the level measured from 
the tumour samples, moderate levels with VVL15 infections, and negligible levels with 
WRDD and PBS. 
 
7.11 Chapter Conclusions 
 
 Recombinant IL10 has no effect on CMT93 cells in vitro at the concentration range 
of 0.001 - 1x10
5
pg/ml. 
 Recombinant IL10 (1x106pg/ml) in combination with VVL15 (MOI  1x10-5 to 1000 
PFU/cell) had an intermediate EC50 compared to VVIL10 alone (higher) and VVL15 
alone (lower).  
 Serum cytokine profiles of immunocompetent mice bearing CMT93 flank tumours 
following IT viral treatments revealed higher levels of pro-inflammatory cytokines  
in conjunction with higher IL10 anti-inflammatory cytokine with VVIL10 compared 
to VVL15. 
 Tumour homongenates of immunocompetent mice bearing CMT93 flank tumours 
following IT treatments revealed high IL10 and IFNγ, whilst VVL15 had high IL8 
and TNFα. 
 High IL10 expression from serum and tumours was demonstrated in a human model 
of pancreatic cancer, PT45, following VVIL10 and to a lesser extent VVL15, 
treatment of flank tumours with IT virus. 
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Discussion 
 
Key Findings 
 
 Lister strain vaccinia virus demonstrated superior anti-tumour potency and cancer-
selective replication in vitro and in vivo, compared to Western Reserve; especially 
in human cancer cell lines. 
 Greater tumour-selective replication following local and systemic delivery of Lister 
strain virus to immunocompetent mice compared to Western Reserve. 
 Reduced local and systemic pro-inflammatory response with Lister strain virus 
treatment; with associated heightened anti-inflammatory IL10 response. 
 An IL10 expressing Lister strain mutant has increased anti-tumour potency and 
tumour selective replication. 
 
 
The Western Reserve (WR) strain of vaccinia virus is the dominant vaccinia strain in 
oncolytic viral gene therapy research due to its perceived superior anti-tumour potency 
and selectivity following publication of recent evidence comparing ten wild-type 
vaccinia virus strains in vitro. 
82
 However this paper compared wild-type viruses which 
we know from clinical trials in the 1970s and 1990s are well tolerated, but exhibit poor 
efficacy. 
60
 Additionally the basis for the conclusion of WR superiority was founded on 
in vitro viral replication studies in two human cancer cell lines. An ovarian carcinoma 
cell line, A2780, and colorectal carcinoma cell line, HCT116, compared to replication in 
two normal cell lines; normal human bronchial epithelial (NHBE) and small airway 
bronchial epithelial (SAEC) cells. This is not a comprehensive panel of cancer cell lines 
to draw such a broad conclusion and relies on a single technique, measuring viral 
replication. A more robust comparison strategy would present data for several cancer 
cell lines and use a variety of techniques, including in vivo experiments.  
 
I present, in this study, experiments using cancer cell lines from multiple organ primary 
sites, both human and murine. Additionally I have utilised two in vitro methods to 
demonstrate anti-tumour potency, both viral replication assays and MTS cell 
proliferation assays; as well as evidence of comparative in vivo efficacy. Although I 
have demonstrated higher anti-tumour potency of WR strains in five murine cancer cell 
lines from multiple primary sites (head & neck, pancreatic, colorectal and ovarian), 
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Lister strain, VVL15, showed greater anti-tumour potency compared to WR strain, 
WRDD, in 11 out of 14 human cancer cell lines. Of the remaining three human cancer 
cell lines, one showed equivalent EC50 values between VVL15 and WRDD (MKN45 
human gastric adenocarcinoma cell line) and the other two exhibited greater anti-tumour 
potency for WRDD compared to VVL15 (A2780 and HCT116). Interestingly these two 
cancer cell lines were used by Steve Thorne’s group to evidence WR superiority over all 
other vaccinia virus strains, 
82
 but appear to be outliers to the general trend. The 
apparent murine tropism of the WR strain is not surprising given it was developed by 
repeated passage of the Wyeth vaccinia virus strain in mice brains. 
246
 
 
Wild-type poxviruses demonstrate wide tissue tropism, 
89
 but some strains have inherent 
tumour selectivity that can be further enhanced by deletions of genes such as thymidine 
kinase 
241
 and vaccinia growth factor. 
83
 To test the tumour selectivity of Lister and WR 
vaccinia virus strains, replication in normal human bronchial epithelial (NHBE) cells 
was compared to replication in specific human cancer cell lines. NHBE was chosen as 
poxviruses generally spread via the respiratory tract or direct skin inoculation, and 
therefore must replicate to some extent in normal epithelial cells of the skin and lung. In 
MiaPaCa2, PT45, PANC1 and SUIT2 human cancer cell lines VVL15 demonstrated 
higher ratios of replication in cancer cells compared to NHBE cell lines; indicating 
superior tumour selectivity. This cancer-selective viral replication was significantly 
better for VVL15 compared to WRDD in equivalent cell lines. 
 
To assess in vivo anti-tumour efficacy, Lister and WR vaccinia virus mutants were then 
administered IT to nude and immunocompetent mice bearing FaDu human HNSCC, 
PT45 human pancreatic carcinoma, CMT93 and CT26 murine colorectal flank tumours. 
In nude mouse  human cancer models, FaDu (HNSCCC) and PT45 (pancreatic), the 
Lister strain VVL15 showed superior anti-cancer activity compared to Western Reserve 
WRDD virus; in keeping with the cytotoxicity and viral replication in vitro data. In 
nude mice bearing murine CMT93 flank tumours, there was reduced tumour 
progression in the WRDD-treated mice. Changing the mouse model to 
immunocompetent C57BL/6 mice bearing CMT93 flank tumours as before, and with 
two treatment regimes of 3 x IT virus injections (days 1,3,5) and 5 x IT virus injections 
(days 1,2,3,4,5), a different pattern was seen where VVL15 showed superior anti-
tumour efficacy over WRDD. This effect seemed dose-responsive with the 5 x IT 
injection regime enhancing the anti-tumour potency with VVL15 treatment. Testing in 
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another immunocompetent murine colorectal cancer model (CT26) improved anti-
tumour efficacy was demonstrated in VVL15-treated mice. 
 
To define the mechanism of enhanced Lister strain anti-tumour potency and evaluate 
viral replication in other, non-tumour, tissues (which may result in host treatment side-
effects/complications), biodistribution studies were performed using IV viral treatment 
in nude and immunocompetent mice bearing CMT93 flank tumours. In the nude mouse 
model, WRDD demonstrated higher levels of replication than VVL15 in the tumour as 
determined by TCID50, qRT-PCR and immunohistochemistry. However WRDD also 
exhibited higher levels of viral replication in the ovary and to lesser extent lungs, liver, 
spleen, brain and bone marrow. Therefore it is apparent that WRDD is able to replicate 
better in all murine tissues compared to VVL15; which again is probably unsurprising 
given the origins of the WR strain.   
 
In the immunocompetent model the titre of virus measured in the tumour samples was 
higher with VVL15 compared to WRDD; with similar levels of both viruses in the 
lungs, liver and spleen. Again WRDD showed very high concentrations in the ovaries, 
which was not seen with VVL15. This finding in the immunocompetent model is 
suggestive of Lister strain having a greater ability than WR strain to replicate in the 
presence of an intact immune system, with the exception of ovarian tissues. Vaccinia 
viruses are known to have a number of strategies to suppress the host immune system 
and therefore reduce their clearance. These include interferon decoy receptors, 
128,129
 
TNF receptors, 
132
 IL1 receptor blocker, 
108
 IL18 binding protein, 
261
 CC chemokine 
inhibitor, 
136
 and serine protease inhibitors. 
137
 More of these immunomodulatory 
proteins have been identified in the Lister strain virus compared to the WR strain, and 
as such may have more powerful mechanisms to subdue the host immune response, and 
hence reduce Lister strain virus clearance. 
 
To investigate functional mechanisms for Lister mutant superiority over WR, 
inflammatory responses to the two viruses were examined through cytokine analysis of 
cancer cells in tissue culture, and in vivo tumours and serum following IT viral 
treatment of flank tumours in immunocompetent mice. Interestingly, WR strain induced 
much higher levels of pro-inflammatory cytokines compared to Lister. IL10 was the 
only cytokine that recorded higher levels in VVL15-treated mice compared to WRDD-
treated animals. IL10 is considered an anti-inflammatory cytokine. This suggested that 
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VVL15 was able to induce a less pro-inflammatory response, explaining the higher viral 
titres of this virus in the immunocompetent mouse biodistribution model and 
consequently the superior anti-tumour efficacy seen in the immunocompetent animal 
models. 
 
To further improve the anti-tumour efficacy of the Lister strain vaccinia virus, a 
transgene was sought to arm the Lister viral backbone. As viral clearance by the host 
immune system is a key factor in determining viral efficacy, mechanisms to suppress 
this immunity were investigated. IL10 is an anti-inflammatory cytokine that has been 
demonstrated to inhibit tumour growth and metastasis. 
157
 A Lister vaccinia virus 
expressing murine IL10 (VVIL10) was constructed; with the IL10 transgene inserted 
into the TK region driven by the synthetic early/late promoter pE/L. 
240
 IL10 expression 
was confirmed by ELISA in CMT93, SCCVII and PT45 cells infected with this virus. 
Endogenous IL10 expression was found with VVL15 (lacking the exogenous IL10 
gene)-infected cells, suggesting a Lister viral IL10 homologue. No endogenous IL10 
expression was found in cells infected with WR strain. Viral IL10 homologues have 
been discovered to be expressed by human cytomegalovirus, human herpes virus 4 and 
Yaba-like disease virus (poxvirus), but not to date by vaccinia virus. 
262
 MTS cell 
proliferation assays demonstrated increased potency of the Lister strain virus encoding 
murine IL10 (VVIL10) compared to control virus (VVL15). Viral replication assays 
were complicated by the effect of marked cell death in the VVIL10-treated group, 
limiting the number of viable cells available for virus replication. The mechanism for an 
in vitro action of IL10 is unclear. 
 
To further investigate the in vitro anti-tumour function of IL10, the effect of 
recombinant IL10 (rIL10) alone and in combination with VVL15 on CMT93 cancer 
cells was examined. Using an MTS cytotoxicity assay technique, there was no evidence 
of a direct cytotoxic effect of rIL10 following a single application at a starting 
maximum concentration of 1x10
5
pg/ml. This finding was also been reported using 
direct application of rIL10 to CT26 cells (concentration range: 800 - 3x10
6 
pg/ml).
59
 
The half-life of recombinant IL10 in vitro is unclear. In mice following intravenous 
administration it has a half life of no more than 20 minutes. 
263
 rIL10 in conjunction 
with VVL15, and compared to VVL15 and VVIL10 alone, demonstrated an 
intermediate cytotoxicity result, between the high EC50 value of VVL15 alone and low 
EC50 value of VVIL10 alone. Clearly rIL10 is able to partially compensate for the lack 
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of the IL10 transgene in VVL15. It is feasible that administering more rIL10 may be 
able to bring the EC50 value of VVL15 + rIL10 closer to VVIL10. 
 
Having established superior cytotoxicity of VVIL10 in vitro compared to VVL15, 
evaluation of VVIL10 in vivo required investigation. Using identical mouse cancer 
models as in the previous WR versus Lister efficacy studies this was achieved. The 
potency of VVIL10 compared to VVL15 and PBS in a nude CMT93 mouse model, 
demonstrated no significant difference in tumour progression. However, in the 
immunocompetent model diminished tumour progression was noted with the VVIL10-
treated mice compared to VVL15 and PBS. This effect was enhanced by increasing the 
dose of VVIL10 administered from a three-day to a five-day regime. Further supportive 
evidence of VVIL10 superiority was obtained in a CT26 murine colorectal model in 
immunocompetent mice. Anti-tumour efficacy was also assessed a human pancreatic 
model of cancer (PT45) in nude mice. Interestingly, in contrast to the nude CMT93 
mouse model, tumour progression was more limited with the VVIL10-treated mice 
compared to VVL15 and PBS. Clearly the effects of IL10 are not restricted to the cell-
mediated immune system, with influences on the residual immune system of nude mice 
(NK cells,
234
 macrophages 
170
) and tumour angiogenesis, as suggested elsewhere. 
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VVIL10 was further examined using similar methodology to the investigation of WR 
and Lister biodistribution and biological time-points studies following IV and IT 
delivery respectively. Biodistribution in an immunocompetent CMT93 mouse model 
demonstrated higher viral concentrations within the tumours for VVIL10-, compared to 
VVL15-, treated mice. This suggests that IL10 transgene expression was able to reduce 
systemic viral clearance allowing more of the virus dose to reach the tumours. 
Additionally when the VVIL10 virus started replicating within the tumour 
microenvironment, IL10 reduced viral clearance locally as demonstrated by the 
biological time-points data. There is also evidence of enhanced tumour selectivity of 
VVIL10 compared to VVL15 with reduced viral concentrations in the spleen, bone 
marrow and lung. Biodistribution and biological time-points were further examined in 
the PT45 human pancreatic model in nude mice. Higher tumour viral concentrations 
were recorded for VVIL10 compared to VVL15 following IT and IV administration, 
again suggesting the importance of the innate immune system in clearing invading 
viruses and how IL10 is able to subdue this response. 
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Investigation of an anti-tumour mechanism of IL10 focused on differences in the 
cytokine profiles following VVL15 and VVIL10 infections. CMT93 cells infected in 
tissue culture, and tumour and serum samples from mouse CMT93 flank tumours 
injected intratumourally were analysed. Cytokine levels from tissue culture and serum 
samples showed a marked elevation of several pro-inflammatory cytokines, including 
IFNγ, IL12, IL6, and IL1β, and elevation of the anti-inflammatory cytokine IL10 
following VVIL10 infection compared to VVL15. These raised pro-inflammatory 
cytokines following VVIL10 infection correlate with higher viral titres from 
biodistribution and biological time-points studies, and superior anti-tumour potency in 
efficacy studies, compared to VVL15. Other studies looked at effect of macrophage 
cytokine expression in vitro following recombinant IL10 administration. 
264-266
 These 
experiments showed a depression of pro-inflammatory cytokines. However these 
experiments did not use virally mediated expression of IL10 and were in vitro studies 
only. IL4 is another important Th2 cytokine that inhibits cell-mediated immune 
responses, like IL10. IL4 vaccinia virus mediated expression has been shown to result in 
reduced pro-inflammatory cytokines following IV virus injection.
156
 Therefore my 
findings would seem contradictory when correlating with higher viral titres and 
enhanced anti-tumour potency following VVIL10 infection, given the findings for 
WRDD and VVL15. Higher levels of pro-inflammatory cytokines were recorded with 
WRDD-treatment, which also demonstrated increased viral clearance and inferior anti-
tumour efficacy compared to VVL15.  However the levels of these pro-inflammatory 
cytokines are much higher following VVIL10-treatment than WRDD, and occur in the 
context of high IL10 levels. The roles of cytokines in tumourigenesis are poorly 
understood and can be paradoxical. They should be considered as a “cytokine network”, 
rather than individual cytokines acting independently.
267
 The effect of dose, timing, cell-
type, effect of other cytokines, nutritional factors and other local mediators are all 
thought to be significant in determining an overall pro- or anti-inflammatory response. 
260
 
 
Finally, a recurrent finding of WR strain vaccinia virus biodistribution research relates 
to the high levels of virus found in ovarian tissue. 
83,96,239,241,268
 Smallpox was known to 
replicate preferentially in areas of increased vascular permeability secondary to injury 
and histamine release. 
269
 It has also been shown that increases in vascular permeability 
induced by hyperthermia leads to increased uptake of vaccinia virus. 
270
 Furthermore 
ovarian tissue has been shown to have high levels of VEGF, which increases vascular 
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permeability and hence vaccinia virus uptake. 
271
 However this does not explain why 
ovary tropism is not demonstrated with VVL15, but tumour tropism is preserved.  
Research has shown partial dependence on asialo-GM1 for WR strain viruses to enter 
cells. 
272
 This potential accessory receptor is widely expressed in ovarian and brain 
tissue; and anti-serum to asialo-GM1 has been shown to abrogate ovarian infection. 
272
 
Further studies have shown that two viral proteins, A27L and H3L, interact with 
heparan sulphate to infect host cells.
92,93
 Heparan sulphate is found abundantly in 
ovarian follicular basal lamina and is a potential candidate for supporting WR vaccinia 
virus entry into ovarian follicles.  
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9. Future work 
 
This study challenges the dogma that the most promising vaccinia virus strain for 
human viral oncolytic gene therapy is Western Reserve. Lister strain virus has a number 
of characteristics, identified in this study, that suggest it might represent a preferred 
choice to WR. IL10 has been shown to have a powerful augmentative effect to the 
Lister strain, improving anti-tumour efficacy and tumour-selectivity. However a number 
of questions remain following this study. 
 
The most significant question arising from my study is the functional mechanism of 
IL10 that results in improved anti-tumour efficacy. I have demonstrated that viral 
persistence is improved with IL10 expressing Lister strain virus.  Other groups have 
reported conflicting data. One group demonstrated that administration of murine IL10 
12 hours after vaccinia virus in a mouse model of pulmonary metastases enhanced viral 
effectiveness; however this was not through an immunosuppressive mechanism as 
vaccinia virus titres were found to be reduced following IL10 adjuvant therapy and CTL 
activity was increased. 
59
 Another group found that the use of an IL10R-blocking 
antibody resulted in reduced viral titres in immunocompetent mice infected with 
lymphocytic choriomeningitis virus. 
237
 Comparison of the biodistribution and anti-
tumour efficacy in immunocompetent IL10R-knockout mice bearing flank tumours 
following IT and IV VVIL10 administration would provide further evidence for the 
effect on IL10 on viral persistence. Administration of IL10R-blocking antibody to 
immunocompetent mice bearing flank tumours following VVIL10 administration would 
also be informative.  
 
IL10 expressed from an adenoviral vector has been shown to inhibit angiogenesis in a 
gastric cancer mouse model. 
157
 This was demonstrated using immunohistochemical 
staining of peritoneal nodules with monoclonal rat anti-CD31 antibody and calculation 
of microvascular density. Similar experiments could be performed on the samples from 
my CMT93 mouse model to evidence repression of angiogenesis following IT virus 
delivery. Furthermore, measurement of angiogenesis-mediating VEGF has been shown 
to be downregulated in a human melanoma cell line transfected with an IL10 expression 
vector and subsequent implantation into nude mice. 
273
 ELISA techniques are available 
to measure VEGF and other angiogenesis mediators such as MMP, as well as tissue 
inhibitors of MMP (TIMP) on existing tumour samples. Angiogenesis inhibition can 
164 
 
also be demonstrated in vitro through the effect of virally-infected cancer cell tissue 
culture supernatants on HUVEC tube formation and proliferation. 
245
 
 
Further proposed mechanisms of IL10 include effects on nitric oxide and the immune 
system. Nitric oxide is released by activated macrophages and neutrophils, and is a 
major defensive weapon against many pathogens. 
274
 IL10 gene transfer has been 
associated with increased inducible nitric oxide synthase (iNOS) protein expression and 
enzymatic activity in vitro and in vivo. 
236
 The in vitro effect of VVIL10 infection on 
cancer cell nitric oxide could be measured using a Greiss reagent, as previously 
described. 
236
 To assess nitric oxide or NOS levels in vivo Greiss reagents could be used 
on existing samples, or iNOS antibody on paraffin embedded tumour samples. 
Additionally anti-tumour efficacy of VVIL10 in iNOS knockout and control mice could 
be compared. The anti-tumour immune mechanisms of IL10 have been demonstrated to 
be dependent on natural killer cells, cytotoxic lymphocytes and macrophages. 
233,234,236,275,276
 Localisation of these cell types to tumours following VVIL10 
administration compared to control virus using immunohistochemistry or FACS would 
be highly suggestive of their role in the mediation of an IL10 effect. Knockout mice or 
neutralising antibodies could also be used to determine the significance of specific 
immune cells on IL10 anti-tumour efficacy. 
 
Finally, the ovarian tropism demonstrated by WR strain vaccinia virus, but not Lister 
strain, requires further investigation. Electron microscopy of the two viruses would 
determine the feasibility of a physical explanation of this tropism; based on the relative 
size of the viruses affecting their ability to pass through the ovarian vasculature 
endothelium. A molecular mechanism could be studied by comparing the infectability 
of ovarian follicular cells using fluorescence microscopy for detection of 
viral protein expression, real time PCR for viral mRNA expression and DNA 
amplification. Yeast hybridisation could also be used to identify new host 
factors or viral proteins that affect the tropism of WR strain vaccinia virus to ovaries.  
 
Further studies using anti-asialo-GM1 antibody and soluble heparan will determine the 
role of asialo-GM1 and heparan sulphate in WR strain follicular attachment and uptake.  
Co-immunoprecipitation or a two-hybrid approach followed by mass spectrometry 
could identify a candidate protein at the surface of the follicular cell that interacts with 
WR proteins. 
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